

Index

Page numbers in **bold** refer to major discussions.

Page numbers referring to figures are suffixed by 'f'; those referring to tables are suffixed by 't'; those referring to boxes are suffixed by 'b'.

Abbreviations used in subentries:

- AF – amniotic fluid
 AFP – alpha-fetoprotein
 CAH – congenital adrenal hyperplasia
 CCAM – cystic adenomatoid malformation of the lung
 CESD – cholesteryl ester storage disease
 CF – cystic fibrosis
 cffDNA – cell-free fetal DNA
 CGH – comparative genomic hybridization
 DSD – disorders of sex development
 DS – Down syndrome
 GAG – glycosaminoglycan
 HCST – hematopoietic stem cell transplantation
 MPS – mucopolysaccharidoses
 NGS – next-generation sequencing
 NIPD – noninvasive prenatal diagnosis
 NIPT – noninvasive prenatal testing
 NTD – neural tube defect
 OSB – open spina bifida
 SMC – supernumerary marker chromosome
- 45,X females *see* Turner syndrome
 45,X males **291**
 45,X mosaicism 223–224, **274–276**
 45,X/46,XX 221, 222, 223, **274**
 45,X/46,XX/47,XXX 275
 45,X/46,XY and variants 222–223, 223t, **275–276**, 289
 45,X/47,XXX 274
 46,X,del(Xq) 273
 46,X,r(X) 273
 46,XX/46,XY chimerism 294
 46,XX/47,XXX 224, **281–282**
 46,XX males **290–291**
 Y-negative 291
 Y-positive 290–291
 46,XX ovotesticular DSD 293–294
 46,X,Xq2 273
 46,XY/47,XXY mosaicism 223, **279**
 46,XY/47,YYY mosaicism 224, **284**
 46,XY females **291–293**
 5 α -reductase deficiency 293
 androgen insensitivity syndrome 292
 mixed gonadal dysgenesis 292–293
- Swyer syndrome 292
 “true hermaphroditism” 293
 47,X,i(Xq),Y 279
 47,XXr(Y)/46,XX 289
 47,XXX *see* triple X syndrome (47,XXX)
 47,XXX males 291
 47,XXX mosaicism 224, **281–282**
 47,XXY *see* Klinefelter syndrome
 47,XXY mosaicism 279
 47,YYY males 202, **282–284**
 clinical features/management 283
 cognitive/psychologic development 283–284
 prenatal counseling 284
 screening tests 186
 48,XXXX 282
 48,XXXY 280
 48,XXYY 279–280
 48,YYYY 284
 49,XXXXX 282
 49,XXXXY 280
 49,XXYY 280
 49,XXYYY 284
 49,XYYYY 284
- ABCA12 gene 399
 ABCD1 gene mutations 849
 abdomen (fetal), MRI 674
 abdominal masses (fetal)
 cysts 556–557, 581
 MRI 674
 abdominal wall, development 552
 abdominal wall defects
 AFChE positive 137
 chromosomal abnormalities with 581
 screening, MSAFP 518
 ultrasound *see* ultrasound (US), prenatal diagnosis
see also gastroschisis; omphalocele
 abortifacients
 intra-amniotic 1021
 systemic 1020–1021
 abortion (induced/elective) **1011–1030**
 after amniocentesis 69
 chromosomal abnormality incidence 182, 184–185, 1011

Genetic Disorders and the Fetus: Diagnosis, Prevention, and Treatment, Seventh Edition.

Edited by Aubrey Milunsky and Jeff M. Milunsky.

© 2016 by Aubrey Milunsky and Jeff Milunsky. Published 2016 by John Wiley & Sons, Inc.

1132 Index

- abortion (induced/elective) (*Continued*)
- CMV infection 961
 - concerns over diagnosis confirmation 1017
 - conscientious objectors 1069, 1115
 - counseling 9, 1053
 - nondirective counseling 14, 1109, 1113
 - second trimester **1021–1022**
 - cystic fibrosis 711–712, 713
 - decision-making **41–42**, 1011, **1052–1054**
 - autonomy in 1115
 - in multiple pregnancies 1054
 - sequel **41–42**, 1011
 - disorders with genetic predisposition 436–437
 - Down syndrome 4
 - due to fetal anomalies 7, 1049, **1052–1054**
 - emotions and somatic symptoms 41, 42t, 1053
 - ethics *see* ethics
 - first trimester **1012–1016**
 - medical 1012, 1016
 - safety 520
 - suction aspiration *see* suction aspiration/curettage
 - unsuccessful 1015
 - follow-up after 41
 - impact of concerns on wrongful birth/life claims **1068–1069**
 - impact on mother 41, 42t, 1053
 - indications 1011
 - indirect referral 1115
 - legal aspects 1065, 1079, 1085
 - laws and regulations 1011, 1022, 1100
 - legal cases 1065
 - maternal mortality 1016, 1016t, 1020t, 1021
 - parental attitudes 41, 1052–1054
 - right to privacy 1065
 - second trimester **1016–1021**
 - abortifacients 1020–1021
 - choice of technique 1021–1022
 - counseling patients **1021–1022**
 - labor induction method 1017
 - morbidity 1016, 1019–1020, 1021
 - mortality 1016, 1020, 1020t, 1021
 - selective, multiple pregnancy 1022–1023
 - techniques 1016–1017
 - see also* dilation and evacuation (D and E)
 - selective in multiple gestations **1022–1025**, 1049, 1054
 - ethics 1115–1116
 - first trimester 1024–1025
 - indications 1115–1116
 - morbidity/mortality 1023, 1024–1025
 - second-trimester 1022–1023
 - techniques 1022–1023, 1024
 - ultrasound-guided KCl injection 1022–1023, 1024
 - sex selective 1100
 - third trimester 1117
 - unsafe, morbidity/mortality 1014
 - after viability
 - ethics 1116–1121
 - indications 1117
 - before viability, ethics 1114–1116
 - views of obstetricians 1057–1058
 - window of time after diagnosis 1053
- abortion (spontaneous; miscarriage) 1048
- see also* fetal loss
- acardiac twins 585
- acetoacetyl-CoA thiolase (T2) deficiency 884
- acetylcholine receptor, antibodies 116
- acetylcholinesterase (AChE), in AF 101, 133, **135–138**
- assay 135
 - elevated AFAFP with 133, 134, 135, 136, 138
 - elevated AFAFP without 134, 135, 136, 139
 - false-positive/-negative rates 136, 137t, 138
 - fetal conditions associated 133, 133b–134b, 136–137
 - normal AFAFP with 138
 - NTDs and 133, 135–138, 136t, 137t, 495
 - recommendations 138–139
- acetyl CoA:α-glucosamine N-acetyl transferase (HGSNAT) deficiency (MPS IIIC) 864
- N-acetylgalactosamine-4-sulfatase (GAL4S) deficiency (MPSVI) 865–866
- N-acetylgalactosamine-6-sulphatase (GAL6S) deficiency (MPS IVA) 865
- N-acetylglucosamine-6-sulfate monosaccharide 865
- N-acetylglucosaminidase (NAGLU) deficiency (MPS IIIB) 864
- N-acetylglutamate synthetase (NAG-S) deficiency 879
- N-acetylhexosamine, sulfated(HNAcS) 865, 866
- β-N-acetyl-D-hexosaminidase (HEXA, HEXB) *see* hexosaminidase A; hexosaminidase B
- aCGH *see* array comparative genomic hybridization (aCGH)
- AChE *see* acetylcholinesterase (AChE)
- achondrogenesis
 - type 1B 692
 - type 2 690, 691
- achondroplasia **685–687**, 686f
 - FGFR3* mutations 685, 686
 - prenatal diagnosis 686
 - gestational age 683
 - noninvasive 458, 459t, 462
 - ultrasound 564, 686, 687f
- aciclovir 966
- acid ceramidase 806, 807
 - deficiency (Farber disease) 806–807
- acid lipase deficiency, lysosomal **807–809**
- acid maltase
 - deficiency (GSD type II) 104, 904t, 906, **908–909**
 - gene 909
- acid sphingomyelinase 803, 804
 - deficiency (Niemann–Pick disease types A/B) 802, 803
- acrocentric chromosomes 235, 326
- action myoclonus renal failure syndrome (AMRF) 793
- acylcarnitine abnormalities 840, 845, 847
- acyl-CoA dehydrogenase, deficiency 425t, 839f, 840, 842t
 - medium-chain (MCAD) 840, **846**
 - multiple (MADD) **847–848**, 892–893
 - short-chain (SCAD) 839f, 841f, 842t
 - VLCAD 840, **845–846**
- acyl-CoA oxidase 851, 852
 - deficiency 848, 848t, 849
- ADAM 12s 506
- adenosine deaminase (ADA) deficiency 759t, **765**
 - gene therapy 763, 765
- adenosine deaminase-deficient SCID 763
- adenosine triphosphate (ATP) 703
- adenosylcobalamin (AdoCbl) 930, 931, 932
- ADHD (attention deficit hyperactivity disorder) 315t, 350–351, 352
- A disintegrin and metalloprotease (ADAM)12s 506
- adolescence
 - preconception care 19
 - triple X syndrome (47,XXX) 281
 - Turner syndrome 272
- adoption, legal case involving 1075

- ADPKD *see* autosomal dominant polycystic kidney disease (ADPKD)
- ADPKD1 and ADPKD2 genes 11
- adrenal hematoma 674
- adrenal hyperplasia *see* congenital adrenal hyperplasia (CAH)
- adrenal insufficiency, congenital 979
- adrenocorticotrophic hormone (ACTH) 976
- adrenoleukodystrophy
- neonatal (NALD) 851
 - X-linked (X-ALD) 848–849, 848t
- adrenoleukodystrophy protein (ALDP) 849
- adrenomyeloneuropathy (AMN) 849
- adult-dominant polycystic kidney disease (ADPKD) *see* autosomal dominant polycystic kidney disease (ADPKD)
- adult onset genetic disorders
- PGD use 437
 - preconception genetic counseling 21–22
- adult polycystic kidney disease (APKD) 11
- family history 29
 - legal case concerning 1080
 - ultrasound 561–562
 - see also* autosomal dominant polycystic kidney disease (ADPKD)
- adult polyglucosan body disease 911
- Advisory Committee on Assisted Reproductive Technology (ACART) (New Zealand) 1098
- AF *see* amniotic fluid (AF)
- AFACHe *see* acetylcholinesterase (AChE), in AF
- AFAFP *see* α -fetoprotein (AFP), in AF
- AFC *see* amniotic fluid cells (AFC) (amniocytes)
- AF Index (AFI) 99
- AFP *see* α -fetoprotein (AFP)
- AFQ056 (mGluR5 antagonist) 357
- African-Americans
- cystic fibrosis 701t, 705, 707
 - galactosemia 915
 - genetic disorders 28t
 - maternal serum screening 513
 - β -thalassemia 723, 739
- Africans (blacks), genetic disorders 28t, 723, 725, 726, 727
- Afrikaners, genetic disorders 28t
- agalsidase alfa and beta 792
- agammaglobulinemia 760t, 767
- age, maternal *see* maternal age
- agenesis
- corpus callosum *see* corpus callosum
 - kidney 557, 558t
- aggressive management 1116
- agyria 667
- agyria-pachygyria 667
- AIDS-related disease, legal cases concerning 1077
- AIRE gene methylation 769
- air embolus 992
- airway obstruction, *ex utero* intrapartum treatment 993, 994
- Alagille syndrome 315t, 317
- albinism, legal case 1083–1084
- albumin, in AF 100–101, 102
- alcohol, effect on the fetus 31, 118, 982
- alglucosidase alfa (Myozyme®) 909
- alkaline phosphatase, in AF 108
- allele drop-out (ADO) 356, 977
- next-generation sequencing, PGD 443
 - PGD misdiagnosis and 423, 734
- allele-specific oligonucleotide hybridization (ASO) 709t, 739
- cystic fibrosis 709t
 - β -thalassemia 739
- allele-specific priming technique
- primers for normal DNA sequences 743t
 - β -thalassemia 741–742, 742t
- α -fetoprotein (AFP) 485
- in AF (FAAFP) 101, 131–132, 132–133
 - brown/green AF 135
 - changes with gestation age 131, 131f
 - cystic hygroma 134
 - Down syndrome 133
 - elevated 132t, 133–135, 136, 138–139
 - elevated, mechanisms 132, 133b–134b, 134
 - elevated in absence of NTDs 133–135, 133b–134b
 - elevated in NTDs 132–133, 132t, 485
 - elevated with AChE negative 134, 135, 136, 139
 - elevated with AChE positive 133, 134, 135, 136, 138
 - elevated with normal sonogram 135
 - after first-trimester fetal reduction 1024
 - low levels 134
 - measurement problems and pitfalls 135
 - Meckel syndrome 135
 - multiple pregnancy 133
 - normal with positive AFACHe 133, 138
 - NTD and pregnancy outcomes 132–133, 132t, 495
 - NTD diagnosis recommendations 138–139
 - source/route to 134
 - third trimester 133
- biology 131–132
- congenital absence 132
 - fetal serum 131–132
 - changes with gestation age 131, 131f
 - peak levels 101
- maternal serum *see* maternal serum AFP (MSAFP)
- newborn plasma levels 132
 - structure 131
 - synthesis 131, 132, 485
- α -thalassemia *see* thalassemia
- Alzheimer's disease 6, 437
- genetic predisposition, PGD use 437–438
- Ambroxol 797
- American College of Medical Genetics and Genomics (ACMG) 706
- CF carrier screening 706–708
 - FISH guidelines 331–333, 334–335
 - incidental findings, reporting 404, 1111
- American College of Obstetricians and Gynecologists (ACOG) 1111, 1113, 1114
- American Society for Reproductive Medicine (ASRM) 1097
- amino acid(s) 877
- in AF 104–106, 108
 - in aneuploid embryos 420
 - maternal serum levels 105
 - metabolism 877, 878f
 - renal transport, disorders 892
 - transport across placenta 1033
- amino acid metabolic disorders **877–902**
- branched chain AAs 883–886
 - lysine disorders 886
 - maternal 877
 - miscellaneous 890–892
 - organic acid disorders 882–883
 - phenylalanine disorders 886–888
 - prenatal diagnosis methods 877–878
 - sulfur amino acids 888–890
 - tyrosine disorders 886–888
 - urea cycle disorders 878–882

1134 Index

- Amish community, genetic disorders 28t, 781, 787, 886, 890, 929
- amniocentesis **68–82**, 80–81
 - advice to patients 79
 - anesthesia for 69
 - antibiotic prophylaxis 113–114
 - care after 70
 - chromosomal abnormalities *see* chromosomal abnormalities
 - CMV infection 953
 - collaborative studies 75, 76–78
 - Canadian 76, 76t
 - Danish 75, 76t, 77
 - Greek 76t, 78
 - Thai 76t, 77–78
 - UK 76–77, 76t
 - US 75–76, 76t
 - comparative studies 80–81
 - early amniocentesis vs CVS 80, 81, 520
 - early vs midtrimester amniocentesis 80–81
 - discolored AF samples 73–74
 - early (<14 weeks) 69, **79–81**
 - comparative trials 80–81
 - initial experience 79–80
 - recommendation against 81
 - risks 80, 119
 - technique 79
 - error rate 33
 - failure 69–70
 - FASTER trial 78–79, 193
 - fetal death rate 71, 79
 - fetal losses 75, 79, 185
 - controversy 78–79
 - early amniocentesis 80
 - FASTER trial 78–79
 - maternal age and 75, 77
 - study conclusions 79

- infectious agents 113–114
 bacteria 113–114
 Candida albicans 114
 CMV DNA 958
 toxoplasmosis detection 945
 viruses 114, 967
 VZV DNA detection 964, 965, 966
 lamellar bodies 103
 leakage, after amniocentesis 74
 lecithin/sphingomyelin (L/S) ratio 103
 maternal urine differentiation 70
 mesenchymal stem cells in 130
 microvilli (intestinal) in 106
 origin (source) of **100–101**, 105
 pressure 98
 proteomics 102
 renal function indication 998
 samples, transport of 129
 turnover 98–99
 volume 69, 98, **99–100**
 abnormal, ultrasound detection 564–566
 for amniocentesis 69
 control, determinants 99
 estimation 99
 fetoscopy 992
 by gestational age 100t
 see also oligohydramnios; polyhydramnios
 see also amniocentesis
 amniotic fluid cells (AFC) (amniocytes) **119–125**, 206
 AF-type 120, 120t, 121f, 122f, 123, 123f, 124
 attachment to culture substrate 119–120
 classification 120, 120t
 colony-forming **120–125**
 biochemistry 123
 characteristics 123
 intermediate filament system 123–124
 longevity 125f
 morphology 120, 123
 nomenclature 120, 123
 numbers 125
 origin 124–125
 pleomorphism 120, 121f
 culture *see* amniotic fluid cells (AFC) culture
 ED cells 124, 124f
 enzyme assays, amino acid metabolism 878
 epithelioid (E) 120, 120t, 121f, 122f, 123, 123f, 124
 fetal distress cells 120
 F-type (fibroblast-like) 120, 120t, 121f, 122f, 123, 123f, 124
 macrophage-like cells 120
 mesenchymal stem cells 130
 molecular analytical techniques 119
 interphase FISH 119, 328–330, 329t, 338
 mosaicism in *see* mosaicism
 noncultivated, maternal cell contamination 238
 types **119–125**
 see also amniocentesis
 amniotic fluid cells (AFC) culture **118–130**
 alternatives to 119
 bloody/cloudy AF 129
 cell harvest **125–126**, 127, 206
 cloning efficiency 125, 126f, 127, 129
 cystinosis diagnosis 935
 cytogenetic error rates 241
 enrichment techniques 127
 extracellular matrix surface, growth 127
 failure **128–130**, 239
 fetal death and 239
 incubator failure 129
 media storage 129
 microbial contamination 129, 239
 plastic ware 129
 rates 118, 128
 syringe/tube toxicity 129, 239
 transport delays 129
 fetal bovine serum in medium **127–128**
 flask technique 126, 206, 225, 226t, 238
 growth enhancement **127**
 growth-factor supplements **128**
 hemoglobinopathy diagnosis 731
 history 366
 in situ procedure 126–127, 206
 laboratory safety 130
 maternal cell contamination 126, **237–238**, 237t
 media for 125–126, 126–127, 128, 129
 metaphase number to study 126
 methods **126–127**
 mosaicism diagnosis *see* mosaicism
 NTDs detection 120
 oxygen supply reduction 127
 period/time 128
 protocol 127
 quality control 130
 record keeping 130
 uses 119
 amniotic fluid (AF) Index 99
 amniotic fluid (AF) space 101f
 amplification-created restriction sites (ACRS) 740
 amplification refractory mutation system (ARMS) 709t
 ARMS-PCR 741–742, 742t
 hemoglobinopathies 719
 α -thalassemia 737
 β -thalassemia 739–740, 741–742, 742t, 743f, 744f
 primers 741, 742t
 amylo-1,6-glucosidase deficiency (type III GSD) 904t, 909–910
 amyloid precursor protein (APP) gene 437
 amylopectinosis (type IV GSD) 904t, **911**
 amyotrophic lateral sclerosis (ALS) 12, 37
 Anderson disease (type IV GSD) 904t, **911**
 Anderson–Fabry disease *see* Fabry disease
 androgenetic chimerism 1037t, 1039
 androgen insensitivity syndrome 292
 anemia
 cobalamin disorders 930
 Diamond–Blackfan 315t, 438
 Fanconi 438
 fetal, parvovirus B19 infection 968
 sickle cell *see* sickle cell anemia; sickle cell disease
 anencephaly 145, 484, 1117
 MSAFP levels and 485, 488, 488t, 496t
 polyhydramnios 100
 ultrasound detection 541, 542, 567, 567f
 anesthesia 990–991
 for amniocentesis 69
 for fetal surgery 990–991
 for induced abortions 1013, 1018
 aneuploidy **483–484**
 cffDNA, prenatal diagnosis 454, **463**
 complex and variegated 219
 cystic hygroma 188, 191
 cytogenetic diagnosis after NIPT 185

1136 Index

- aneuploidy (*Continued*)
- high risk, ultrasound anomalies 192
 - importance of prenatal diagnosis 178
 - incidence 2, 179–185
 - low risk, ultrasound anomalies 192
 - mechanisms/origin 203
 - moderate risk, ultrasound anomalies 192
 - oocytes 438, 440
 - phenotypic expression, second trimester 574
 - preimplantation embryo metabolism and 420
 - prenatal diagnosis indications *see under* chromosomal abnormalities
 - risk factors
 - advanced maternal age 193
 - advanced paternal age and 193–194
 - previous child with DS 198
 - screening 463, 515–516
 - first-trimester 185–187, 186t
 - repeat measures 504–505
 - second-trimester 187
 - sex chromosome *see* sex chromosome abnormalities (SCA)
 - spontaneous abortion 484
 - testing, PGD *see* preimplantation genetic diagnosis (PGD)
 - ultrasound abnormalities 188, 191, 191t, 574
 - very high risk, ultrasound 188, 191–192
 - see also* chromosomal abnormalities; mosaicism; trisomy
- “aneuploidy by recombination” 197
- Angelman syndrome 21
- chromosome 15 SMC 231, 235
 - deletions 314, 315t
 - legal case involving 1075
 - Prader–Willi syndrome ~~24, 478~~ 50to
- angiogenesis, placental 1032
- anhydramnios 632, 634
- animal studies 1123
- aniridia–Wilms tumor 315t, 317
- “anomaly scan” 193, 486–487, 505
- anorectal anomalies 555, 674
- anti-arrhythmic drugs 602, 981
- antibacterial agents, in AF 113
- antibiotics
- amniocentesis 113–114
 - distribution in AF 114
 - resistance 700
- antibody deficiency 760t–761t, **766–767**
- tests 758
- anticipation (genetic) 12, 37, 38, **387–389**
- disorders with 389b
- anticonvulsants
- in AF 116
 - legal cases involving 1079
 - teratogenicity 25, 118, 982
- antidepressants, in AF 118
- anti-D immunoglobulin 72, 73, 457
- antimicrobial activity, AF 113
- antinuclear antibodies 357
- antiretroviral therapy 75
- antisocial behavior, 47, XYY males 283
- antithyroid drugs (ATD) 981
- α_1 -antitrypsin 102, 112
- antiviral drugs 959, 966
- Antley–Bixley syndrome 976
- anxiety, prenatal diagnosis indication 203
- aorta, descending 610

- ASM gene mutations 802
 ASO *see* allele-specific oligonucleotide hybridization (ASO)
 aspirin 519, 1036
 assisted reproduction 10
 CF prenatal diagnosis 713
 Down syndrome and 511–512
 Italian law 1096
 PGD regulation and 1097–1099
 pregnancy reduction in multiple pregnancies 1054
 astrocytes 663
 ataxia
 Friedreich 37
 FXTAS *see* fragile X-associated tremor/ataxia syndrome (FXTAS)
 spinocerebellar *see* spinocerebellar ataxia
 ataxia–telangiectasia 761t, 768
 atelosteogenesis type 2 692
 ATM (ataxia–telangiectasia mutated) gene 768
 ATP, GFTR protein action 703
 atrial ectopic beats 602
 atrial flutter 602, 603f, 979
 atrial septal defects 608–609
 atrial septostomy, fetal 611
 atrial septum, intact/restrictive, hypoplastic left heart 611
 atrioventricular (AV) discordance 610
 atrioventricular (AV) heart block 602, 606f–607f, 979
 fetal therapy 980, 981
 incidence, and causes 980
 atrioventricular septal defects (AVSD) 608–609
 atrioventricular valve regurgitation 606f–607f
 ATTCT repeats 388
 attention deficit hyperactivity disorder (ADHD) 315t, 350–351, 352
 Australia, legal/regulatory status of PGD 444–445, 1094–1095, 1098
 autism spectrum disorder (ASD) 350–351, 398
 fragile X mutations 350–351, 352, 353
 multiple-hit model 398
 autoimmune disorders 271, 277
 autoimmune lymphoproliferative syndrome (ALPS) 761t, 769
 autoimmune polyendocrinopathy with candidiasis and ectodermal dysplasia (APECED or APS1) 769
 autonomy 1106, **1107**
 in decisions on abortion 1115, 1117
 disclosure of fetal sex 1110
 DS screening 520, 1112, 1113
 fetus as a patient and 1107–1108
 preivable fetus 1108–1109
 gene transfer research 1122
 nondirective genetic counseling and 13, 1113
 reproductive 8, 1068
 respect for, ethics **1107**
 risk assessment strategies 1112, 1113
 autophagy 859
 autopsy 43, 953
 report, review 44
 autosomal dominant disorders 2, 2t, 370, 389
 of immune system 757
 NIPD using cffDNA 458, 459t
 recurrence risks, *vs* mosaicism 39
 see also individual disorders
 autosomal dominant polycystic kidney disease (ADPKD) 400
 family history, genetic counseling 11, 29
 legal case concerning 1080
 presymptomatic testing 35
 ultrasound 561–562
 autosomal monosomy mosaicism 218–219
 autosomal mosaicism 211–218
 see also specific chromosomes, trisomies
 autosomal recessive disorders 2, 2t, 370
 of immune system 756–757
 NIPD using cffDNA 459t–460t, 461t, 462
 see also individual disorders
 autosomal recessive polycystic kidney disease 11, 400
 autosomal recessive villus atrophy syndrome 108
 autosomal trisomy *see* trisomy
 autosomal trisomy pseudomosaicism 209–210, 210t
 azoospermia 26, 202, 276, 288
 azoospermic factor (AZF) 288
 azygos vein 610

 BACs-on-Beads™ method 333
 bacteria
 in AF 113–114
 AF cell culture contamination 129
 bacterial artificial chromosome (BAC) 367, 442
 bacterial infections
 in immunodeficiency disorders 756, 757t
 protection against, in AF 113
 bacteriostatic effect, AF 113
 bad news, giving 39–40, 1057–1058
 B-allele frequency plots 367, Plate 8.2
 “banana” sign 486, 505, 543f–544f, 638, 639f
 Bardet–Biedl syndrome 397
 Barth syndrome 397, 885
 Bartter syndrome 134
 Batten disease *see* neuronal ceroid lipofuscinoses (NCL)
 B cell disorders 756, 767
 antibody deficiency 760t–761t, **766–767**
 infections associated 756
 T cell disorders with *see under* lymphocyte deficiencies
 Becker muscular dystrophy 27, 399
 Beckwith–Wiedemann syndrome 213, 552, 556, 1035
 placental mesenchymal dysplasia 1039
 behavior, sex chromosome disorders 295
 47,YYY males 283
 fragile X mutations 352
 Klinefelter syndrome 278
 Turner syndrome 272
 Belgium, legal issues relating to PGD 444, 1095
 beneficence 1106, **1107**, 1117, 1118
 autonomy-based obligations *vs* 1119
 fetal reduction and 1116
 fetal surgery research and 1123
 hydrocephalus and 1118, 1119–1120
 benefits rule in wrongful birth 1066
 bereavement 1049, 1058
 see also grief
 beta-blockers, Marfan syndrome 23
 betaine 929
 betamethasone 978, 980
 β-glycoproteins 101, 115t
 β-thalassemia *see* thalassemia
 BH4 deficiency 887–888
 bias
 ascertainment 211, 268
 mosaicism prevalence 211
 publication bias 211, 268
 sex chromosome abnormalities 268
 “viability”, DS screening 487, 497
 bile acids, in AF 103

1138 Index

biliary defects, MRI 674
biochemical disorders 927-941
 cobalamin *see* cobalamin (vitamin B12)
 cystinosis 934-935
 genetic disorders, fetal therapy 982-983
biomarkers, mucopolysaccharidoses 862, 869, 870

- CAH *see* congenital adrenal hyperplasia (CAH)
calcium, urinary, obstructive uropathy 563, 563f
campomelic dysplasia (dwarfism) 293, 684, 684f
Canada
 collaborative amniocentesis studies 76, 76t
 legal/regulatory status of PGD 445, 1093, 1097, 1101
Canadians, genetic disorders 28t
cancer
 breast 36
 colon 19, 401
 genetic predisposition to 29
 Klinefelter syndrome 277
 PGD use 437
 Turner syndrome 269, 271
cancer syndromes, presymptomatic testing 35–36
Candida albicans 113, 114
cannon-wave 603f
Cantrell, pentalogy 552
capillary gel electrophoresis 381, 729
N-carbonylglutamate 879
carbonylphosphate synthetase (CPS) deficiency 879
carbohydrate metabolism disorders **903–926**, 904t–905t
 dietary therapy *see* diet/dietary therapy
 fructose 916–917
 galactose 914–916
 gluconeogenesis 917–918
 glycogen *see* glycogen storage diseases (GSDs)
 glycogen synthase deficiency 914
 hepatic glycogenesis with Fanconi syndrome 914
 pentosuria 905t, 918
 see also glycogen storage diseases (GSDs)
carcinogens 118
cardiac arrhythmias (fetal) 603f, **979–981**
 autosomal dominant, carrier screening 385
 medical therapy 86, 980, 981
 recommendations (therapy/diagnosis) 981
 recurrence rate 605
 third trimester detection 601–605, 603f–604f, 979
cardiac defects 192
 chromosomal abnormalities with 191–192, 580, 600
 22q11 deletion 317–318, 370
 trisomy 21 568
 Turner syndrome 270, 568
 copy number variants with 192
 critical 549
 fetal surgery **1005–1006**
 incidence 600
 mortality rate 549
 prenatal diagnosis advantages 600
 screening 518, 600
 third trimester diagnosis **599–615**
 ultrasound *see* echocardiography (fetal); ultrasound (US),
 prenatal diagnosis
 see also congenital heart disease; *specific disorders*
cardiac diseases, inherited, PGD indication 437
cardiac rhabdomyoma 22, 980
cardiac tumors 22, 980, 1003
cardiocentesis

1140 Index

- cell-free fetal DNA (cffDNA) (in maternal plasma) (*Continued*)
- technical approaches 463
 - validation 465–466
 - audit of results from 456–457
 - CAH detection 456, 457
 - chromosomal abnormalities 466–467
 - detection 453, 455–456
 - discordant/inconclusive results 467–470, 468t–469t
 - enrichment techniques 733
 - ethical and psychological issues 470–471
 - factors affecting levels of 454–455
 - fetal blood group detection 457, 458
 - fetal RhD genotyping 453, 455, 457–458
 - see also* RhD genotyping
 - fetal sex determination 456–457
 - fragments/fragmentation 453–454, 733
 - future developments 462, 463, 733
 - gestational age affecting levels 453, 455
 - historical milestones 454t
 - levels/percentage, fetal fraction 454, 455
 - increased, pre-eclampsia 1036
 - low, inconclusive results 185, 467–468
 - multiple pregnancies 455, 466
 - noninvasive prenatal diagnosis (NIPD) by 453, 455, 457, 733
 - single gene disorders *see below*
 - noninvasive prenatal testing (NIPT) by 453, 455
 - aneuploidies *see above*
 - validation 465–466
 - quantification 455–456
 - sex chromosome mosaics and 467
 - single gene disorders 458–463, 459t–461t, 733
 - achondroplasia 458, 462
 - hemoglobinopathy 460t, 733
 - thalassemia 460t, 733
 - thanatophoric dysplasia 458, 462
- celomic fluid 101f, 105, 115
- CEMAT trial 80, 81
- central nervous system (CNS)
- 3D/4D ultrasound 573–574
 - CMV anomalies, ultrasound 954–955
 - glycosphingolipids in 780
 - malformations
 - MRI 664–669
 - third trimester 635–650
 - MRI *see* magnetic resonance imaging (MRI) (fetal)
 - ultrasound *see* ultrasound (US), prenatal diagnosis
 - see also* brain; neural tube defects (NTDs)
- cephalocentesis 1118–1121
- ceramide 780, 781, 806
- ceramide synthase 781, 782
- cerebellar cortical dysplasia 669
- cerebellum
- abnormalities, ultrasound 543f–544f, 544, 545, 647, 648f–649f, 650
 - “absent” 543f–544f, 544
 - development 662
 - hypoplasia 647, 669
- cerebral folate deficiency 928–929, 928t
- cerebral hemisphere
- congenital absence 546
 - development 664
 - malformations 671
- cerebral infarction, *in utero* second-trimester 670
- cerebral porencephaly 670
- cerebrosides 780
- cervical dilation/softening
- for D and E 1018
 - for suction aspiration 1012, 1013
- cervical laceration, postabortion 1015
- cervical “priming” 1013
- “cervical shock” 1013
- cervical softening, for suction aspiration 1012, 1013
- cervical teratoma 1001–1003, 1002f
- cesarean delivery, refusal 1119
- cffDNA *see* cell-free fetal DNA (cffDNA)
- CFTR gene *see under* cystic fibrosis (CF)
- CFTR modulators 702
- CFTR potentiator 702
- CFTR protein 702–703
- CGG-repeat expansions 350, 354, 387
 - “AGG” interruptions 357–358
- Chang-type medium 127, 128
- CHAOS *see* congenital high airway obstruction (CHAOS)
- chaperone therapy 792, 797
- Charcot–Marie–Tooth disease 318, 367
- Chediak–Higashi syndrome 762t, 767–768
- chemotherapy, parental, prenatal cytogenetic diagnosis 203
- cherry-red spot, macula 787, 803
- chest (fetal), MRI 673–674
- Chiari II malformation 638, 666, 1004
- chicken pox *see* varicella
- childhood cerebral ALD (CCALD) 849
- children
- costs of raising, damages (legal) 1066, 1067
 - presymptomatic testing 36
 - surviving, after sibling’s perinatal death 46, 1052
 - testing, after prenatal diagnosis of fetus 42–43
 - unwanted, wrongful pregnancy 1065–1066
 - wrongful life claim 1067–1068
 - see also* siblings
- chimerism 294
 - androgenetic 1037t, 1039
- China
- genetic disorders in 28t
 - law on prenatal diagnosis 1093
 - sex selection prohibition 1100
- chloride, cystic fibrosis 701
- choledochal cysts 556
- cholesterol
- in amniotic fluid 101, 102
 - elevated, familial hypercholesterolemia 779
 - HDL *see* high-density lipoprotein (HDL)
 - LDL *see* low-density lipoprotein (LDL)
 - Niemann–Pick disease 803, 804, 805
- cholesteryl ester storage disease (CESD) 778t, 807–809
- chondrodysplasia punctata 400
- chondrodysplasia with multiple dislocations 693
- chondroectodermal dysplasia 564
- chondroitin sulfate (CS) 857
- chorioamnionitis 995, 1033
- chorionic villi 204, 1031
 - components 84
- chorionic villus sampling (CVS) 82–85
 - analysis of samples
 - FISH 331, 333–335, 334t
 - see also* cytogenetic diagnosis (prenatal)
 - chromosomal abnormalities
 - Down syndrome, maternal age 181t
 - error rates 241
 - fetal loss rates 179, 182, 182t

- incidence 182
 - mosaicism *see below*
 - twin pregnancies 238–239
 - see also* chromosomal abnormalities
 - combined B-cell/T-cell deficiency 764
 - comparative studies
 - early amniocentesis *vs* 80, 81
 - transcervical *vs* transabdominal CVS 83, 84t
 - complications 83
 - confined placental mosaicism 84, 204, 1034–1035
 - congenital adrenal hyperplasia 977
 - fetal abnormalities after 84–85
 - fetal DNA preparation 732
 - fetal losses 83, 83t, 84t, 185, 718
 - chromosomal abnormalities 179, 182, 182t
 - before fetal reduction 1025
 - first trimester 82, 186
 - glycogen storage diseases 908, 909, 910
 - hemoglobinopathies 718, 731–732
 - history of procedure 82, 178
 - indications for 185
 - aneuploidy screening 186
 - NIPT positive result 185
 - legal cases involving 1078
 - maternal cell contamination 236–237, 909
 - maternal DNA contamination 731
 - mosaicism diagnosis 204–206, 205t, 219
 - autosomal monosomy 219
 - involving autosomal structural abnormality 220
 - sex chromosome 221–222
 - trisomy 16 mosaicism 215
 - trisomy 21 mosaicism 217, 218
 - trisomy 22 mosaicism 218
 - see also* mosaicism
 - mucopolysaccharidoses 867
 - multiple pregnancies 84
 - pseudomosaicism 204
 - reliability of results 84
 - safety 83, 520
 - Tay–Sachs disease 788–789
 - technique 82–83
 - timing (gestational age) 718
 - transabdominal 82–83, 84t, 731
 - transcervical 82, 83, 84t, 731
 - ultrasound guidance 731
 - choroid, gyrate atrophy 881
 - choroid plexus cysts 547, 548f, 577
 - chromosomal abnormalities 178–266, 483–484
 - amniocentesis 68, 178, 185
 - fetal loss 179, 180–181, 182t
 - incidence data 179, 181, 181t, 182, 184t
 - maternal age and 179, 181t, 183t, 193
 - see also* cytogenetic diagnosis; mosaicism
 - aneuploidy *see* aneuploidy
 - cardiac defects with 191–192
 - in cystic hygroma 188, 191–192
 - cytogenetic diagnosis *see* cytogenetic diagnosis
 - detection, interpretation issues 227–239
 - chromosome polymorphisms 234–236
 - chromosome rearrangements 227–234
 - de novo* rearrangements 227–232, 232–234
 - familial rearrangements 227
 - inversions and structural variations 234–236
 - maternal cell contamination *see* maternal cell contamination (MCC)
 - mosaicism/pseudomosaicism 203–227
 - uniparental disomy 232–234
 - detection/screening tests 484
 - AFC *see* amniotic fluid cells (AFC) culture
 - chromosomal microarrays 188, 242
 - CVS *see* chorionic villus sampling (CVS)
 - factors affecting success/accuracy 238–239
 - fetal blood sampling 85
 - first trimester 185–187, 186t
 - indications 185–203
 - oocytes 439, 439f, 440, 440t
 - see also* cytogenetic diagnosis (prenatal)
 - fetal loss 179, 182t
 - abnormality type 182
 - amniocentesis/CVS 179, 180–181, 182t
 - incidence 182, 182t, 184t
 - incidence 179–185
 - amniocentesis data 179, 181–182, 181t, 183t, 184t
 - CVS data 181t, 182
 - induced abortion data 182, 184–185
 - livebirth data 179, 180t
 - maternal age and 179, 181t, 183t, 193, 577
 - second-trimester 181
 - spontaneous abortion data 182, 182t, 184t
 - stillbirths and neonatal death 182, 184–185, 184t
 - infertility and 25
 - IUGR with 192, 582–583
 - legal cases involving 1077, 1081
 - limitations of prenatal diagnosis 32
 - numerical *see* aneuploidy; monosomy; trisomy
 - oocytes, rate 439, 440, 440t
 - previous DS child and 198, 198t, 199, 199t, 507–509, 508t
 - screening marker(s) 484–485
 - patterns 185–187, 186–187, 186t
 - screening tests *see above*
 - sex chromosomes *see* sex chromosome abnormalities (SCA)
 - structural *see* chromosomal structural rearrangements
 - translocations *see* chromosomal translocations
 - ultrasound anomalies 188, 189t–190t
 - incidence 574–576
 - see also* individual chromosomes
- chromosomal karyotyping *see* karyotype/karyotyping
- chromosomal microarrays (CMA) 40, 119, 319, 366–379
- cardiac defects 192
 - chromosomal abnormality detection 188
 - communication of all information 32
 - definition 367
 - disclosure of incidental findings 1111
 - ethics 1110, 1111
 - indications and uses 188
 - maternal age 193
 - informed consent 32–33
 - intellectual deficiency syndromes 367–369
 - karyotyping *vs* 185, 242
 - multiple congenital anomalies 367–369
 - products of conception 373
 - recurrent/nonrecurrent imbalances 367
 - spontaneous abortion frequency 182
 - trisomy 16 mosaicism 215
 - see also* array comparative genomic hybridization (aCGH)
- chromosomal structural rearrangements
- array CGH, missed by 372
 - balanced 179, 372
 - array CGH not detecting 372
 - carriers 194–198, 194t

1142 Index

- chromosomal structural rearrangements (*Continued*)
- de novo* 228–230, 229t, 234
 - mosaicism diagnosis 221
 - deletions 314, 367
 - cryptic 319, 320
 - detection methods 382
 - somatic mutations 393
 - see also* microdeletions; *specific deletions*
 - de novo* 228–232
 - apparently balanced 228–230, 229t, 234
 - diagnosis recommendations 234
 - frequencies 228, 229t
 - outcome 229–230, 229t
 - PGD for 436
 - supernumerary chromosomes 230–232, 231t
 - unbalanced 230, 234
 - uniparental disomy in 232–234
 - see also* supernumerary marker chromosomes (SMCs)
 - diagnosis, recommendations/conclusions 234
 - duplications *see* duplication of chromosomes
 - familial 228
 - incidence 179
 - amniocentesis data 181–182, 184t
 - liveborn babies 180t
 - maternal age 181
 - insertions 198
 - inversions 196–198, 197t
 - “common” 235–236
 - paracentric 197–198, 286
 - pericentric 197, 197t, 236, 286
 - X chromosome 197, 286
 - Y chromosome 197, 236, 289
 - isochromosomes 220, 221
 - mosaicism 220–221
 - parental karyotype studies 227–228
 - subtle/cryptic rearrangements 318–320
 - deletions 319, 320
 - translocations 320, 321f
 - translocations *see* chromosomal translocations
 - unbalanced
 - de novo* 230
 - incidence 194
 - previous child with, prenatal cytogenetic diagnosis 200
 - size and risk 194–195
- chromosomal translocations
- 3 : 1 segregation patterns 195
 - balanced
 - non-Robertsonian, uniparental disomy 233–234
 - Robertsonian *see* Robertsonian translocation
 - “balanced” reciprocal, in males, infertility 26
 - carriers, male *vs* female 195
 - centric fusion type *see* Robertsonian translocation
 - chromosomes 15/16, FISH use 320
 - common/rare 235, 236
 - cryptic rearrangements 320, 321f
 - de novo* 229, 234, 372
 - familial X/autosomal 228
 - reciprocal 194
 - balanced, subtle deletions in 319
 - parental, prenatal diagnosis indication 194–195, 194t
 - Robertsonian *see* Robertsonian translocation
 - t(11;22)(q23.3;q11.2) 236
 - X-autosome *see* X-autosome translocations
 - X;X translocations 287–288
 - X;Y translocations 290
 - Y-autosomal *see* Y-autosome translocations
 - Y;Y translocations 290
- chromosome(s)
- acrocentric 235, 326
 - analysis techniques 179
 - see also* cytogenetic diagnosis (prenatal); karyotype/karyotyping
 - duplication *see* duplication of chromosomes
 - libraries, FISH analysis 313, 319
 - marker *see* marker chromosomes
 - mosaicism *see* mosaicism
 - number 294
 - polymorphisms 234–236
 - acrocentric chromosomes 235
 - chromosomes 1, 9, 15, 16, 21, Y 235
 - heterochromatin 235–236
 - maternal cell contamination 234
 - types/variants 234–235
- chromosome 1
- pericentric inversions 236
 - polymorphisms 235
 - trisomy 1 mosaicism 211
- chromosome 2, trisomy 2 mosaicism 211
- chromosome 3, trisomy 3 mosaicism 211–212
- chromosome 4
- D4Z4 repeats 399
 - ring chromosomes from 325–326
 - trisomy 4 mosaicism 212
- chromosome 5, trisomy 5 mosaicism 212
- chromosome 6, trisomy 6 mosaicism 212
- chromosome 7, trisomy 7 mosaicism 212
- chromosome 8
- 8p23.1 duplication 318, 328
 - duplications 327–328, 328f
 - trisomy 8 mosaicism 212–213
- chromosome 9
- pericentric inversions 236
 - polymorphisms 235
 - trisomy 9 mosaicism 213
- chromosome 10
- del(10)(q11.2) 221
 - del(10)(q23) 221
 - deletion, legal case involving 1075
 - mosaicism 213, 221
- chromosome 11 213
- 11q23.2 (FRA11B) site 221
 - 15q11 balanced translocations 228
 - microdeletions 317
 - translocation t(11;22)(q23.3;q11.2) 236
 - trisomy 11 mosaicism 213
- chromosome 12, trisomy 12 mosaicism 213
- chromosome 13
- trisomy *see* trisomy 13 (Patau syndrome)
 - trisomy 13 mosaicism 213–214
- chromosome 14
- trisomy *see* trisomy 14
 - trisomy 14 mosaicism 214
 - uniparental disomy 214, 232
- chromosome 15
- deletions 314
 - dicentric 323, 324f
 - markers 323
 - polymorphisms 235
 - supernumerary marker chromosome 231, 233–234
 - translocation, FISH analysis 320, 321f

- trisomy 15 mosaicism 214
 uniparental disomy 232
 chromosome 16 214–215
 polymorphisms 235
 translocation, FISH analysis 320, 321f
 trisomy *see* trisomy 16
 trisomy mosaicism 214–215
 chromosome 17
 17p12 microduplication 318
 deletions 314
 trisomy 17 mosaicism 215–216
 chromosome 18
 trisomy *see* trisomy 18 (Edwards syndrome)
 trisomy mosaicism 216
 chromosome 19 1032
 19 miRNA cluster (C19MC) 1032, 1033, 1039
 trisomy mosaicism 216
 chromosome 20, trisomy mosaicism 216–217
 chromosome 21
 cryptic rearrangements 199–200
 monosomy mosaicism 218, 219
 polymorphisms 235
 Robertsonian translocation 195–196, 196t
 trisomy *see* Down syndrome (DS)
 trisomy mosaicism 217–218
 chromosome 22
 deletions 186–187, 314
 22q11 317–318
 22q11.2 186–187, 318, 333, 766
 22q11 and cardiac defects 317, 318, 370
 FISH analysis 318, 333
 duplication, 22q11 370
 monosomy mosaicism 218
 supernumerary marker chromosome 231–232
 trisomy mosaicism 218
 chronic granulomatous disease (CGD) 762t, 767
 CHST3 mutations 693
 cisterna magna 666, 669
 citrin deficiency 881
 citrulline, in AF 105
 citrullinemia
 type 1 880
 type 2 881
 cleft lip/palate, MRI 672–673
 clinical trials
 ethical considerations 1122, 1124
 fetal surgery 1124
 stopping 1124
CLN1, CLN2, CLN3 genes, mutations 809, 811
 cloacal exstrophy, ultrasound 553–554
 cloacal malformations, MRI 674
 clubfoot (talipes) 692
 CMA testing *see* chromosomal microarrays
 CMV *see* cytomegalovirus (CMV) infection
 CMV infections, legal cases concerning 1067, 1087
 coarctation of aorta (CoA) 270, 610
 cobalamin (vitamin B12)
 in AF 111
 deficiency, masking by folic acid in food 141
 derivatives, functions 927, 930
 inborn errors of metabolism 927, 928t, **930–934**
 prenatal diagnosis, fetal therapy 933–934
 uptake disorders 930
 utilization disorders 931
 COBRA FISH 366
 cocaine 116, 118, 1088
 coelocentesis 119
 cognitive impairment 1, 2, 11, 187
 47,YYY males 283–284
 diagnosis, array CGH **367–369**, 368t
 fragile X syndrome 351–352
 genome sequencing for 31
 Klinefelter syndrome 277–279
 risk, *de novo* balanced structural rearrangements 229
 sex chromosome disorders 295
 triple X syndrome (47,XXX) 281
 Turner syndrome 271–272, 274
 see also IQ
COL1A1 and *COL1A2* mutations 684, 688, 689
COL2A1 gene mutations 691
COL3A1 gene 396
 collagen 681
 degradation products in AF 101
 collagen type II disorders 681, **690–692**
 mutations 684
 prenatal diagnosis 691–692, 692f
 colorectal cancer 19, 401
 colpocephaly 643f
 common variable immunodeficiency (CVID) 761t, 767
 communication by physician, failure to inform of results 33, 1074, 1075, 1080, 1086
 communication in genetic counseling 9, 14, 15, 17, 32, 33
 efficacy 46
 failure, after prenatal testing 33
 need for 9
 nondirective counseling 14, 17, 1109, 1113
 when fetus has abnormality 40–41
 comparative genomic hybridization (CGH) 178, 366
 genome-wide array *see* array comparative genomic hybridization (aCGH)
 competence, prenatal diagnosis **1110**
 competitive oligonucleotide priming (COP) 739
 complement deficiencies 756, 762t, **768**
 tests 758t
 computed tomography (CT), skeletal dysplasias 682
 “conceptus” 1097
 confidentiality
 genetic counseling and **16**, 19
 of prenatal diagnosis results 1111
 confined fetal mosaicism (CFM) 203–204
 confined placental mosaicism (CPM) 21, **84**, 203, **1034–1035**
 CVS and **84**, 204–205, 1034–1035
 definition 1034
 detection 204–205, 1034
 developmental aspects 1034–1035
 false-positive NIPT 185, 467, 1035
 incidence 1034
 IUGR 1033, 1034
 level of abnormal cells 1035
 trisomy 16 1034, 1035, 1036, 1037t
 congenital adrenal hyperplasia (CAH) **976–979**
 enzyme deficiencies (less frequent) 976
 fetal DNA analysis 978
 fetal sex determination by cffDNA 456, 457
 genotype analysis 977
 21-hydroxylase deficiency 976–979
 mutations causing 977
 nonvirilizing congenital lipoid adrenal hyperplasia **979**
 PGD 978

1144 Index

- congenital adrenal hyperplasia (CAH) (*Continued*)
 prenatal diagnosis 115–116, 977
 NIPT 459t, 461t, 463
 prenatal treatment (dexamethasone) 456, 976, 977
 controversies 977–979
 protocol and timing 977, 978
 teratogenicity, late effects 978–979
 unnecessary treatment 978
 virilizing 976–977
- congenital bilateral absence of vas deferens (CBAVD) 26, 701, 704–705, 707, 713
 mutations associated 704, 704t, 707
- congenital cystic adenomatoid malformation of lung (CCAML) *see*
 cystic adenomatoid malformation of lung
- congenital diaphragmatic hernia (CDH) 550
 associated malformations 673, 996
 chromosomal abnormalities 580
 differential diagnosis 621
ex utero intrapartum treatment (EXIT) 993
 fetal surgery 550, 996–998
 endoscopic tracheal occlusion 997–998
 open 996–997
 percutaneous balloon tracheal occlusion 997, 997f
 incidence and mortality 550, 673, 996
 MRI 672f, 673
 postnatal care 996
 prognostic indicators 996
 third trimester diagnosis 618, 621–622, 621f
 third trimester management 622
 ultrasound 550, 550f, 580, 621–622
- congenital heart disease 599
 chromosomal anomalies 600
 detection rates 600, 601t
 family history 29
 fetal alcohol syndrome and 982
 incidence/prevalence 2–3, 4
 maternal obesity and 4
 maternal phenylketonuria and 982
 recurrence risk in sibling 548
 risk factors 29, 599–600
 third trimester diagnosis 599–615
see also ultrasound (US), prenatal diagnosis
see also cardiac defects
- congenital high airway obstruction (CHAOS)
 MRI 673
 ultrasound 618, 620f
- congenital hydrothorax 618
- congenital ichthyosis, autosomal recessive 777t
- congenital infections *see individual infections*
- congenital lipoid adrenal hyperplasia (CLAH) 979
- congenital malformations
 fetal medical therapy 982
 wrongful birth/life claims *see* wrongful birth; wrongful life
- congenital pulmonary airway malformations (CPAM)
 fetal surgery 999–1000, 1000f
see also cystic adenomatoid malformation of lung
- congenital rubella syndrome 1067
 legal cases involving 1074, 1076–1077, 1084, 1085, 1087
see also rubella
- congenital toxoplasmosis 942, 943, 947–948
see also toxoplasmosis (fetal)
- congenital varicella syndrome 965t, 966, 9634
see also varicella
- connective tissue disorders 681–699
 joint dislocations 693
- consanguinity 4, 31, 34, 385
- conscientious objectors, abortion 1069, 1115
- consent, informed *see* informed consent
- consent forms 33, 34
- contiguous gene syndromes 314, 315t–316t
- Contingent cfDNA test 521
see also Down syndrome (DS)
- contraceptives 31, 1065, 1080
- Convention on the Rights of the Child 1092
- Cooley's anemia 1080
- coping strategies 1054
- copper
 in AF 111
 transport, Menkes disease 982–983
- copy number variants (CNVs) 187, 188, 367, 369
 benign, diseases due to 370
 benign vs pathogenic 369, 369–370
 cardiac defects with 192
 information for reproductive choice 373
 in intellectual disability 368
 in normal people 369
 pathogenic 368, 398
 detection by array CGH 368, 369, 370, 372
 PGD 374
 reporting approaches 373
 somatic mosaicism 390
 susceptibility CNVs, array CGH 372
- cordocentesis *see* fetal blood sampling
- Cori disease (GSD type III) 904t, 909–910
- Cornelia de Lange syndrome 108, 393, 517–518
 legal case involving 1083
- cornstarch 907
- coronary heart disease 779
- corpus callosum 666
 agenesis
 associated anomalies 665–666, 670
 MRI 642, 664–666, 665f
 ultrasound 577, 577f, 641–642, 645
 anomalies 641
 ultrasound 573, 641–642, 643f–645f
- cortisol
 in AF 116
 deficiency, CAH 976
- Costeff syndrome 885
- Costello syndrome 13, 393, 395
- cotinine, in AF 112, 116
- counseling 17, 32
 about second trimester abortion 1021–1022
 before elective abortion 41
 genetic *see* genetic counseling
 grief, after elective abortion 41–42
 before PGD 1096
 selective abortion in multiple pregnancies 1024
- CPAM *see* congenital pulmonary airway malformations (CPAM)
- CPAM volume ratio (CVR) 999
- CpG dinucleotides 758
- CpG nucleotide methylation 395
- CPM *see* confined placental mosaicism (CPM)
- craniospinal defects *see specific disorders/defects*
- craniosynostosis 11, 459t
- creatine kinase, glycogen storage disorders 908–909, 910, 912
- creatinine, in AF 99, 112
- cricoid pressure 990
- cri-du-chat syndrome, legal case concerning 1080
- cross reactive immunomaterial (CRIM) 909

- Crouzon's syndrome 459t
- crown-rump length (CRL) 567, 568, 572b
 bladder longitudinal diameter ratio 568
 NT thickness 570, 571, 572b
- cryptic rearrangements *see* chromosomal structural rearrangements
- CTG repeats 12
- CTTG expansion 389
- culture media 125–126, 126–127, 128, 129
- Curlender* court opinion (California) 1068
- curvilinear bodies (CL) 809
- CVS *see* chorionic villus sampling (CVS)
- cyclodextrin 806
- CYP21A2 mutations 977, 978
- cyst(s)
 abdominal 556–557, 581
 branchial cleft 671
 bronchogenic 673
 choledochal 556
 choroid plexus 547, 548f, 577
 intrathoracic 550
 mesenteric 557
 omental 557
 ovarian 556–557
 subependymal 670
- cystathione β -synthase (CBS) deficiency 889
- cystatin C 112, 632
- cysteamine 934
- cystic adenomatoid malformation of lung 549–550, 616, 618, 619f
 fetal surgery 616, 618, 999–1000, 1000f
in utero medical treatment 616, 1000
 MRI 673
 natural history, survival rates 616
 ultrasound 549–550
- cystic fibrosis (CF)
 carriers 26, 705
 frequencies 700, 701t
 carrier screening 21, 27
 “analyte-specific reagents” 708
 costs 711, 712
 ethics 707
 expanded panels 708, 710–711
 future directions 713
 kits and platforms 708, 709t–710t
 laboratory methods 708, 709t–710t
 male partners 25
 population, mutation panel 705–708, 706t
 program outcomes (US) 711–712
 sequential 706, 707, 712
 universal population screen 706–708
- CBAVD in 26, 701, 704–705, 707, 713
- CFTR* gene 702–703
 discovery 702, 706
 whole-exome sequencing 383, 705
- CFTR* gene mutations 381, 701, 703, 706
 classes 703, 703t
 Δ F508 mutation 38, 702, 703, 704, 705
 detection 381
 diagnosis by 381, 701
 ethnicity and 705
 expanded panels 708, 710–711
 G542X 703
 G551D 702, 703
 I148T 707, 711
 modifier genes 705
 nomenclature 703
 panel for carrier screening 705–708, 706t
 PCR 381
 R117H 703, 704, 704t, 707
 rare 710–711
 severe/mild CF 703, 704
 W1282X 705
- CFTR modulators 702
- CFTR potentiator 702
- CFTR protein 702–703
- clinical features 700–701
- diagnosis 701
- disaccharidase activity in AF 106, 108
- environmental factors affecting 705
- epidemiology 700
- ethnicity and 700, 701t, 705, 707
- genetic counseling 24, 25, 47, 712, 713
 preconception 21
 genetics 381, 700
- genotype-phenotype associations 38, 703–704, 704t, 714
- legal cases concerning 1080–1081, 1083, 1086
- maternal 23, 24–25
- newborn screening 713
- postnatal/neonatal diagnosis 701
- prenatal diagnosis 700–717
 assisted reproduction 713
 echogenic bowel 712–713
 indications 705, 712
 noninvasive 25, 459t, 461t, 462
 positive family history 712
 positive-negative couples 712
 special situations 712–713
- treatment 701–702
- cystic hygroma 119, 188
 AFAP in 134
 chromosomal abnormalities 188
 FaSTER trial 498
 nuchal 579–580
 nuchal edema *vs* 188, 191
 prevalence 498
- cystine 934, 935
- cystinosis 934–935
- cystinuria 892
- cystoscopy, fetal 635
- cytochrome P450 aromatase deficiency 976
- cytochrome P450c21 deficiency 976–977
- cytogenetic diagnosis (prenatal) 178
 error rates 241
 indications 185–203
 abnormal parental karyotype 202
 advanced maternal age 193
 advanced paternal age 193–194
 anxiety 203
 carriers of balanced structural rearrangements 194–198, 194t
 fetal demise 201
 fetal loss, fetal karyotype 201
 first-trimester screening for aneuploidy 185–187, 186t
 folate metabolism variations 200
 “genetic sonogram” 193
 infertility or subfertility 201–202
 miscellaneous reasons 203
 MSAFP elevation 187–188
 NIPT low fetal fraction 185
 NIPT positive result 185
 for nonchromosomal disorder 203
 parental chemotherapy/radiation 203

1146 Index

- cytogenetic diagnosis (prenatal) (*Continued*)
 prenatal sex determination 202–203
 previous child with NTD 200
 previous child with trisomy 198–200, 198t, 199t
 previous child with unbalanced rearrangement 200
 reduced ovarian complement 202
 repeated fetal losses 200–201
 second-trimester screening for aneuploidy 187
 ultrasound abnormality 188–193
 X-linked disorders 202–203
 interpretation 203–227
 mosaicism/pseudomosaicism *see* mosaicism
 karyotyping vs molecular genetic testing 241–242
 laboratories, technical standards 239–242
 molecular *see* molecular cytogenetics
 oocytes 438–439, 439f, 440, 440t
 screening marker patterns 185–187, 186t
 techniques 178, 179
 see also amniotic fluid cells (AFC) culture; chorionic villus sampling (CVS)
 see also chromosomal abnormalities
- cytogenetics laboratories
 guidelines 240–241
 technical standards 239–242
- cytokeratin filaments 124, 125
- cytomegalovirus (CMV) infection 948–961
 antibodies 112–113, 948, 950
 congenital/fetal infection 114, 951–958
 anomalies 948, 949, 950–951, 951, 957
 asymptomatic 951
 brain MRI 956–957
 epidemiology 948–949, 950t
 pathogenesis 949–950
 PCR 953, 954, 958
 pregnancy termination 961
 prenatal diagnosis 953–957
 prevention 958, 960–961
 prognosis 957–958
 screening 961
 symptomatic 951
 treatment 958–961
 ultrasound signs 954–955
 ultrasound value/prognosis 955–956, 957
- DNA (CMV)
 in AF 958
 in maternal blood 953
- maternal 949
 clinical features 951–952
 diagnosis, serology 952
 management 952–953, 959
 prevention 961
 primary infection 949, 951–952, 957, 959
 reinfection 949
- neonatal evaluation 953–954
 pathology 950–951
 prevention recommendations 961
 seroprevalence, maternal 948
 transmission 949–950, 958, 960
 vaccination 958, 960–961
 viral load quantification 958, 959
 virology 948, 950
- cytotrophoblasts 1031
- D2-protein 101, 139
 D4Z4 repeats 399
- Dandy–Walker malformation 547, 647, 666
 legal cases involving 1084
 MRI 665f, 666
 ultrasound 542, 547, 548f, 647, 648f–649f
- DANSR assay 464
- databases, in genetics 384b
- D-bifunctional protein (DBP) deficiency 848, 848t, 849–850
- DCX gene mutations 13
- DeI* restriction enzyme 746, 748f
- deafness *see* hearing loss
- deaths, evaluating the cause 43, 44t
- debrancher enzyme deficiency (type III GSD) 904t, 909–910
- DECIPHER database (of CNVs) 369
- decision making
 after counseling 47
 elective abortion *see* abortion (induced/elective)
 maternal serum screening 520
 after prenatal diagnosis 10, 14, 40–41, 1011, 1053
 respect for autonomy, ethics 1107
 right to privacy 1065
 risk assessment for genetic disorders 1112
 too many choices 1112
- Declaration of the Rights of the Child 1092
- decorin 860
- β -defensin-2 113
- 7-dehydrocholesterol (7-DHC) 103, 517
- dehydroepiandrosterone sulfate (DHEAS) 485
- deletions *see* chromosomal structural rearrangements
- dementia 12
see also Alzheimer's disease
- denaturing gradient gel electrophoresis (DGGE) 734, 741
- denaturing high performance liquid chromatography (DHPLC) 740
- Denmark, collaborative amniocentesis study 75, 76t, 77
- de novo* mutations (DNM) *see* chromosomal structural rearrangements
- Denys–Drash syndrome 293
- deoxyribonuclease- α 702
- depression, after bereavement 1051
- dermatan sulfate (DS) 857, 860
 accumulation, MPS II 863
- Desbuquois syndrome 693
- “designer babies” 445
- detection rate (DR) 485
- development
 of brain *see* brain, development
 of lung 997
- developmental problems
 brain 664–669, 665f, 668f
 Klinefelter syndrome 278, 279
- dexamethasone
 AV heart block 980, 981
 CAH prenatal therapy *see* congenital adrenal hyperplasia (CAH)
 gestational, safety/late effects 978
- dextrocardia 605, 621f
 legal case involving 1087
- DGCR8 protein 355
- DHH gene mutations 293
- diabetes mellitus 5
 gestational 4
 maternal 25, 512, 982
 DS screening 512
 legal case involving 1075
 polyhydramnios 565
 pregnancy effects on 25, 982

- Diamond-Blackfan anemia 315t, 438
 diaphragm, eventration 621
 diaphragmatic hernia *see* congenital diaphragmatic hernia (CDH)
 diastrophic dysplasia (DTD) 692, 693f
 diastrophic dysplasia sulfate transporter (DTDST) mutations **692-693**
 dicarboxylic aminoaciduria 892
 diet/dietary therapy
 amino acid metabolism disorders 879, 882, 884, 888
 phenylketonuria 886, 887, 982
 galactose metabolism disorders 915
 gluconeogenesis disorders 917
 glycogen storage disorders 903, 907, 910, 912, 913
 glycogen synthase deficiency 914
 diethylstilbestrol 18
 differentially methylated regions (DMRs) 1035, 1040
 diffusion tensor imaging (DTI) 661, 664
 digenic inheritance 396, 397
 DiGeorge syndrome 145, 314, 315t, 318, 760t, **766**
 dihydrofolate reductase deficiency **929-930**
 dihydropteridine reductase (DHPR) deficiency 887, 888
 Dilantin 1079
 Dilapan 1012, 1013
 dilated cardiomyopathy 397, 403t
 dilation and evacuation (D and E) **1017-1020**, 1021-1022
 forceps for 1018b
 KCl before 1017
 morbidity/complications 1019-1020
 mortality 1017, 1020, 1020t
 reasons for not performing 1017
 technique 1017, 1018-1019
 ultrasound before 1018
 dinoprostone (PGE₂) 1020
 diploid/tetraploid mosaicism 225
 diploid/triploid mosaicism 225
 direct-to-consumer genetic testing 34
 disaccharidases, in AF **106-108**
 clinical uses 107-108
 cystic fibrosis 106, 108
 development 107, 107f
 intestinal obstruction 106, 107-108
 origin 106
 disclosure
 guidance 16
 of information 1065
 of nonpaternity 16, 19
 of prenatal diagnosis results 16, 1110, 1111
 ethics 1110-1111
 failure to inform on 33, 1074, 1075, 1080, 1086
 to relatives/third parties/family 16
 of risk information, duty to recontact and 18
 disorders of sex development (DSDs) **290-293**
 45,X males 291
 46,XX males 290-291
 46,XY females 291-293
 47,XXX males 291
 ovotesticular 293-294
 DNA 1035
 amplification, PCR *see* polymerase chain reaction (PCR)
 cell-free, in AF 101-102, 731
 cell-free, in maternal plasma *see* cell-free DNA (cfDNA) (in maternal plasma)
 cell-free fetal, in maternal plasma *see* cell-free fetal DNA (cffDNA)
 fetal *see* fetal DNA
 fragment, Sanger sequencing 381-382
 in situ hybridization 313
 methylation *see* DNA methylation
 mitochondrial 401, 403
 probes 313, 317, 320, 739
 repair 367, 368
 repetitive 313
 replication 367
 single-copy probes 313
 DNA analysis/testing 380, **381-384**
 amino acid metabolic disorders 878
 mutation detection, prenatal diagnosis 386-387
 PGD 423
 presymptomatic/predictive **385-387**
 sample types 380, 381
 single base changes, PCR with fluorescent probes 381
 source of DNA for 381
 techniques 380, **381-384**, 423
 α-thalassemia 734-737
 β-thalassemia 737-744
 see also specific techniques
 DNA breakage syndrome 768
 DNA ligase 740
 DNA methylation 395
 fetal, hypermethylation 464
 fragile X syndrome 352
 hypomethylation, placenta 1039
 imprinted differentially methylated regions 1035, 1040
 IUGR and 1035
 maternal, hypomethylation 464
 NIPT by cell-free fetal DNA 456
 placenta 1035, 1039, 1040
 testing 352
 X-inactivation evaluation 1040
 DNA sequencing
 CF carriers 710t, 711, 713
 costs 711
 multigenes, CVS DNA 386
 prenatal diagnosis advances 713
 Sanger method 381-382, 719
 unknown β-thalassemia mutations 741
 dominantly inherited inclusion body β-thalassemia 723-724
 do no harm (nonmaleficence) 18-19, 1107
 donor sperm, legal cases involving 1077
 "double bubble" sign 192, 555, 624, 625f
 double hit mechanism 350
 Down syndrome (DS) (trisomy 21) 217
 abnormal gene expression 383
 abortion 4
 AFAFP levels 133
 age-specific rates 179, 181t, **489-490**
 Alzheimer's disease and 6
 cardiac defects 568, 580
 clinical factors affecting screening tests **507-514**
 assisted reproduction 511-512
 ethnicity 513-514
 maternal age 507, 507t, 511
 maternal diabetes 512
 maternal weight 514
 multiple pregnancies 511
 other factors 514
 previous affected pregnancy **198-200**, 198t, 199t, **507-509**, 508t
 previous false positive 512-513
 renal transplant 512

1148 Index

- Down syndrome (DS) (trisomy 21) (*Continued*)
- smoking 513
 - twin pregnancy 509–511, 509t
 - counseling 520
 - defects/complications associated 6, 7t, 568, 580, 624
 - duodenal atresia in 624
 - excess skin, ultrasound 570
 - femur length 503, 582
 - fetal loss rate 179, 490
 - growth retardation 491
 - humerus length 503, 582
 - incidence/prevalence 3, 179, 484, 489, 498
 - legal cases concerning 1072–1073, 1074, 1078, 1079, 1080, 1081–1082, 1083, 1086, 1088
 - life expectancy, 5-7, 5f, 6-7t 5–6, 5t
 - likelihood ratios (LRs) 491, 495, 499, 500, 503
 - maternal age and 179, 181t, 489–490, 507
 - assisted reproduction and 511
 - rates by age 181t
 - screening test policies 507, 507t, 511
 - twin pregnancies and 509
 - mortality and causes of death 5–6, 5t, 6f
 - mosaicism 199, 202, 217–218
 - NIPT based on cfDNA 464, 470–471
 - nuchal edema 580
 - oral contraceptives and 31
 - other trisomy risk after 198, 199
 - placental pathology 1037t
 - prenatal diagnosis
 - cfDNA by NGS 464, 470
 - FISH analysis 335, 336
 - NIPD, benefits and uptake 471
 - previous child, risk of chromosome anomalies 198–200, 198t, 199t, 507–509, 508t
 - previous child with NTD 200, 508–509
 - previous false positive 512–513
 - recurrence 198–199, 198t, 199t, 507–509
 - reasons/causes 199
 - risk assessment 1112
 - nondirective offer, woman's response 1112–1113
 - twin pregnancies 510
 - risk at term (age-specific) 489–490
 - risk at time of test 490–491
 - risk factors 489
 - risk screening 488–489, 571
 - screening
 - autonomy and decision-making 520, 1112
 - cfDNA 521
 - economic evaluations 520–521
 - impact, birth prevalence 498
 - minimum standards 521
 - planning of program 519–521
 - screening tests/markers 185–186, 186t, 485, 1111–1112
 - ADAM12s 506
 - amniocentesis vs other methods 78–79
 - clinical factors affecting *see above*
 - “Combined” test 493, 494–495, 495t, 496t, 498, 499, 500, 501, 507t
 - Contingent cfDNA test 521
 - “Contingent” test 494, 495, 496t, 498–499, 500, 507t
 - correlation coefficient 491–493, 492t
 - detection rates 485, 493, 494, 497, 510, 571t
 - Double test 493, 494t, 497
 - false-positive rate 485, 491–493, 492t, 494, 498, 512–513, 571t
 - first and second trimester markers 493–494
 - first trimester 185–186, 186t, 497
 - first trimester, advantages 493, 520
 - first trimester Combined test 494, 495t, 499, 500, 501, 502t
 - first trimester Contingent test 498–499, 514
 - first trimester serum markers (additional) 501
 - first trimester Triple/Quad tests 501
 - highly correlated markers 504–505
 - “Independent Sequential” test 494
 - “Integrated” Test 494, 496t, 497, 498, 514
 - invasive trophoblast antigen 506, 507
 - marker distributions 487–488, 488t
 - by maternal age 507, 507t
 - maternal serum hCG, free α -hCG 485, 493, 494, 495t, 496t, 501, 502t, 504
 - maternal serum inhibin A 486, 493, 501, 502t
 - maternal serum PAPP-A levels 486, 501, 504, 512
 - maternal serum PIGF 486, 501, 502t
 - maternal serum uE₃ 486, 501, 502t
 - maternal urine total estriol 485
 - modeling performance 491–493, 492t
 - MSAFP 485, 488t, 501, 512
 - multi-marker policies 493–495, 494t, 495t, 496–498, 496t, 498–503, 521
 - multiples of median (MoM) 487, 501, 509–510, 512
 - NT *see* nuchal translucency (NT)
 - other aneuploidies detected 516
 - pregnancy specific glycoprotein-1 506
 - prospective confirmation of model 496–498
 - Quadruple test 493, 494t, 498, 501, 502t, 507t
 - repeat measures 504–505
 - second trimester 186t, 187, 198, 485, 493, 494t, 497, 501
 - second trimester Combined Test 501–503, 502t
 - sequential tests 494, 495, 496t, 497, 503, 504, 514
 - sequential tests, advantages 520
 - Serum Integrated 495, 497
 - single samples 493
 - standard deviations 491–493, 492t
 - “Step-wise Sequential” test 494, 495, 496t, 497, 498
 - Triple test 493, 494t, 497, 501
 - twin pregnancies 510–511
 - two sample Combined Test 504–505
 - ultrasound markers *see* ultrasound (US)
 - urinary hCG 506–507
 - short stature 503
 - tricuspid regurgitation 500
 - ultrasound anomalies *see* ultrasound (US), prenatal diagnosis

DROSHA protein 355

drugs

 - in AF 116–118, 117t
 - teratogenic *see* teratogenic drugs

drugs of abuse, in AF 116, 117t

DS *see* Down syndrome (DS) (trisomy 21)

Duchenne muscular dystrophy (DMD) 399

 - female carriers 27
 - gonadal mosaicism 39
 - legal cases concerning 1082
 - prenatal diagnosis and PGD 399

ductus venosus blood flow, abnormal 500, 518

Dulbecco's modified Eagles' medium (DMEM) 128

duodenal atresia 554, 555, 624–626

 - chromosomal anomalies 581, 624
 - MRI 674
 - third trimester 624–626, 625f
 - management/outcome 624, 626
 - ultrasound 555, 581, 624–626, 625f

- duodenal obstruction 555, 624
 duodeno-duodenostomy 626
 duodeno-jejunostomy 626
 duplication of chromosomes 327–328
 chromosome 8 327–328, 328f
 FISH analysis 318, 327–328
 inter-/intrachromosomal 327
 unbalanced 327
 duplication of genes 318
 detection methods 382
 dural sinus malformation (DSM) 669
 duty (duties)
 to inform patients, legal case 1074, 1075
 to recontact patient 18
 to warn relatives/third parties 19–20
 dwarfism
 campomelic 293, 684, 684f
 see also skeletal dysplasias
 dysrhythmias *see* cardiac arrhythmias
 dystrophin gene 337, 399

 E/A ratio, heart function 612, 614
 ears, small size, chromosomal anomalies 579
 Ebstein anomaly 609
 echocardiography (fetal)
 2D/3D speckle tracking 614
 annular displacement 612, 615
 cardiac defect diagnosis (third trimester) 549, 599–615
 abnormal cardiac size 605
 abnormal heart axis 605, 608f
 abnormal heart position 605
 abnormal heart rate 601–605, 603f–604f, 979
 atrioventricular valve abnormalities 609
 functional assessment 612, 614–615
 heart block 605, 606f–607f
 hypoplastic left heart 610–612, 613f, 615
 septal defects 605, 608–609
 ventricular morphology anomalies 609–610
 vessels behind heart 610
 see also individual defects
 four-chamber view (4CV) screening 542, 600, 601f, 608
 abnormalities 600–615
 B-mode 608, 609
 detection rates 600, 601t
 “heart cross” absence 608, 609
 indications 599, 979, 981
 real-time directed M-mode, cardiac defects 549, 612
 speckle tracking (STE) 614
 technical/programmatic requirements 599
 tissue Doppler imaging (TDI) 614, 615
 echogenic bowel *see* bowels, hyperechogenic
 economic evaluation, DS screening 520–521
 EcoRI sites 747
 ectopia lentis 396
 ectopic pregnancy 1015
 education
 counselees 17
 pregnancy planning 19
 Edwards syndrome *see* trisomy 18 (Edwards syndrome)
 Ehlers–Danlos syndrome 22, 396, 402t, 693
 elastin gene 324, 325f
 electrocardiography (ECG), Turner syndrome 270
 electron-transfer flavoprotein (ETF) cycle 839, 840, 847, 893
 disorders 840, 893
 electron-transfer flavoprotein (ETF) dehydrogenase 847
 electron-transfer flavoprotein (ETF):ubiquinone oxidoreductase (ETF-QO) 847, 893
 electrophoresis
 capillary gel 381, 729
 hemoglobin 729
 polyacrylamide gel, AChE in AF 135, 136
 Eliglutstat tartrate 793, 797
 ELISA, FMR1 protein (FMRP) 352
 embryo
 aneuploid, transfer 440
 biopsy
 blastomere 421–422
 cleavage stage 422, 423
 chromosomal abnormality rate 438
 legal and ethical issues 1095
 preimplantation, metabolism 420
 religious views, moral standing 1124, 1125
 research, legal status 444–445
 sexing 337
 spare, analysis 420
 testing, UK law 1098
 viability after PGD 421, 441
 viability after polar body analysis 421
 see also preimplantation genetic diagnosis (PGD)
 embryonic stem cell research *see* human embryonic stem cell (hESC) research
 emotions
 after elective abortion 41, 42t, 1053
 after pregnancy reduction 1054–1055
 empathy in genetic counseling 10
 emphysema, congenital lobar 673
 empowering pregnant women 1107
 encephalitis, CMV 950
 encephaloceles 147, 484
 AChE in AF 135–136
 ultrasound detection 542
 endocardial fibroelastosis (EFE) 612
 endocervical canal, dilation 1012, 1018
 endoglin 1036
 β -endorphin, in AF 116
 energy production disorders 892–893
 environmental factors
 affecting cystic fibrosis 705
 hazards to fetal health 31
 enzyme(s)
 in AF 101, 103–104, 106–108
 in fetal serum 103
 enzyme replacement therapy
 cystic fibrosis 702
 Fabry disease 792
 Gaucher disease 796
 glycosphingolipidoses 784
 GSD type II (Pompe disease) 909
 mucopolysaccharidoses 857, 868–869, 870
 neuronal ceroid lipofuscinoses 811
 Niemann–Pick disease 804
 Wolman disease and CESD 808
 epidermolysis bullosa 400
 epidermolytic ichthyosis 399
 epididymal sperm aspiration 26
 epigenetic modifications, DNA 395, 1033, 1039
 fetal vs maternal DNA 464
 epigenetic studies, placenta *see* placenta

1150 Index

- epilepsy
 legal cases involving 1079
 maternal
 congenital malformations and 5
 medication use 25, 118, 982
 pregnancy risks to mother/fetus 25
 neurogenetic basis 398–399
 epihycan 860
 Epstein–Barr virus (EBV) 768–769
 erythroblast(s), NIPD using 732
 erythroblastosis fetalis (hemolytic disease of newborn) 458, 1085
 erythropoietin, in AF 116
Escherichia coli, inhibition by AF 113
 Eskimos, genetic disorders 28t
 esophageal atresia 554, **580–581**, 622, 623
 chromosomal anomalies 622
 duodenal atresia with 624
 incidence, cause, types 622
 MRI 673–674
 newborns 624
 third trimester diagnosis/management **622–624**
 ultrasound 554, 580–581, 622–624
 essential fructosuria 905t, **916**
 estriol
 maternal urine, screening by 485
 unconjugated (uE₃), maternal serum
 DS screening 486, 501, 502t
 Edwards syndrome 515
 molar pregnancy 518
 Patau syndrome 515
 Smith–Lemli–Opitz syndrome 517
 STS deficiency 516–517
 X-linked ichthyosis 516–517
 estrogen, supplemental, Turner syndrome 270
 ETF cycle *see* electron-transfer flavoprotein (ETF) cycle
 ethanol, effect on the fetus 31, 118, 982
 ethics 1102, **1106–1130**
 abortion 1057–1058, 1117
 fetal reduction 1115–1116
 after viability 1116–1121
 before viability 1114–1116
 autonomy *see* autonomy
 background to 1106
 beneficence *see* beneficence
 clinical trials 1122, 1124
 conflicts, hydrocephalus management 1119
 definition 1106
 disclosure of information/results 18, 1110–1111
 fetal surgery 989–990, 1006
 fetus as a patient **1107–1108**
 genetic counseling (prenatal) 18, **1109–1110**
 recontacting patient 18
 regarding previable fetus **1109–1110**
 regarding viable fetus **1109**
 genetic disorder diagnosis **1110–1114**
 competence and referral 1110
 confidentiality of results 1111
 result disclosure 1110–1111
 risk assessment, routine 1111–1114
 risk assessment in trisomy 21 1112–1113
 woman's response to nondirective offer 1112–1113
 woman's response to results 1114
 see also risk assessment
 hydrocephalus management 1118–1121
 informed consent 1121
 invasive genetic diagnosis **1111–1114**
 management of pregnancies with genetic disorders **1114–1121**
 abortion 1117
 aggressive management 1116
 cephalocentesis 1118–1121
 nonaggressive management 1117–1118
 NIPT based on cfDNA **470–471**
 nondirective counseling 1109, 1113
 nonmaleficence 1107
 obligation to inform patients 1124
 PGD **444–446**
 preimplantation HLA typing 438
 previable fetus as a patient **1108–1109**
 professional responsibility model **1106–1109**, 1109, 1112, 1117
 research **1121–1128**
 fetal surgery 1123–1124
 gene transfer 1121–1123
 human embryonic stem cell 1124–1128
 respect for autonomy **1107**
 viable fetus as a patient **1108**
 ethnicity 4, 27, 28t–29t
 cystic fibrosis 700, 701t, 705, 707
 DS screening 513–514
 genetic disorders associated 27, 28t–29t
 EUCROMIC study 204–205
 eugenics 1091, 1093, 1094, 1095, 1102
 Europe, sex selection, regulation 1101
 European Society of Human Reproduction and Embryology (ESHRE) 1092, 1101
 exercise, avoidance, GSD type V 912
 exome sequencing 33, 382
 exomphalos *see* omphalocele
 exon arrays 382
 exosomes 1032, 1033
 exploitation, human embryonic stem cell research 1125
 extracellular matrix (ECM), AF cell growth on 127
 extravillous trophoblasts (EVTs) 1031
 extremity malformations, chromosomal anomalies 582
ex utero intrapartum treatment (EXIT) 672, **993–994**, 994f
 cervical teratoma 1001–1002
 eye defects
 CMV infection 950–951
 toxoplasmosis infections 946–947
 FA2H gene mutations 781
 Fabry disease 776f, 778t, 783, **790–793**
 laboratory diagnosis 791–792
 prenatal diagnosis 792
 therapy 792–793
 facial anomalies
 3D/4D US 572–573, 573t
 achondroplasia 687f
 chromosomal abnormalities and 578–579
 type II collagen dysplasia 691
 facial cleft 578
 factor V Leiden deficiency 29
 factor VIII coagulant antigen 112
 factor VIII-related antigen 112
 factor IX levels 983
 FAD-dependent dehydrogenases 839
 false-positive rates (FPR) 32, 485
 see also specific tests, diseases
 familial adenomatous polyposis *see* familial polyposis coli
 familial cancer syndromes 35–36
 familial combined hyperlipidemia 779

- familial hypercholesterolemia (FH) 403t, 779, 780
 familial iminoglycinuria 892
 familial medullary thyroid cancer 402t
 familial polyposis coli 35, 37, 402t
 legal cases involving 1074
 familial prion disease 12
 familial structural rearrangements 228
 family
 disclosure of prenatal diagnosis 16
 genetic counseling 19–20
 after perinatal death 44–46, 1050–1051
 warning, duty of counselors 19–20
 see also parents
 family balancing 1101
 family history of genetic disorder 29, 31
 Fanconi anemia 438
 Fanconi syndrome 914, 934
 Farber disease 778t, **806–807**
 Farber lipogranulomatosis 806
 fascioscapulohumeral muscular dystrophy (FSHD) 399
 Fas defects 769
 FaSTER study 487–488, 494–495, 498, 504, 511
 amniocentesis **78–79**, 193
 fathers
 age *see* paternal age
 nonpaternity and *see* nonpaternity
 fatty acid(s)
 in AF 102, 103
 transfer across membranes 839
 fatty acid 2-hydroxylase (FA2H) 781
 fatty acid oxidation 773, 838
 beta-oxidation 838, 841f, 847
 mitochondrial disorders **840–847**
 mitochondrial *vs* peroxisomal 838, **839–840**, 839f
 peroxisomal disorders **848–852**, 848t
 mechanisms (alpha-, beta-, omega-) 838
 see also mitochondrial disorders; peroxisomal disorders
FBN1 gene mutation 396, 694
 femur
 fractures, osteogenesis imperfecta 689, 690
 lateral curvature in fetus 564
 femur length 192, 564
 Down syndrome 503, 582
 short, chromosomal anomalies and 582
 skeletal dysplasias 683, 686, 689
 fenobam 357
Feres doctrine 1087
 fertility problems *see* infertility
 fetal abnormalities, ultrasound *see* ultrasound (US), prenatal diagnosis
 fetal alcohol syndrome 31, 118, 982
 fetal anemia, parvovirus B19 infection 968
 fetal blood sampling **85–89**
 fetal losses 87, 718
 fetomaternal transfusion and outcomes 88
 first trimester 88
 indications 85–86
 combined B-cell/T-cell deficiency 764
 hematological disorders 85–86
 hemoglobinopathies 718, 731
 infection diagnosis 86, 958, 959, 963
 karyotyping 85
 maternal complications 87
 multiple pregnancies 88
 safety 87–88
 sampling sites 86, 87
 single umbilical artery 88
 techniques 86
 ultrasound guidance 86
 fetal bovine serum, in AF cell cultures 127–128
 fetal catheter interventions, aortic stenosis 981
 fetal cells
 in AF *see* amniotic fluid cells (AFC) (amniocytes)
 for fetal DNA isolation 732
 in maternal blood 732–733
 FISH interphase studies 335–336
 types for NIPD 732
 fetal demise *see* fetal loss
 fetal distress (FD) cells 120
 fetal distress with hypoxia 981
 fetal DNA
 from AF cells 731
 see also amniotic fluid cells (AFC) culture
 cell-free
 in AF 102–103, 731
 in maternal plasma *see* cell-free fetal DNA (cffDNA)
 CVS samples 731
 from fetal cells in maternal blood 732
 fragmented 453–454, 733
 hemoglobinopathy diagnosis 731–732
 fetal endoscopic tracheal occlusion (FETO) 622
 fetal exsanguination 1022
 fetal fraction, cffDNA 454
 fetal glomerular function, maturation 99
 fetal growth
 abnormal, skeletal dysplasia 683–684
 nutrient delivery, placenta role 1032–1033
 poor *see* intrauterine growth restriction (IUGR)
 retardation, Down syndrome 491
 second trimester delay 683
 fetal health/survival
 environmental exposure threat **31**
 maternal genetic disorder threat **24**
 fetal heart rate (FHR) *see* heart rate (fetal; FHR)
 fetal hydantoin syndrome 116, 1067, 1079
 fetal infections **942–975**
 CMV **948–961**
 cortical malformations and 671
 fetal blood sampling for 86, 958, 959, 963
 parvovirus B19 **967–969**
 rubella **962–963**
 toxoplasmosis **942–948**
 varicella **963–967**
 see also individual infections
 fetal injury
 after amniocentesis 74–75
 after CVS **84–85**
 fetal loss (spontaneous abortion) 2, 1048
 AFC culture failure 239
 amniocentesis and *see* amniocentesis
 aneuploidy 272, 484
 blood sampling and 87, 718
 chromosomal abnormalities 179, 182, 182t, 184t, 201, 438
 CMV infection 953
 CVS and *see* chorionic villus sampling (CVS)
 cytogenetic analysis after 201
 data after, genetic counseling 12
 diagnosis by array CGH **373**
 early, implantation/invasion failure 1032
 after first-trimester fetal reduction 1024–1025

1152 Index

- fetal loss (spontaneous abortion) (*Continued*)
 grief after *see* grief
 habitual 25–26, 200–201
 history, psychological distress 1050
 infertility and 25
 karyotype, cytogenetic diagnosis indication 201
 legal cases involving 1085
 maternal age 75, 77, 490
 maternal genetic disorders 23, 24
 maternal serum screening 518–519
 multiple/singleton pregnancies 584, 1022
 novel bacteria causing 114
see also fetal loss; perinatal death/loss
- fetal maturity, assessment 104, 112
- fetal medical therapy **86, 976–988**
 biochemical genetic disorders 982–983
 bleeding disorders 983
 CAH *see* congenital adrenal hyperplasia (CAH)
 CCAML 616, 1000
 congenital malformations 982
 congenital pulmonary airway malformations 616, 1000
 dysrhythmias 86, 602, 980–981
 gene therapy *see* gene therapy
 inborn errors of cobalamin 933–934
 thyroid disorders 86, 981–982
 toxoplasmosis *see* toxoplasmosis (fetal)
- Fetal Medicine Foundation, NT measurement protocol 572b
- fetal membranes 98
- fetal nasal bone (NB), absence 487
- fetal neurosonography 635
- fetal–placental weight ratio 1031, 1034
- fetal reduction (multiple gestations) **1022–1025, 1049**
 CVS with FISH prior to 334
 ethics 1115–1116
 grief/reactions **1054–1055**
 indications 1115–1116
see also abortion, selective
- fetal rights 1108
- fetal sex determination *see* sex determination (fetal)
- fetal skin 104, 119
 biopsy, revertant mosaicism 395
- fetal surgery **989–1010**
 anatomic defects amenable **996–1000**
 CCAM 616, 618, 999–1000, 1000f
 congenital diaphragmatic hernia 550, 996–998
 congenital pulmonary airway malformation 999–1000, 1000f
 obstructive uropathy 998–999
 background to 989, 990
 benefits 989
 cardiac anomalies **1005–1006**
 hypoplastic left heart 611, 1005
 clinical trials 1124
 complications 994–995
 ethical aspects 989–990, 1006
 fetal/placental risks 995–996
 framework for 990
 indications 989–990
 intraoperative/postoperative monitoring 991, 992
 maternal risks 995
 minimal access 616, **992–994**
ex utero intrapartum (EXIT) 993–994, 994f, 1002–1003
 fetoscopy *see* fetoscopy
 percutaneous approach 992–993
 teratomas 1001
- myelomeningocele 638, **1003–1004**
 open **991–992**, 994, 1004
 congenital diaphragmatic hernia 996–997
 research, ethics 1123–1124
 spina bifida aperta 638, 641, **1003–1004**
 techniques 990–991
 teratomas **1000–1003**
 timing 992
 twin anomalies **1004–1005**, 1005f
 urinary tract anomalies 634, 998–999
 uterus closure after 994
- fetal therapy
 blood transfusion 85
 laser *see* laser therapy
 medical *see* fetal medical therapy
 surgical *see* fetal surgery
- fetal urine, sampling 999
- FETO (Fetal Endotracheal Occlusion) 997–998
- fetomaternal plasma concentration gradient 105
- fetomaternal transfusion 88
- fetoplacental risks, fetal surgery 995–996
- α -fetoprotein *see* α -fetoprotein (AFP)
- fetoscopy 85, 112, 541, 990, **992**
 complications/risks 995, 996
 operating room set-up 992, 993f
 procedure and indications 992
- fetus
 burying 1057
 genetic counseling regarding *see* genetic counseling
 mother bonding with 1110
 as a patient, ethics 1106, **1107–1108**, 1116
 selective termination and 1116
 as a person, legal issues 1085, 1102
 previable, as a patient **1108–1109**, 1122
 fetal surgery research 1123
 genetic counseling regarding 1109–1110
 viable, as a patient **1108**
- FGFR3 disorders **685–687**
see also achondroplasia; hypochondroplasia; thanatophoric dysplasia
- FGFR3 gene mutations 668–669, 684, **685–686**, 687
 gain of function 685
- FGly-generating enzyme (FGE) deficiency 799
- fibrillin, gene mutation 694
- fibroblast(s) (skin), FXTAS 355
- fibroblast growth factor receptor (FGFR) mutations *see* FGFR3 gene mutations
- fibromyalgia 353
- filamin B (*FLNB*) gene mutations 693
- “filipin” test 805
- Finnish mutation 692
- Finnish nephrotic syndrome 400, 561
- Finns, genetic disorders 28t
- first trimester *see more specific index entries*
- FISH *see* fluorescence in situ hybridization (FISH)
- “FlashFISH” test 328
- fluid exchange, fetus/mother 98–99
- fluorescence in situ hybridization (FISH) 178, 313, 318
 cardiac defects 192, 317–318
 DiGeorge syndrome 766
 interphase analysis, prenatal diagnosis 119, 313, **328–338**
 22q microduplications 318, 333
 accuracy and detection rates 330, 331
 advantages 328, 330
 AFC (noncultivated/“direct analysis”) **328–330**, 329t, 338

- alternative technologies 333
 aneuploidy 314, 330–331, 335, 336, 337, 374, 439–440, 442
 cell-free DNA 335–336
 criteria for use/guidelines 331–333, 334–335
 CVS 333–335, 334t
 false-positives/-negatives 331, 333
 fetal cells in maternal blood 335–336
 fetal cells from uterine cavity 336
 fetal sex determination 336
 limitations 330, 374
 mosaicism detection 204, 337
 pattern of analysis 331, 332f
 PGD 336–338, 374, 439–440, 442
 polar bodies 439–440
 technical improvements 330–331, 333
 transcervical samples 336
 uses 314, 328, 330, 331, 335, 338
 karyotyping result discordance 241–242
 metaphase analysis 313–314, 314–328, 338
 chromosome 15/16 translocation 320, 321f
 cryptic rearrangements 318–320, 321f
 duplications 318, 327–328
 marker chromosomes 320–327
 microdeletions 314–318, 315t–316t, 317f, 338
 steroid sulfatase deletions 187, 316t, 318
 multicolor, techniques 366
 principles 313, 366
 probes 313, 338
 Turner syndrome 269
 fluorescence resonance energy transfer (FRET) 709t
FMRI gene
 mRNA 350, 351, 353
 abnormal, in FXTAS 354, 355, Plate 7.1
 mutations 350, 387
 see also fragile X mutations
 FMR1 protein (FMRP)
 deficiency/absence 350
 monoclonal antibody method 356
 neurodevelopmental disorders 351, 354
 dysregulation, seizures 351, 353
 functions 350, 351
 measurement methods 352
 see also fragile X mutations; fragile X syndrome
 folate/folic acid
 adverse effects 144–145
 derivatives, functions 927
 education of women, and use levels 145
 food fortification 141, 144, 145
 inborn errors of metabolism 927–930, 928t
 cerebral deficiency 928–929
 dihydrofolate reductase deficiency 929–930
 glutamate formiminotransferase deficiency 929
 hereditary malabsorption 927–928
 MTHFD1 deficiency 930
 MTHFR deficiency 929
 metabolism, genetic variations 200
 neurotoxicity 144
 NTDs and see neural tube defects (NTDs)
 placental levels 1033
 receptors 1033
 red cell level recommendations 145
 supplementation 3–4, 20, 982
 therapeutic use 929
 folinic acid 945t, 947
 follicle-stimulating hormone (FSH) 276
 FOLR1 gene mutations 929
 Food and Drug Agency (FDA) 1097
 food fortification, folic acid 141, 144, 145
 foramen of Morgagni hernia 621
 Forbes disease (GSD type III) 904t, 909–910
 FORTE (fetal-fraction optimized risk of trisomy evaluation) 464–465
 fourth ventricle, open spina bifida 505
 fractures, osteogenesis imperfecta 688, 689
 fragile sites, deletions at, mosaicism 221
 fragile X-associated primary ovarian insufficiency (FXPOI) 353, 354, 355
 fragile X-associated tremor/ataxia syndrome (FXTAS) 351, 353, 355
 molecular pathogenesis 353–355
 myotonic dystrophy vs 354
 neuropathology 354
 skin fibroblasts 355
 fragile X mental retardation 1 gene see *FMRI* gene
 fragile X mutations 350–365, 387
 carrier testing 31, 352, 358
 cascade testing of family 357, 358
 epidemiology 351
 full mutation (>200 repeats) 350, 387
 phenotype/clinical features 351–353
 see also fragile X syndrome (FXS)
 genetic counseling 357–358
 male carriers, prevalence 351
 molecular prenatal diagnosis 355–356
 newborn screening 357, 358
 pathogenesis 353–355
 PCR 355–356
 PGD 356, 358
 polar-body analysis 356
 premutation (55–200 repeats) 350–351, 353, 357, 387
 carriers, detection 358
 phenotype/clinical features 350–351, 353
 see also fragile X-associated tremor/ataxia syndrome (FXTAS)
 prenatal screening 358
 Southern blot analysis 355–356
 treatment 350, 352, 356–357
 see also *FMRI* gene
 fragile X syndrome (FXS) 27, 350, 387
 carriers 25–26
 clinical features 350, 352
 legal cases involving 1069, 1082
 neurobiologic advances and treatment 356–357
 treatment trials 350
 unstable repeats and anticipation 387
 France
 congenital CMV infection 950t
 law relating to prenatal diagnosis 1093
 legal issues relating to PGD 444, 1095
 Fraser syndrome 460t
 French Canadians, genetic disorders 28t
 FRET testing, FMR1 protein (FMRP) 352
 Friedreich ataxia 37
 frontal lobe
 shortened 577–578
 underdevelopment 667
 frontal-maxillary facial angle (FMF) 500, 503
 frontotemporal dementia 12
 frontotemporal lobe degeneration 12
 fructokinase deficiency 916

1154 Index

fructose 903
 intolerance 905t, 916–917
 metabolism disorders 905t, **916–917**
fructose-1,6-diphosphatase deficiency 905t, **917**
fructose-1-phosphate aldolase B deficiency 905t, **916–917**
fructosuria, essential 905t, **916**
FTCD gene mutations 929
fumarylacetoacetate hydrolase (FAH) deficiency 888
fungal infections in immunodeficiency disorders 756, 757t
fungi, in AF 114
funicentesis

- genetic counseling 1–67
 45,X/46,XY 275–276
 aims 8
 before amniocentesis 68
 both partners 17, 32
 carrier detection and 384–385
 characteristics of a good counselor 14, 39
 for chromosomal abnormalities
de novo balanced rearrangements 230
 mosaicism 226–227
 communication in *see* communication in genetic counseling
 consent 32–34
 cystic fibrosis 21, 24, 25, 47, 712, 713
 after cytogenetic diagnosis 242
 decision making after 10, 14, 40–41, 47, 1053
 directive approach 14, 1109
 disclosure of genetic information 16
 disclosure of new risk information 18
 Down syndrome 520
 efficacy of 46–48
 measures and evaluation 46
 ethics *see* ethics
 failure of counselee's comprehension 47
 family history of genetic disorder 31
 fetal brain abnormalities 650
 follow-up after 41, 46–47
 fragile X mutations 357–358
 genetic heterogeneity awareness 11
 glycosphingolipidoses 783–784
 guiding principles 11–20, 1109
 accurate diagnosis 11–13
 concern for individual 15
 confidentiality and trust 16
 counselee education 17
 do no harm 18–19
 duty to recontact 18
 duty to warn 19–20
 nondirective counseling 13–15, 17, 1109, 1113
 parental counseling 17
 timing 16–17
 truthfulness 15–16
 improvements to 47–48
 key questions to ask 9
 Klinefelter syndrome 279
 limited efficacy 47–48
 for mosaicism 38–39, 205
 nondirective 13–15, 17, 1109, 1113
 near-viable fetuses 1109–1110
 nonpaternity and 16, 41
 NTDs 139–141
 options available to patients 9–10
 perinatal 43–48
 efficacy 46–48
 family matters 44–46
 parental support 44
 after perinatal death/stillbirth 45–46
 surviving children 46
 twin pregnancy 43
 phenylketonuria (maternal) 24
 postcounseling letter to physician 47
 preconception *see* preconception genetic counseling
 before prenatal diagnosis 32–39, 242
 amniocentesis 68
 anticipation (genetic) 37
 carrier detection 34
 expansion mutations 37
 genotype–phenotype associations 38
 imprinting 37–38
 informed consent 32–34
 mosaicism 38–39
 presymptomatic/predictive testing 34–37
 prerequisites 8–11
 empathy and sensitivity 10, 40–41
 referral for 8, 9, 27
 relatives 19–20
 SCID 764
 sex chromosome abnormalities *see* sex chromosome abnormalities (SCA)
 skeletal dysplasias 682, 685, 687
 success criteria 47
 supervision by physician 1110
 time required 9
 timing of 16–17
 triple X syndrome (47,XXX) 281
 Turner syndrome 273–274, 275–276
 when fetus has abnormality 39–43, 242
 abortion *see* abortion (induced/elective)
 anxiety, doubts and disbelief 40
 breaking bad news 39–40, 1057–1058
 communication after 40–41
 decision-making 10, 14, 40–41, 1053
 question anticipation 40–41
 testing other children 42–43
- genetic counselors
 assessment by patients 10
 disability training 41
 knowledge of 8–9, 41, 46
 personal views/characteristics 14, 39
 role 32, 41
 training 13, 41
- genetic disorders, catalog 380
- genetic heterogeneity 11, 21, 31
- genetic predisposition, disorders with, PGD 436–438
- genetics, molecular *see* molecular genetics
- genetic sonogram 193, 486–487
 Down syndrome 503–504, 579
- genetic testing, siblings of affected fetus 42–43
- gene transfer research 1121–1123
 ethics 1121–1123
 germline harm, and control 1123
 informed consent 1121–1122
 institutional publicity 1122–1123
 moral lessons 1122
 uses 1122
see also gene therapy
- genitalia
 46,XX males 290, 291
 46,XY females 291, 292
 ambiguous, CAH 976, 977
 congenital lipoid adrenal hyperplasia 979
 ovotesticular DSD 293, 294
- genital tract, anomalies, in CF 701
- genome sequencing 11, 31
see also whole-exome sequencing (WES)
- genome-wide aneuploidy screening 374
- genome-wide SNP analysis 374
- genomic disorders 367
- genomic imbalance 1033

1156 Index

- genomic imprinting 37–38, 395–396, 396t
 differentially methylated regions 1040
 disorders, in Klinefelter syndrome 277
 IUGR and 1035
- genotype–phenotype associations 38, 396–397
 cystic fibrosis 38, 703–704
- genotyping, gametes 420
- Germany, legal issues relating to PGD 444, 1095–1096
- germinal matrix, volume, brain development 662, 663f, 664
- germline harm 1123
- gestational age
 amniotic fluid volume 100t
 cfDNA levels 453, 455
 disaccharidase activity in AF 106, 107, 107f
 MSAFP levels 131, 131f, 132
 routine ultrasound scans 541
 rubella infection risk and 962, 962t
 suction aspiration 1012
 toxoplasmosis transmission 944
- gestational diabetes 277
- GGGGCC repeats 387–388
- GLA* gene mutations 791, 792
- GLB1* gene mutations 785
- globin chains 719
 α-like 719
 deficiency *see* thalassemia, α-
 β-like 719
 deficiency/absence *see* thalassemia, β-
 γ-, in HPFH 746
- globin genes 719–720
 α-globin 719
 β-globin
 deletions, gap-PCR 735t, 740
 deletions, Hb Lepore 745–746
 deletions, δβ-thalassemia 744, 745
 haplotypes, sickle cell disease 725, 726
 rare variants with Hb S 728
- globoid-cell leukodystrophy *see* Krabbe disease
- globosides 781–782
- globotriaosylceramide (Gb3) 790
- glomerular filtration rate (GFR), markers 112, 632
- β-glucocerebrosidase 782, 783
 deficiency, Gaucher disease 793, 794, 795
 gene *see* *GBA* gene
 recombinant 796
- glucocorticoids
 fluorinated, fetal heart block 605
 in pregnancy 978
see also dexamethasone
- gluconeogenesis, disorders 903, 905t, 917–918
- glucosamine-6-sulphatase (GNS) deficiency (MPS IIID) 864–865
- glucose 903, 905–906
- glucose-6-phosphatase (G6Pase) deficiency (type I GSD) 906, 908
- glucose-6-phosphate translocase (G6PT), deficiency 906, 907
- α-glucosidase
 in AF 104
 deficiency (GSD type II, Pompe disease) 104, 904t, 906,
 908–909
- β-glucosidase
 acidic, deficiency in Gaucher disease 793, 794, 795, 796
 in AF 104
 gene *see* *GBA* gene
- glucosylceramide 781
 accumulation, Gaucher disease 793, 796
- glucosylsphingosine 793
- β-D-glucuronidase (GUSB)
 deficiency (MPS VII) 866, 867
 gene and pseudogene 866
- GLUT-2 defects 914
- glutamate formiminotransferase deficiency 929
- α-glutamyl transferase, in AF 99, 108
- γ-glutamyl transferase, in AF 99, 104, 106
- glutaric acidemia type I 886
- glutaric aciduria type II 840, 892
- glutaryl-CoA dehydrogenase deficiency 886
- tigln* AF 745

- treatment 784
 X-linked *see* Fabry disease
see also lysosomal storage disorders
- glypicans 860
- GM₁-ganglioside 785, 800
- GM₁-gangliosidosis 776f, 778t, **784–786**
 laboratory diagnosis 785–786
- GM₂-activator protein 786
 deficiency 789–790
- GM₂A gene 786, 789
- GM₂-gangliosides 786, 806
- GM₂-gangliosidosis 776f, 778t, **786–790**, 861
 AB-variant 776f, 778t, 783, **789–790**
 B variant *see* Tay–Sachs disease
 Sandhoff disease *see* Sandhoff disease
 therapy 786
- GM2 synthase deficiency 777t, 782
- GM2 synthase gene mutation 782
- GM₃-gangliosides 806, 863
- GM3 synthase defect 777t, 781–782
- goiter, fetal 116, 981
- gonadal dysgenesis
 46,XY females 292
 complete (Swyer syndrome) 292
 mixed (46,XY partial) 292–293
 Turner syndrome 270, 273, 275
- gonadal mosaicism *see* mosaicism, gonadal
- gonadectomy, Turner syndrome 269, 275
- gonadoblastoma 269, 275, 288, 292
- granular osmiophilic deposits (GROD) 809
- granulocyte colony-stimulating factors 908
- granulocyte disorders 756
- Graves disease 981, 982
- Greece, collaborative amniocentesis study 76t, 78
- Greig cephalopolysyndactyly 315t, 317
- grief **1048–1062**, 1049
 childless women 1052
 clinical implications and therapy **1056–1059**
 complicated 1048, 1050
 counseling, elective abortion and 41–42
 after diagnosis received 1057
 gender differences **1055–1056**, 1055t
 incongruent 1056
 negative health consequences 1050, 1051, 1056
 normal process 1049
 online support after 1057
 after perinatal loss **1048–1062**
 pregnancy reduction in multiple pregnancies
1054–1055
 prolonged 1050
 reactions **1049–1051**, 1058
 risk and protective factors 1051–1052, 1051t
 reduced by seeing baby's body 1051, 1058
 after stillbirth 1051, 1057
 unplanned pregnancy, loss 1052
- growth *see* fetal growth
- growth factors
 AF 125
 placental development 1032
 supplements, AF cell culture 128
- growth-hormone therapy 269–270
- guanosine triphosphate cyclohydrolase I (GTPCH) 887,
 888
- guardians, legal case involving 1087
- guidelines *see* professional guidelines
- guilt
 multifetal pregnancy reduction 1055
 parental 10–11, 44, 1050, 1052
 survivor, in siblings 11
- gynecomastia 276
- halogenated anesthetics 990, 991
- haploid set of autosomes (HAL) 194–195
- haplotype analysis 742, 744, 745t
- Harlequin ichthyosis 399
- Hartnup disease 892
- Hb A₂ 719, 723, 729
 absence, conditions with 744
 measurement 729
 normal 730t
 reduced red cell indices with 730, 730t
 raised, reduced red cell indices with 729, 730t
- Hb AE Bart's disease 724–725
- Hb Bart's hydrops fetalis syndrome 720, 721, 732
- Hb C **746–747**
 mutations 746–747
- Hb Constant Spring 724, 725, 737
- Hb D-Punjab 747, 747t
- Hb E 460t, 724, 747
 mutation 747
 oligonucleotide primers for detection 747t
- Hb E disorders **724–725**, 724t
 Hb AE Bart's disease 724
 Hb E/E plus $\alpha^{c8}\alpha/\alpha^{c8}\alpha$ 725
 Hb EF Bart's disease 725
 Hb E-

1158 Index

- heart (fetal)
- abnormal axis 605, 608f
 - abnormal position 605
 - abnormal size 605
 - defects *see* cardiac defects; cardiovascular defects
 - E/A ratio 612, 614
 - echogenic foci in 580
 - functional assessment 612–615
 - long-axis ventricular function 612, 614
 - MRI 673–674
 - septal defects 605, 608–609
- heart block
- congenital 24, 602, 605, 606f–607f
 - fetal 979, 980
 - second-degree 605
 - see also* atrioventricular (AV) heart block
- heart rate (fetal; FHR)
- abnormal, 4CV echocardiography 601–605, 603f–604f
 - aneuploidy affecting 516
- heat exposure, avoidance in early pregnancy 31
- μ-heavy chain deficiency 760t
- heavy metals, in AF 111, 111t
- height, Y chromosome gene 288
- HELLP syndrome 877
- hemangiomas 1039
- hematological disorders, fetal blood sampling for 85–86
- hematopoiesis, placenta 1033
- hematopoietic stem cell transplantation (HSCT)
- metachromatic leukodystrophy 799
 - mucopolysaccharidoses 868
 - Niemann–Pick disease type C 805
 - preimplantation HLA typing 438
 - SCID 763
- hemimegalencephaly 13
- hemochromatosis 674
- hemoglobin
- abnormal 746–747
 - adult 719
 - Bart's 720
 - electrophoresis 729
 - embryonic 719
 - fetal *see* Hb F
 - Portland 720
 - structure 719–720
 - switches between types 719
 - see also* entries beginning *Hb*
- hemoglobinopathies 718–754
- carrier screening 728–731
 - identification methods 729
 - reduced red cell indices, normal Hb A₂ 730, 730t
 - reduced red cell indices, raised Hb A₂ 729, 730t
 - clinical types 719
 - DNA diagnosis 734–746
 - incidence 718
 - PGD and 734
 - prenatal diagnosis 731–734
 - abnormal hemoglobins 746–747
 - amniocentesis 718, 731
 - background to 718, 731
 - best practice guidelines 749
 - CVS 718, 731–732
 - diagnostic pitfalls/errors 747–749
 - fetal blood sampling 718, 731
 - maternal DNA contamination 748
 - noninvasive 732–733
 - PCR 718–719
 - requirements 719
 - strategy for 730–731
 - technical errors 748–749
 - see also* individual disorders
- hemolytic disease of newborn (HDFN) 457, 458, 1085
- hemopexin 101
- hemophilia A 400–401, 983
- carriers 27, 29, 400, 983
 - labor/delivery complications 24, 27
 - pregnancy in 400, 983
 - fetal blood sampling 86
 - fetal medical therapy 983
 - genotype–phenotype association 38
 - legal cases concerning 1086, 1088
 - mutations 38, 400, 401
 - prenatal diagnosis 400–401, 983
 - noninvasive (NIPD) 461
- hemophilia B 983
- mutations 400
 - prenatal diagnosis 102
 - noninvasive 461, 462
- hemorrhage
- intracranial 670
 - maternal, after fetal surgery 995
 - postabortion 1014, 1015, 1019
 - see also* bleeding
- heparan sulfate (HS) 857, 860
- accumulation, MPS II 863
- heparan sulfate (HS) proteoglycans 860
- heparan sulfate (HS)-uria 864
- heparin co-factor II-thrombin complex 862
- hepatic adenoma 907, 910
- hepatic glycogenosis with renal Fanconi syndrome 914
- hepatic involvement in glycogen storage diseases 907, 910, 911, 914
- hepatocyte growth factor (HGF) 115
- hepatomegaly 880
- hepatorenal type tyrosinemia (type I) 888
- hepatosplenomegaly 556
- herbicides 117t
- hereditary breast and ovarian cancer 402t
- hereditary fructose intolerance (HFI) 905t, 916–917
- hereditary malabsorption of folate 927–928, 928t
- hereditary nonpolyposis colon/rectal cancer 29
- hereditary paraganglioma-pheochromocytoma syndrome 402t
- hereditary persistence of fetal hemoglobin (HPFH) 723, 740, 744, 746
- deletion types, prenatal diagnosis 744–745
 - molecular diagnosis 746
 - non-deletion type 746
- hereditary sensory neuropathy type I 777t
- hereditary spastic paraplegia (HSP) 398
- hereditary tyrosinemia type I 888
- hermaphroditism
- 46,XX/46,XY chimerism 294
 - “true hermaphroditism” (46,XY) 293
- hernia, diaphragmatic *see* congenital diaphragmatic hernia (CDH)
- Hers disease (GSD type VI) 904t, 912–913
- heterochromatin, polymorphisms 235–236

- heterotaxy syndrome 602, 605, 610
heterotopia 667
HEXA gene 786
 mutations 787, 788
 sequencing 788
 see also hexosaminidase A (HexA; $\alpha\beta$)
hexanucleotide repeat 12, 37, 387–388
HEXB gene 786
 mutations, Sandhoff disease 789
hexosaminidase(s) 786
 α - and β -subunits 786
 α -subunit mutations 787–789
 β -subunit mutations 789–790
hexosaminidase A (HexA; $\alpha\beta$) 27, 783, 786
 activity in AF 104
 deficiency, Tay–Sachs disease 104, 787, 788
 measurement 788
 pseudodeficiency 788
 see also HEXA gene
hexosaminidase B (HexB; $\beta\beta$) 786, 789
 pseudodeficiency 789
 Sandhoff disease 104, 789–790
 in Tay–Sachs disease 787
 β -subunit mutations 104, 789
 see also HEXB gene
hexosaminidase S ($\alpha\alpha$) 787, 789
 deficiency 787, 789
HHH syndrome 881
high-density lipoprotein (HDL) 776, 780
 disorders affecting 774t
high performance liquid chromatography (HPLC) 729
 denaturing (DHPLC) 740
Hippocratic oath 1107
Hirschsprung disease 108, 674
histone deacetylase inhibitors 806
hitchiker thumbs 692, 693f
HIV infection 1126
 legal cases concerning 1077
 mother-to-fetus transmission 75
 replication, AF effect on 113
HLA-A antigens, in AF 112
HLA-B antigens, in AF 112
HLA typing, preimplantation 419, 438, 445
 ethics 438, 445
 international legal issues 1095, 1098
HMG-CoA lyase deficiency 886
Hofbauer cells 1031, 1033
holocarboxylase synthase gene, methylation 464
holoprosencephaly 546, 641, 666
 alobar 642f, 666
 chromosomal defects and 576
 legal case involving 1075
 lobar, and semilobar 666
 MRI 666
 subtypes 641
 ultrasound 546, 547t, 576
 third trimester 641, 642f
homocysteine 889
 in AF 105
homocystinuria 22, 889, 928t
 with methylmalonic aciduria 928t, 932–933
 without methylmalonic aciduria 931, 932
homozygosity 4
hormones, in AF 115–116, 115t
HPFH *see* hereditary persistence of fetal hemoglobin (HPFH)
- HRAS gene mutation 13
HSD17B4 gene mutations 850
human chorionic gonadotropin (hCG) 1032
 AF cell types 125
 DS screening 485, 493, 494, 495t, 496t, 501, 502t
 ethnicity and 513
 repeat measures 504
 smoking effect 513
 Edwards syndrome (trisomy 18) 515, 515t
 fetal demise and 518
 free α -hCG 485
 free β -hCG 506, 518
 maternal serum, screening marker 485, 493
 urinary, Down syndrome 506–507
human embryonic stem cell (hESC) research 1124–1128
 exploitation prevention 1125
 fairness 1125, 1126, 1127, 1128
 moral burden 1125–1126, 1126–1127
 political influence, public policy 1125, 1127
 religious objections 1124–1126
Human Fertilization and Embryology Act (UK) 1098
Human Fertilization and Embryology Authority (HFEA) (UK) 1098
human platelet antigen (HPA-1a) 983
humerus length 192
 Down syndrome 503, 582
Hunter syndrome *see* mucopolysaccharidoses (MPS), MPS II
Huntington disease (HD)
 anticipation in triplet repeats 38
 CAG repeats 12, 387
 carriers 34
 homozygotes 36
 juvenile 36
 mutation (new) 387
 nondirective genetic counseling and 14–15
 noninvasive prenatal diagnosis 459t
 PGD, legal issues 1095
 prenatal testing 397
 without partner knowledge 36
 presymptomatic testing 18, 34, 35, 36, 397
 suicide after predictive testing 35
Huntington disease-like symptoms, lack of CAG triplet expansion 12
Hurler syndrome *see* mucopolysaccharidoses (MPS), MPS I
HYAL deficiency 867
hyaluronan (HA) 857
hyaluronidase deficiency (MPS IX) 867
hydatidiform mole 201, 518
 complete (CHM) 1036, 1037–1039, 1037t, 1038f
 maternal serum screening 518
 partial 1039, 1038f
 pseudo (placental mesenchymal dysplasia) 1039, 1038f
 placental changes 1036–1039
hydranencephaly 546
hydrocephalus 669–670, 1118
 abnormalities associated 1119, 11120
 congenital 545–546
 ethics of cephalocentesis 1118, 1119
 legal cases involving 1077–1078, 1079, 1088
 management, ethics and 1119–1121
 MRI 669–670
 prolonged 670
 ultrasound 545–546, 546t
hydrocortisone, prenatal treatment of CAH 977
hydrography, fetal 671

1160 Index

- hydrometrocolpos 557
 hydronephrosis 100, 562, 633f
 fetal surgery 999
 hydrops fetalis 550–551
 congenital hydrothorax 618
 cystic adenomatoid malformation of lung 616
 Hb Bart's hydrops fetalis syndrome 720
 maternal serum patterns 519
 MPS VII 866
 nonimmune 670
 nuchal cystic hygroma and 579, 580
 parvovirus B19 infection 967, 968
 pericardial teratoma 1003
 survival rate/outcomes 618
 tachyarrhythmias and, treatment 602
 ultrasound 550–551, 580
 hydrothorax 618
 3-hydroxy-3-methylglutaryl-CoA lyase deficiency 886
 4-hydroxybutyric aciduria 891
 hydroxychloroquine 605
 hydroxycobalamin 934
 D-2-hydroxyglutaric aciduria 892
 L-2-hydroxyglutaric aciduria 892
 5-hydroxyindole-3-acetic acid 108
 3-hydroxyisobutyric aciduria 884–885
 11b-hydroxylase deficiency 976
 21-hydroxylase deficiency *see* congenital adrenal hyperplasia (CAH)
 4-hydroxyphenylpyruvate dioxidase (HPD) deficiency 888
 17-hydroxyprogesterone 977
 3b-hydroxysteroid dehydrogenase deficiency 976
 hyperammonemia 22, 879, 880, 881
 organic acid metabolic disorders 882
 hyperargininemia 880–881
 hypercholesterolemia, familial 403t, 779, 780
 hypercoagulability, increased in pregnancy 983
 hyperechogenic bowel *see* bowels, hyperechogenic
 hyperglycinemia, nonketotic 890–891
 hyper-IgE syndrome 761t, 768
 hyper-IgM syndrome 760t, 766
 hyperimmune globulin (HIG), CMV infection 959–960
 hyperlipidemia
 GSD type I (von Gierke disease) 906, 907
 GSD type III 910
 hypermelanosis 216
 hypermethioninemia 889
 hypermethylation 464
 hyperornithinemia 881
 hyperornithinemia, hyperammonemia and homocitrullinuria (HHH) syndrome 881
 hyperoxygenation test 611
 hyperphenylalaninemia 887–888
 hyperprolinemia 892
 hypertension, maternal 1035
 hyperthermia, malignant 25, 403t
 hyperthyroidism 981, 982
 hypertriglyceridemia, von Gierke disease (GSD type I) 906
 hypertrophic cardiomyopathy 397, 403t, 980
 hyperuricemia, von Gierke disease (GSD type I) 906, 907
 hypervalinemia 884
 hypochondrogenesis 690, 691, 691f, 692f
 hypochondroplasia 685–687
 FGFR3 mutation 685, 686
 prenatal diagnosis 686–687
 ultrasound 688f
 hypoglycemia
 GSD type I (von Gierke disease) 906, 907
 GSD type III 910
 hypoketotic 838, 840, 845, 846, 847
 hypogonadism, Klinefelter syndrome 276
 hypohaploidy 438
 hypomelanosis of Ito 216
 hypomethylation 464, 1039
 hypophosphatasia 564
 hypoplastic left heart (HLH) 609, 610–612, 613f, 1005
 incidence and key features 610, 615
 intact/restrictive atrial septum 611
 mortality 611, 615
 postnatal surgery 611, 615
 hypothyroidism
 fetal 5, 116
 therapy 981
 fragile X premutation 353
 Turner syndrome 271
 hysterectomy, pregnancy termination 1021
 hysterotomy 990, 992
 absorbable stapling device 994, 995
 maternal risks 995
 pregnancy termination 1021
 I-cell disease 104, 783
 ichthyosis 399
 ICSI *see* intracytoplasmic sperm injection (ICSI)
 iduronate-2-sulphatase (IDS) 862–863
 deficiency *see* mucopolysaccharidoses (MPS), MPS II
 gene and pseudogene 863
 α -L-iduronidase (IDUA) 859, 862
 deficiency 861, 862
 gene mutations (p.Q70X, p.W402X) 862, 870
 measurement 862
 ileal obstruction 555
 Illumina 382, 708, 711
 Imerslund-Gräsbeck syndrome 930
 immune disease, neonatal 113
 immune response/system 755
 placental role 1033
 immunoblot method 910
 immunodeficiency disorders, primary 755–772
 antibody deficiencies *see* antibody deficiency
 autosomal dominant 757
 autosomal recessive 756–757
 classification 759t–762t
 complement deficiencies *see* complement deficiencies
 family history 755–757
 immune regulatory disorders 769
 immunologic tests 758, 758t, 769
 infections in 756, 757t, 766, 768
 lymphocyte disorders *see* lymphocyte deficiencies
 mutations causing 758
 neonatal detection 755
 phagocyte defects 758t, 762t, 767–768
 unclassified 768–769
 X-linked 757
 immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) 762t, 769
 immunoglobulin(s) (Ig)
 in AF 112–113
 deficiencies 760t, 766–767
 subclass deficiency 761t

- immunoglobulin A (IgA)
 in AF 112
 deficiency 756, 760t, 767
 immunoglobulin E (IgE), deficiency 760t
 immunoglobulin G (IgG)
 in AF 112–113
 CMV infection 952
 deficiency 760t
 immunoglobulin M (IgM)
 in AF 112, 114
 CMV infection 952
 rubella diagnosis 963
 immunoreactive trypsinogen (IRT) 701
 immunosuppression 755
 implied contract (legal) 1064
 imprinted genes 232, 1040
 imprinting *see* genomic imprinting
 inborn errors of metabolism 840
 enzyme deficiencies in AF 104
 MRI 670
 see also individual disorders
 incidence, of genetic disorders and congenital defects 1–5, 2t
 factors influencing estimates 3t
 maternal age and 20
 incidental findings 372–373
 communicating to parents 404, 1111
 diseases 402t–403t
 reporting 404, 1111
 incubators, for AFC culture, failure 129
 India
 law on prenatal diagnosis 1093
 PGD regulation 1096–1097
 sex selection prohibition 1100
 indomethacin 991
 induced abortion *see* abortion (induced/elective)
 infantile Refsum disease (IRD) 851
 infant mortality 5–6
 infections
 fetal *see* fetal infections
 immunodeficiency disorders association 756, 757t, 766, 768
 maternal *see* pregnancy; *individual infections*
 placental protection against 1033
 postabortion 1020
 recurrent, family history 756
 timing, immunodeficiency disorders 756
 infectious agents, in AF 113–114
 infertility 25–26, 41
 cystic fibrosis 701, 704
 cytogenetic causes 201–202
 Klinefelter syndrome 276
 information
 breach of duty of physician 1074, 1075, 1080, 1086
 disclosure 1065
 informed consent 1065, 1111
 disclosure of information 1065
 ethical issues 1121
 incomplete recording of results 1110
 legal cases involving 1073
 nondirective process 1121–1122
 paternal 1122
 for prenatal diagnosis 32–34, 1114
 for research 1121
 gene transfer research 1121–1122
 risk assessment and 1114
 role, legal aspects 1065
 use of word ‘therapy’ 1121
 inhibit A
 DS screening 486, 493, 501, 502t
 fetal demise and 518
 trisomy 16 mosaicism 215
 inhibit B 486
 insertional oncogenesis 984
 insertions, chromosome 198
 instant risk assessment (IRA) 493
 insula, open 662
 insulin, in AF 108
 insulin-like growth factor 1 115
 analogue 357
 insulin-like growth factor 3 115
 intellectual disability *see* cognitive impairment; IQ
 interchromosomal effect 195
 interferon, in AF 114
 interleukin-2 (IL-2), IL2RG gene defect 763
 interleukin-6 (IL-6) 114
 interleukin 7 (IL-7) receptor deficiency 759t
 intermediate filament structures, AF cells 123–124
 International Federation of Gynecology and Obstetrics (FIGO) 1092
 international perspectives 1091–1105
 PGD 1091, 1094–1099
 prenatal diagnosis 1091, 1092–1094
 interphase analysis, FISH *see* fluorescence in situ hybridization (FISH)
 intestinal herniation 627
 intestinal microvilli, disaccharidases 106, 107–108, 107f
 intestines *see* bowels
 intra-amniotic pressure 98
 intrachromosomal duplications 327
 intracranial aneurysm 35
 intracranial hemorrhage 670
 intracytoplasmic sperm injection (ICSI)
 46,XX/46,XY karyotype 294
 Down syndrome and 511
 men with sex chromosome abnormalities 268, 277
 Y chromosome microdeletions 26
 intranuclear inclusions, EXTAS 354, 355
 intrauterine fetal death *see* fetal loss; perinatal death/loss
 intrauterine growth restriction (IUGR) 85, 1033, 1033–1034
 CMV infection 957
 fetal causes 583
 functional assessment of heart 614
 genetic causes 192, 582–583, 1033, 1034, 1037t
 CPM *see* confined placental mosaicism (CPM)
 DNA methylation changes 1035
 imprinted gene disruption 1035
 imprinting and 1035
 prenatal diagnosis 1034
 trisomies 211, 212, 1034, 1037t
 trisomy 16 CPM 1034, 1035
 trisomy 16 mosaicism 214, 215, 1034
 trisomy 22 mosaicism 218
 MRI 662
 placental insufficiency 583, 1033
 pre-eclampsia and 1035
 prenatal diagnosis 1033–1034
 spiral artery remodeling insufficiency 1032
 intrauterine transfusion, parvovirus B19 infection 968
 intravenous immunoglobulin (IVIg) 605, 769, 983

1162 Index

- intrinsic factor deficiency 930
in utero surgery *see* fetal surgery
in utero treatment *see* fetal medical therapy
 invasive trophoblast antigen (ITA) 506
 inversions, chromosome *see* chromosomal structural rearrangements
in vitro diagnostics (IVDs) 708
in vitro fertilization (IVF) 1091
 aneuploidy testing benefits 441
 Down syndrome and 511–512
 embryo selection 442
 ethics 444
 multiple pregnancies 442
 poor prognosis, chromosomal abnormalities 441
 three-parent 403
 Ion-Torrent 382
 IPEX syndrome 769
 IQ
 48,XXXX 282
 49,XXXXX 282
 fragile X mutations 351, 352, 353
 Klinefelter syndrome 277–278
 triple X syndrome (47,XXX) 281
 Turner syndrome 271
 see also cognitive impairment
 Ireland, genetic disorders 28t
 isochromosome 20q 221
 isochromosome 21q 200
 isochromosome Xp (i(Xp)) 286
 isochromosome Xq (i(Xq)) 273, **286**
 isochromosome Yp (i(Yp)) 288
 isochromosome Yq (i(Yq)) 288
 isodicentric Yp (idic(Yp)) 288–289
 isodicentric Yq (idic(Yq)) 289
 isoelectric focusing, hemoglobinopathies 729
 isofagomine 797
 isoleucine metabolism disorders 885
 isovaleric acidemia 883
 isovaleryl-CoA dehydrogenase deficiency 883
 Israel
 law relating to prenatal diagnosis 1093
 PGD regulation 1098
 sex selection, regulation 1101
 Italy
 genetic disorders 28t
 PGD regulation 1096
 IUGR *see* intrauterine growth restriction (IUGR)
 ivacaftor (Kalydeco®) 702
 IVF *see in vitro* fertilization (IVF)

 Jacobsen syndrome 221
 JAK3 deficiency 759t, 764
 JAK3 SCID 764
 Japan
 genetic disorders and ethnicity 28t
 PGD regulation 1097
 sex selection prohibition 1100
 Jarcho–Levin syndrome 569
 jejunal obstruction 555
 jejunoileal atresia 555
 Jervell and Lange–Nielson syndrome 29
 Job syndrome (hyper-IgE syndrome) 761t, 768
 joint dislocations **693**
 junctophilin-3 gene 12
 J-wave syndromes 385

 Kallmann syndrome 187, 315t, 400, 516
 karyotype/karyotyping 25, 366
 abnormal, legal case 1078
 alternatives to 119
 chromosomal microarrays *vs* 185, 242
 fetal blood sampling 85
 limitations 366
 molecular *see* chromosomal microarrays (CMA)
 molecular genetic testing discordance 241–242
 oocytes 421, 439
 parental, abnormal 202
 parents with history of fetal losses 200–201
 prenatal, history **366–367**
 products of conception 373
 resolution 366
 time requirement 32, 366
 see also chromosomal abnormalities
 keratan sulfate (KS) 785, 857
 ketolytic disorders 884
 ketones 884
 β-ketothiolase deficiency 884
 “key-hole sign” 632, 633f, 635
 kidney
 amniotic fluid formation 99
 cystic 400
 horseshoe 270
 pelvic 561
 ultrasound 557
 see also renal anomalies
 kidney disorders 558t–560t
 agenesis 557, 558t
 cystic 559t–560t
 glycogen storage diseases 907
 microcysts 674–675
 MRI 674
 multicystic 560t
 obstructive anomalies 559t
 pelvic kidney 561
 polycystic *see* polycystic kidney disease
 structural 558t
 Turner syndrome 270
 ultrasound 557, 558t–560t, 561–562
 Klinefelter syndrome 15, **276–280**
 47,X,i(Xq),Y karyotype 279
 47,XXY karyotype 202, 276, 294, 295
 48,XXXY karyotype 280
 48,XXYY karyotype 279–280
 49,XXXXY karyotype 280
 49,XXYY karyotype 280
 array CGH 372
 clinical features 276–277
 cognitive/psychologic development 277–279
 ICSI and IVE, birth defect risk 277
 incidence 276
 management 276–277
 mosaicism 279
 noninvasive prenatal diagnosis (cffDNA) 465
 paternal age effect 276
 prenatal counseling 279
 screening tests 186
 steroids in AF 115–116, 115f
 knee, dislocations 693
 Kniest dysplasia 691
 Korea, genetic disorders and ethnicity 28t

- Krabbe disease 776f, 778t, **800–802**
 carrier detection 802
 laboratory/prenatal diagnosis 801–802
- labor and delivery
 gastroschisis 631
 hemophilia A carriers 24, 27
 labor induction method 1017
 Marfan syndrome 23
 preterm *see* preterm labor/birth
- laboratories
 prenatal cytogenetics, technical standards **239–242**
 safety 130
- lactase, development in fetus 106
- lactose 903, 914–915
 diet free of 915
- “lambda” sign 509
- lamellar bodies 103
- lamin A/C 355
- Laminaria japonicum* 1012–1013, 1018
- Langer–Gideon syndrome 315t, 317
- language impairment, Klinefelter syndrome 278
- Larsen syndrome **693**
 legal cases concerning 1082
- laryngeal atresia 618
- laser therapy
 CCAM 616, 618
 twin-to-twin transfusion syndrome 1004–1005, 1005f
- lateral ventricles
 in corpus callosum agenesis 664
 dilatation *see* ventriculomegaly
 ultrasound 573, 635–636
- latex allergy 147
- lawsuits 1064
- LDLR* gene mutations 779
- lead, in AF 111–112
- learning difficulties
 47,XY males 283
 Klinefelter syndrome 278
 triple X syndrome (47,XXX) 281
 Turner syndrome 271–272
see also cognitive impairment
- Leber congenital amaurosis 460t, 1081
- lecithin/sphingomyelin (L/S) ratio 103
- left ventricular hypoplasia 609, 610–612
- legal issues *see* medicolegal aspects
- legal system, USA 1064
- Leigh syndrome 403
- “lemon” sign 486, **505**, 542, 543f–544f, 544, 638, 639f
- leptin, in AF 116
- Leptotrichia* 114
- leucine metabolism disorders 885, 886
- leucinosi 883–884
- leukocyte(s) (fetal)
 DNA analysis sample 381
 NIPD using 732
see also lymphocyte deficiencies
- leukocyte adhesion (LAD) deficiency 762t, 767–768
- Lewis blood group substance 112
- Li–Fraumeni syndrome 402t
- likelihood ratio (LR) 489
 Down syndrome **491**, 495, 499, 500, 503
- limb-girdle muscular dystrophy 11, 25, 397
- limb reduction deficits/deformities 563–564, 564t, 565f
 CVS association 84–85
- limit dextrin 910
- limit dextrinosis (type III GSD) 904t, **909–910**
- LIMP-2 793
- LIPA* gene 808
- lipid(s) 766, 773
 in AF 102–103
- lipid metabolism 773
- lipid metabolism disorders **773–837**
 lipoprotein-associated *see* lipoprotein-associated disorders
 types 773
see also fatty acid oxidation
- lipomeningocele 638
- lipoprotein(s) 773
- lipoprotein-associated disorders 774t–775t, **776**, **779**, **779–780**
 prenatal diagnosis 780
- lipoprotein receptors 776
- liquid bead arrays 709t
- lissencephaly 666–667
 Walker–Warburg 667
- litigation *see* medicolegal aspects
- liver
 adenoma 907, 910
 glycogen storage 905–906
 in glycogen storage diseases 907, 910, 911, 914
 glycogen synthase deficiency 914
 herniation 996
 MRI 674
 in omphalocele 553f, 626, 627, 627f
 transplantation 808, 907, 911
 tumors 674
 ultrasound 554
- liver phosphorylase deficiency (type VI GSD) 904t, **912–913**
- lobar emphysema 673
- Loeys–Dietz syndrome 22, 402t
- long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)
 deficiency 846
- long-chain fatty acid oxidation, defects 838
- long QT syndrome 403t, 980
 duty to warn 19
 family history 29
 gene mutations and diagnosis 980
 Turner syndrome 270
- long-term depression (synaptic), fragile X syndrome 350, 357
- low birthweight, chromosomal defects and 583
- low copy repeats 367, 368t
- low-density lipoprotein (LDL)
 disorders affecting 774t–775t
 receptor 776, 779
- lower urinary tract obstruction (LUTO) 631–632, 631t
 diagnosis 632
in utero treatment 632, 634
 prognosis 635
 ultrasound 632, 633f
see also obstructive uropathy
- Luminex, FMR1 protein (FMRP) measurement 352
- lung
 abnormalities, MRI 673
 development 997
 echogenic defects, diagnosis
 second trimester **549–552**
 third trimester **615–622**
- hypoplasia
 congenital diaphragmatic hernia 673, 996
 hypoplastic left heart 611–612
 MRI 673

1164 Index

- lung (*Continued*)
- lesions, *ex utero* intrapartum treatment (EXIT) 993
 - maturity
 - lamellar body count 103
 - third-trimester amniocentesis for 81
 - transplants 702
 - ultrasound *see* ultrasound (US), prenatal diagnosis
 - volume 673
- lung-to-head ratio (LHR) 996
- lupus erythematosus, maternal 24, 980
- luteinizing hormone (LH), Klinefelter syndrome 276
- lymphangioma 671
- lymphedema, Turner syndrome 270–271
- lymphocyte deficiencies 758, 763–766
- B-cell *see* antibody deficiency
 - combined B and T cell 758, 759t–761t, 763–766
 - prenatal diagnosis 764–766
 - see also* severe combined immunodeficiency (SCID)
 - T-cell *see* T-cell(s), deficiencies
- Lynch syndrome 402t
- β-lysin 113
- lysine 882
- in AF 104
- lysine metabolism disorders 886
- lysine protein intolerance (LPI) 882
- Lyso-Gb3 790
- lysosomal acid lipase deficiency 807–809
- lysosomal enzymes 766f, 773, 781
- in AF 104
 - defects 766f, 773
 - glycosphingolipid catabolism 776f, 782–784
- lysosomal hydrolase 782
- deficiency 783
- lysosomal storage disorders 773, 778t, 783–784
- definition 783
 - enzyme replacement therapy 868–869
 - GAG types/sizes stored 863
 - lipid metabolism 773, 778t, 783, 784, 784–809
 - see also* glycosphingolipid(s); glycosphingolipidoses; GM₁-gangliosidosis; GM₂-gangliosidosis; *individual disorders as listed on 778t*
 - mucopolysaccharidoses *see* mucopolysaccharidoses (MPS)
 - neuronal ceroid lipofuscinoses 810t, 809
 - pathogenesis 859
 - as state of deficiency 859
- lysosomal sulfatases 783
- lysozyme 113
- macrocephaly 1118
- with hydrocephalus 1119–1121
- macroglossia 578–579
- macrophage defects 756
- macrophage-like cells, in AF 120
- Maffucci syndrome 395
- magnesium sulfate 991
- magnetic resonance imaging (MRI) 660, 660–680
- 3.0 T system 661
 - advantages 660, 671
 - bronchopulmonary sequestration 616, 673
 - CNS/brain 660–671
 - abnormal development 664–669, 665f, 668f
 - brain injury 670–671
 - CMV infection 956–957
 - corpus callosum agenesis 664–666, 665f
 - genetic disorders 669–670
 - inborn errors of metabolism 670
 - indications for 661–662
 - malformations 664–669, 665f, 668f
 - after normal brain ultrasound 661
 - normal development 662–664, 663f
 - subependymal cysts 670
 - technical issues 660–661
 - timing 661, 662
 - ventriculomegaly 669–670
 - dynamic cine 2D sequence 671, 673
 - maternal sedation for 661
 - non-CSN systems 671–675
 - abdomen and pelvis 674
 - chest 616, 673–674
 - genital tract 674–675
 - heart and mediastinum 673–674
 - neck 671–673, 672f
 - skeletal malformations 675, 682
 - technical issues 671
 - urinary tract and kidney 674–675
 - phosphorus, type V GSD 912
 - post-mortem 660
 - safety issues 660–661
 - techniques 660, 661, 671
 - magnetic resonance spectroscopy (MRS) 661, 671
 - Mahalinobis distance 485, 488, 488t, 501
 - malabsorption
 - cobalamin 930
 - folate, hereditary 927–928
 - malformation of cortical development (MCD) 665
 - malignant hyperthermia susceptibility 25, 403t
 - maltase 106
 - Management of Myelomeningocele Study (MOMS) 638, 641, 989, 995, 1004
 - MOMS II study 1004
 - manual vacuum aspiration (MVA) 1013–1014
 - Maoris, genetic disorders 29t
 - maple syrup urine disease (MSUD) 883–884
 - Marfan overlap disorders 694
 - Marfan syndrome 35, 402t, 694
 - genotype–phenotype associations 38
 - labor and delivery 23
 - maternal 22–23, 694
 - neonatal form 694
 - postpartum care 23, 694
 - preconception care 22–23
 - pregnancy care 23, 694
 - prenatal diagnosis 694
 - marital relationships, NTD in child, effect 148
- marker chromosomes 320–327
- analysis approaches 321, 322f, 324f, 325f
 - autosomal 322–324
 - dicentric 323, 324f
 - FISH analysis 320–327, 321f, 322f, 324f, 325f
 - syndromes detected 326
 - formation 322, 325–326
 - frequency 320–321
 - nonsatellited 322, 323, 324, 325f, 326
 - phenotype–karyotype correlations 321, 322, 326
 - postnatal identification 320
 - satellited 322, 323, 324f
 - sex chromosomes 286, 289, 321–322, 323t
 - small supernumerary (sSMC) 326
 - supernumerary *see* supernumerary marker chromosomes (SMCs)
- Maroteaux-Lamy disease (MPS VI) 858t, 865–866

- massively parallel sequencing (MPS) 463, 464, 466
- mass spectrometry
 electrospray tandem (ESI-MS/MS) 878
 time-of-flight 710t
- maternal age 20
 amniocentesis indication *see* amniocentesis
 chromosomal abnormalities 179, 181t, 183t, 193
 FISH analysis 331
 chromosomal microarray indication 193
 cytogenetic diagnosis indication 193
 DS risk analysis 489–490, 490
 fetal losses 75, 77, 490
 increase in number over 35 years 179
 NIPT indication 193
 PGD and 422
 preconception genetic counseling 20
 trisomy 18 (Edwards syndrome) risk 514
- maternal blood
 fetal DNA from fetal cells in 732
 serum *see* maternal serum
- maternal cell contamination (MCC) 236–238
 of AFC cultures 126, 237–238, 237t
 of CVS 236–237, 909
 detection 234, 236, 237, 238
- maternal deaths *see* maternal mortality
- maternal DNA contamination 748
- maternal–fetal complications, maternal serum screening 519
- maternal–fetal surgery 1123–1124
- maternal–fetal transmission
 CMV 950, 958, 960
 HIV infection 75
 parvovirus B19 967
 toxoplasmosis 944
 varicella 964–965, 966
- maternal health
 amniocentesis risks 74
 CVS risks 83
 fetal blood sampling risks 87
 fetal surgery risks 995
 genetic disorders in pregnancy
 Marfan syndrome 22–23
 pregnancy aggravated by 24–25
 threatening fetal health/survival 24, 982
 threatening maternal health 22–24
 metabolic disorders 22
see also pregnancy; *specific disorders*
- maternal history, unreliability 11–12
- maternal hyperoxygenation (MH) 611, 612
- maternal mortality
 amniocentesis and 74
 dilation and evacuation 1017, 1020, 1020t
 after fetal surgery 995
 legal abortions 1016, 1016t
 selective abortion in multiple pregnancies 1023
 suction aspiration/curettage 1016, 1016t
 unsafe abortions 1014
- maternal serum 483–540
 cell-free fetal DNA *see* cell-free fetal DNA (cffDNA)
 screening 119, 483–540
 for abdominal wall defects 518
 adverse maternal–fetal complications 519
 for cardiac abnormalities 518
 for chromosomal abnormalities 515–516
 for Cornelia de Lange syndrome 517–518
 decision-making and autonomy 520
 for DS *see* Down syndrome (DS)
 for Edwards syndrome 514–515, 515t
 fetal demise 518–519
 for moles 518
 for NTDs 485
 for Patau syndrome 515–516
 for placental mesenchymal dysplasia 518
 for Smith–Lemli–Opitz syndrome 517
 for X-linked ichthyosis 516–517
- screening markers 485–487
 AFP *see* maternal serum AFP (MSAFP)
 distributions 487–488
 hCG *see* human chorionic gonadotropin (hCG)
 inhibin A *see* inhibin A
 multiples of the median (MoMs) 487, 488, 488t
 PAPP-A *see* PAPP-A
 placental growth factor 486, 501, 502t
 uE₃ (estriol) *see* estriol
 screening program planning 519–521
- maternal serum AFP (MSAFP) 132, 483
 abdominal wall defects 518, 626–627
 anencephaly 485
 autosomal recessive nephrotic syndrome 400
 changes with gestation age 131, 131f, 132
 elevated 131, 134
 aneuploidies 188
 cytogenetic diagnosis indication 187–188
 gastroschisis 518, 553
 NTDs 131, 187, 483, 485, 488, 488t
 open spina bifida 485, 488, 488t, 545
 fetal demise and 518
 after first-trimester fetal reduction 1024
 first trimester screening, open spina bifida 505–506
 legal cases concerning 1074, 1080, 1085, 1086
 molar pregnancy 518
 peak levels 132
 reduced, DS screening 485, 488t, 501
 maternal diabetes and 512
 “unexplained” elevated 188
- maternal urine, total estriol excretion, screening 485
- maximum vertical pockets (MVP) 99, 100
- McArdle disease (GSD type V) 904t, 906, 911–912
- McKusick–Kaufman syndrome 557
- MCP (middle cerebellar peduncles) sign 353
- mean cell volume (MCV) 730t
 reduced
 normal Hb A₂ 730, 730t
 raised Hb A₂ 729, 730t
 screening for hemoglobinopathies 725, 729
- mean corpuscular hemoglobin (MCH) 723, 729, 730t
 reduced
 normal Hb A₂ 730, 730t
 raised Hb A₂ 729, 730t
 β-thalassemia 729
- Meckel–Gruber syndrome 400
 MRI 672f
 ultrasound 542, 542f
- Meckel syndrome 101, 135
- meconium, intraluminal, bowel obstruction 555
- meconium ileus 556, 701
- meconium peritonitis 555–556
- MECP2 285
- mediastinal shift 619f, 621, 621f
- mediastinum, MRI 673–674
- medical geneticists, referral to 8, 9, 27

1166 Index

- medical malpractice 1063
 concepts **1063–1065**
 legal process 1064
 medical negligence 1064
 medicolegal aspects **1063–1090**
 consent forms 34
 damages 1064, 1066, 1067, 1069, 1074, 1078, 1083, 1086, 1087
 future trends, wrongful birth/life claims 1069
 informed consent *see* informed consent
 litigation 9, 15, 19
 prenatal diagnosis errors/failures 33, 34
 medical malpractice *see* medical malpractice
 PGD **444–446**
 prenatal diagnosis **1093**
 privacy in reproductive decisions 1065
 summaries of cases 1069, 1070t–1072t, 1072–1088
 wrongful birth *see* wrongful birth
 wrongful life *see* wrongful life
 wrongful pregnancy/conception 1065–1066
 Mediterranean peoples, genetic disorders 29t
 medium-chain acyl-CoA dehydrogenase (MCAD) deficiency 840, 846
 mega cisterna magna 666
 megacystis 569f, 632, 633f
 first trimester ultrasound **568–569**
 megacystis-microcolon-intestinal hypoperistalsis syndrome 563
 meiosis 203, 228
 MELAS syndrome 403
 Menkes disease 982–983
 Mennonite people, genetic disorders 28t, 884
 “menstrual extraction” 1013–1014
 mental illness, after perinatal loss 1050, 1051, 1056
 mental retardation, nonspecific, FISH 315t
 meperidine 116
 mercury, in AF 111
 mesenchymal stem cells (MSC) 130
 mesenteric cysts 557
 mesocardia 605
 metabotropic glutamate receptor 5 (mGluR5)
 antagonists 357
 in fragile X syndrome 350, 357
 metachromatic leukodystrophy (MLD) 776f, 778t, **797–799**
 clinical features, subtypes 797–798
 genetics and mutations 797, 798, 799
 laboratory diagnosis 798–799
 prenatal diagnosis 104, 798–799
 pseudodeficiency allele (Pd) 700, 798
 therapy 799
 metaphase karyotype analysis *see* karyotyping
 metaphyseal dysplasia of Schmid 21
 methadone 116
 methimazole 982
 methionine adenosyltransferase (MAT) deficiency 889
 methionine synthase 930, 932
 deficiency 930
 2-methylacyl-CoA racemase (AMACR) deficiency 850–851
 methylation, of DNA *see* DNA methylation
 methylation-specific PCR 356
 2-methylbutyryl-CoA dehydrogenase deficiency 885
 methylcobalamin (MeCbl) 930, 931
 isolated deficiency **932**
 3-methylcrotonylglycinuria, biotin-resistant 885
 methylene blue 71
 methylenetetrahydrofolate reductase (MTHFR) 929
 deficiency 200, 890, **929**
 3-methylglutaconic aciduria 885
 methylmalonic acidemia (MMA) **882–883**, 931
 B12-responsive/-nonresponsive types 883
 noninvasive prenatal diagnosis 461t, 462
 prenatal diagnosis 105
 methylmalonic aciduria 928t
 combined with homocystinuria 928t, 932–933
 isolated 928t, **931–932**
 treatment 932
 without homocystinuria 931, 932
 methylmalonyl-CoA mutase 930
 deficiency 882–883, 930
 mevalonate kinase (MVK) deficiency 891
 mevalonic aciduria 891
 MFISH (multicolor FISH) 366
 MHC class II deficiency 759t, 766
 microarray analysis *see* chromosomal microarrays (CMA)
 microarray hybridization, CF carriers 710t
 microcephaly 192, 547, 667
 chromosomal defects and 576–577
 CMV infection 950, 954, 957
 legal cases concerning 1077, 1085–1086
 MRI 667
 ultrasound 547, 576–577, 954
 microcolon 674
 microdeletions
 contiguous gene syndromes **314–318**, 315t–316t
 cryptic rearrangements with 318
 detection by FISH **314–318**, 315t–316t, 338
 NIPT using cfDNA 185, 466–467
 Xp22 187
 α -thalassemia 315t, 720, 737
 see also chromosomal structural rearrangements; *specific chromosomes*
 microduplication syndromes
 cytogenetics and features 315t–316t
 FISH analysis 318
 NIPT using cfDNA 466–467
 β_2 -microglobulin 101, 632
 micrognathia 578
 micromanipulation, DNA from single fetal cell 732–733
 microRNA, cluster, chromosome 19 1032, 1033
 microvesicles, placenta 1032, 1033
 microvillar enzymes, in AF 106
 microvilli, intestinal, fetal origin 106, 107f
 middle cerebral artery (MCA), peak systolic velocity 968
 midwives, giving bad news 1057–1058
 mifepristone (RU486) 1013, 1020, 1021
 migalastat 792–793
 miglustat (N-butyldeoxyjirimycin) 786, 796–797, 806
 Miller–Dieker syndrome 314, 315t, 318
 minimal access fetal surgery *see under* fetal surgery
 minocycline 357
 miscarriage (spontaneous abortion) 1048
 see also fetal loss
 misoprostol 1013, 1021
 mitochondria
 DNA 401, 403
 fatty acid beta-oxidation 838, 841f, 847
 disorders *see* mitochondrial disorders
 peroxisomal beta-oxidation *vs* 838, **839–840**, 839f
 fatty acid degradation 840
 straight-chain fatty acid oxidation 843f

- mitochondrial disorders 401, 403–404, **838–856**
 fatty acid beta-oxidation 838, **840–847**, 842t
 enzyme pathways 841f, 843f
 genes, and deficient proteins 842t
 neonatal screening 840
 primary **840–847**, 842t
 secondary 840, 842t, **847–848**
 GM3 synthase defect 782
 inheritance 401
 nuclear 404
 PGD 403, 436
 prenatal diagnosis 401, 403–404
 primary 401
 mitochondrial trifunctional protein (MTP) 846
 deficiency 846–847
 mitral atresia 609, 610, 612, 613f
 mitral valve, prolapse 2
 “mixture model” 493
 MLD *see* metachromatic leukodystrophy (MLD)
 MLPA *see* multiplex ligation-dependent probe amplification (MLPA)
 MMAA gene mutations 931–932
 MMAB gene mutations 931
 MMAHC gene mutation 933
*M*nlI restriction enzyme 746, 747
 modifier genes 383
 molar pregnancy 201, 518
see also hydatidiform mole
 molecular cytogenetics **313–349**
see also fluorescence in situ hybridization (FISH)
 molecular genetics **380–418**
 advances 380
 carrier detection **384–385**
 clinical caveats, cautions, limitations **387–401**
 additional cautions, specific disorders 397–401
 adult onset disorders 401
 anticipation 387–389
 dynamic mutations 387–389
 genotype-phenotype correlations 396–397
 imprinting 395–396
 irreversible decisions 397
 mosaicism 389–395, 391t–393t, 394t–395t, 401
 uniparental disomy 395–396
 databases 384b
 diagnostic methods **381–384**
 methods 380, 381–384
 source of DNA for analysis 381
see also DNA analysis/testing
 incidental results, reporting **404**, 1111
 conditions, genes, variants 402t–403t
 karyotyping result discordance 241–242
 mitochondrial disorder prenatal diagnosis **401–404**
 mutation detection *see* mutations
 for PGD *see* preimplantation genetic diagnosis (PGD)
 presymptomatic/predictive DNA tests **385**
 molecular karyotyping *see* chromosomal microarrays (CMA)
 molybdenum co-factor deficiency 889–890
 MOMS *see* Management of Myelomeningocele Study (MOMS)
 monoclonal antibodies, FMRP deficits, fragile X syndrome 356
 monogenic disorders 425t–435t
 cfDNA, prenatal diagnosis **458–463**, 459t–461t, 470
 communication of prenatal results 33
 gene therapy 984
 genotype-phenotype associations 38, 396–397
 gonadal mosaicism 394t–395t
 mutation dosage for diagnosis 462, 462f
 PGD *see* preimplantation genetic diagnosis (PGD)
 somatic mosaicism 390, 391t–393t, 393
see also specific disorders
 21-monooxygenase deficiency 976–977
 monosomy 203
 monosomy 1p36 315t
 monosomy X 207, 465
 Monte Carlo simulation, DS screening 491–493, 492t
 moral burden, hESC research 1125–1126, 1126–1127
 moral risk 1113
 morbidity 5–6
 Morquio disease (MPS IVA) 858t
 Morquio disease (MPS IVB) 784–786, 858t, 865
 mortality rates 5–6
 maternal *see* maternal mortality
see also individual disorders
 mosaicism 2, **38–39**, **203–220**, 389–395
 autosomal monosomy 218–219
 autosomal pseudomosaicism *see* pseudomosaicism
 autosomal structural abnormalities **220–221**
 frequency 226, 227t
 autosomal trisomy *see* trisomy mosaicism; *specific chromosomes*
 chromosome involved 39, 204, 205, 206, 211–218
see also individual chromosomes, trisomies
 complex and variegated 219
 definition 203
 del(10)(q11.2) 221
 deletions at fragile sites 221
 diagnosis 39
 AFC, trisomies 216, 218, 220t
 AFC cultures 206–211, 207t, 208t, 209t, 210t, 219, 220–221
 AFC flask method 206, 225, 226t, 238
 autosomal mosaicism 220–221
 CVS 204–206, 205t, 219, 220
 error rates 241
 FISH 204, 337
 guidelines 225–226, 226t
in situ AFC 126, 225, 226t, 238
 NIPT 205–206
 preimplantation FISH 337
 recommendations 206, 211, 219–220
 sample source 381
 sex chromosome mosaicism 221–225
 “true mosaicism” criteria 206
 diploid/tetraploid 225
 diploid/triploid 225
 disease examples 38–39
 exclusion difficulty 206, 209
 frequency 206, 207t, 208t, 226, 227t
 CVS samples 205, 205t
 gain of autosome 211–218, 219–220
 genetic counseling for 38–39, 205, 226–227
 gonadal 12, 38–39
 epilepsy and 398
 monogenic disorders with 394t–395t
 PGD for *de novo* mutation 436
 vs somatic mosaicism 39, 390
 isochromosome i(20q) 221
 loss of chromosome 218–219, 219–220, **221**
 management guidelines 226, 226t
 mechanisms/causes 203, 274
 in osteogenesis imperfecta 688
 phenotype 203
 revertant 395

1168 Index

- mosaicism (*Continued*)
 selective pressures 203
 sex chromosomes 221–225, 267
 45,X/46,XX 221, 222, 223
 45,X/46,XY 222–223, 223t, 289
 45,X cell lines 223–224
 46,XX/47,XXX 224, **281–282**
 46,XY/47,XXY 223
 46,XY/47,XXY 224
 47,XXX females 281–282
 47,XXY males 284
 AFC culture 222–225, 222t
 CVS 221–222
 frequency 226, 227t
 NIPT discordant results 467
 occult Y chromosome 224–225
 poly-X syndromes 281–282
 recommendations 225
 structurally abnormal X chromosome 224
 structurally abnormal Y chromosome 224
 Turner syndrome 221, 222, 224
 types diagnosed 222, 222t
 somatic *see* somatic mosaicism
 uniparental disomy 203, 204
see also pseudomosaicism
 mother *see entries beginning maternal*
 motor skills, Klinefelter syndrome 278
 mourning
 duration 45–46
 process 42, 44–46
 MRI *see* magnetic resonance imaging (MRI)
 mRNA
FMR1 gene *see FMR1* gene
 next-generation sequencing 383
 MSAFP *see* maternal serum AFP (MSAFP)
MstII restriction enzyme 746
MTHFD1 deficiency 930
MTHFR gene mutations 670, 929
MTR gene mutations 932
 mucopolipidosis II/III 104, 783
 mucopolysaccharides 857
see also glycosaminoglycans
 mucopolysaccharidoses (MPS) 11, **857–876**
 biochemical features 858t
 biochemical genetics 862–867
 biomarkers for monitoring 862, 869, 870
 characteristics 858–859
 clinical progression and GAG type 860
 diagnosis 861
 future directions 869–870
 gene mutations 857, 858t, 870
 genotype-phenotype 869
 heterogeneity 859
 inheritance (autosomal recessive) 857
 MPS I (Hurler; Scheie) 858t, **862**
 clinical features 858–859
 enzyme replacement therapy 869
 GAG storage products 861
 α -L-iduronidase (IDUA) 859, 861, 862
 PGD 870
 prenatal diagnosis 862
 treatment 868
 MPS II (Hunter) 858t, **862–863**
 clinical features 858–859
 enzyme replacement therapy 869
 prenatal diagnosis 863
 MPS III (Sanfilippo) 858, 858t
 MPS IIIA **863–864**
 MPS IIIB **864**
 MPS IIIC **864**
 MPS IIID **864–865**, 867
 MPS IV (Morquio) 858t
 enzyme replacement therapy 869
 prenatal diagnosis 865
 type IVA **865**, 869
 type IVB 784–786, 858t, **865**
 MPS VI (Maroteaux-Lamy) 858t, **865–866**, 869
 enzyme replacement therapy 869
 prenatal diagnosis 866
 treatment 868
 MPS VII (Sly) 858t, **866–867**
 MPS IX (Natowicz disease) 858t, **867**
 multiple sulfatase deficiency vs 800
 pathogenesis and pathophysiology 859, 860
 PGD 870
 prenatal diagnosis 862, 863, 865, 866, **867–868**
 treatment 868–870
 enzyme replacement therapy 868–869, 870
 HSC T 868
 mucosulfatidosis 783
 multiple acyl-CoA dehydrogenase (MADD) deficiency 847–848,
 892–893
 multiple-cell pseudomosaicism (MCPM) 204, 207, 209, 209t, 210t
 multiple congenital anomalies (MCA), array CGH
 (aCGH) **367–369**
 multiple endocrine neoplasia (MEN)
 type 1 402t
 type 2 35–36, 402t
 multiple pregnancies
 amniocentesis 71–72
 cell-free fetal DNA (cffDNA) 455, 466
 CVS 84
 discordancy 584–585, 1022
 Down syndrome 511
 fetal blood sampling 88
 fetal loss risk 584
 fetal reduction *see* fetal reduction
in vitro fertilization 442
 NTDs 133
 prenatal diagnosis 583–584
 selective abortion *see* abortion (induced/elective)
 spontaneous abortion 1022
 ultrasound *see* ultrasound (US), prenatal diagnosis
see also twin pregnancies
 multiple sclerosis 353
 multiples of the median (MoM) 487
 Down syndrome screening 487, 501, 512
 twin pregnancies 509–510, 509t
 Edwards syndrome screening 515
 NTD screening 495, 496t
 multiple sulfatase deficiency (MSD) 778t, **799–800**
 multiplex allele-specific PCR 739
 multiplex ligation-dependent probe amplification (MLPA) 13, 382
 hemoglobinopathies 719, 736, 740–744, 746
 multivitamins, NTD prevention claims 145
 muscle, glycogen storage diseases 906, 910, 911–912
 muscleblind-like protein 1 (MBNL1) 355
 muscle phosphorylase deficiency (type V GSD) 904t, 906,
911–912
 muscular dystrophy
 Becker 27, 399
 Duchenne *see* Duchenne muscular dystrophy (DMD)

- fascioscapulohumeral 399
 limb-girdle 11, 25, 397
 myotonic *see* myotonic muscular dystrophy
- mutagenetically separated PCR 740
- mutations
de novo, PGD for 436
 detection of 380, 386
 deletions 382
 false-negative result 386
 methods 381–384, **386–387**
 presymptomatic testing 386–387
 dynamic 387–389
 detection in parent 387
 repeat expansions 387–389, 388t
 expansion 37
 point, detection, in β -thalassemia 740
 types *see* chromosomal structural rearrangements
- mut* gene mutations 883
- mycobacterial infections 756, 757t
- Mycoplasma*, contamination of AFC cultures 129, **239**
- myelin 780, 781
- myelination, changes during brain development 662–663, 664
- myelination gliosis 663
- myelomeningocele 638, 1004
 fetal surgery 638, 641, **1003–1004**
 MRI 666
 “two hit” hypothesis, and *in utero* correction 1004
see also open spina bifida (OSB)
- myelomeningocele sac 636
- MYH-associated polyposis 402t
- myocardial Performance Index 612, 614
- myoglobinuria 844, 912
- myopathies 25, 397
 prenatal diagnosis and PGD 399
- myophosphorylase deficiency (type V GSD) 904t, 906, **911–912**
- myotonic muscular dystrophy
 FXTAS vs 354
 NIPD for 459t
 pregnancy complications 24, 399
 prenatal diagnosis and PGD 399
 severity and maternal transmission 12
 triplet repeat size and severity 37, 388, 399
 type 1 (DM1) 12, 388–389, 399
 type 2 (DM2) 12, 389, 399
- Myozyme® (alglucosidase alfa) 909
- nail-patellar syndrome 112
- nasal abnormalities 578
- nasal bone (NB)
 absence, DS screening 487, 499–500, 499t, 501
 length (NBL), Down syndrome 503
 measurement, in Down syndrome 501, 503
 quality assurance of ultrasound 500
- National Center for Biotechnology Information (NCBI) 383
- National Down Syndrome Cytogenetic Register (NDSCR) 490, 491, 498
- Natowicz disease (MPS IX) 858t, **867**
- natural killer (NK) cell, deficiency 763
- NATUS (next-generation aneuploidy test using SNPs) 465
- neck abnormalities
 chromosomal defects and 579–580
 lateral masses 671–672
 MRI 671–673, 672f
 ultrasound 579–580, 671
- negligence 1064
 legal cases involving 1067, 1073, 1074, 1076, 1077, 1081
 screening gamete donors 1069
- neonatal adrenoleukodystrophy (NALD) 851
- neonatal alloimmune thrombocytopenia 983
- neonates
 CF screening 113, 755
 chromosomal abnormalities incidence 182, 184–185, 184t
 CMV infection 953–954
 death, definition 182, 184, 1049
 immune disease/deficiency 701
 Marfan syndrome 694
 varicella 963
see also entries beginning *congenital*
- nephrotic syndrome, congenital 400, 561
- Netherlands, legal issues relating to PGD 444, 1095
- neural tube defects (NTDs) **484**
 AF cell types 120
 AF constituents
 AChE 135–138, 136t, 495
 AFP 132–133, 132t, 485, 495
 AFP and AChE recommendations 138–139
 amino acids 108
 complications 145–148, 146t
 congenital defects associated 140
 etiology/risk factors 139–140
 folic acid and 3, 4, 5, 141
 food fortification 141, 144–145
 NTD cases despite supplements 141
 recommendations 141
 genetic counseling 139–141
 incidence/prevalence 3
 legal cases concerning 1074, 1078, 1086
 life expectancy 145–148
 maternal serum screening
 detection rates 495
 marker distributions 487–488, 488t
 model performance 495–496, 496t
 MSAFP 131, 131f, 187, 483, 485, 488, 488t
 moral, ethical, medicolegal aspects 147–148
 MRI 666
 multiple pregnancies and 133
 prenatal diagnosis **130–148**
 AFAFP/ACHE in AF *see above*
 false-positive results 131
 first trimester 567–568
 high-resolution ultrasound 130–131, 133
 second trimester 505–506
 techniques 139
 third trimester 636, 638–641
 ultrasound and amniocentesis 131, 139
 unsuccessful marker assays 131, 139
 prevalence 141
 previous child with
 cytogenetic diagnosis indication 200
 Down syndrome and 200, 508–509
 primary prevention 139–145
 folic acid *see above*
 multivitamins 145
 nutritional supplementation 141, 144–145
 recurrence risk in relatives 139, 140, 140t
 risk calculation 495–496
 sacral, diagnosis missed 134
 syndromes associated with 142t–144t
 ultrasound *see* ultrasound (US), prenatal diagnosis
see also spina bifida (SB)

1170 Index

- neuroblastoma, MRI 672f
- neurodegenerative disorders 18
- prenatal diagnosis 18, 21–22, 401
 - presymptomatic testing 18
- neurodevelopmental disorders 398
- fragile X mutations 352, 353
 - reduced FMRP levels 351
- neurofibromatosis
- delayed diagnosis (children) 21
 - legal cases concerning 1077, 1087
 - type 1
 - maternal, pregnancy complications 23–24
 - NF1 gene microdeletions 393
 - somatic mosaicism 13, 393
 - type 2 393, 402t
- neurofilament proteins, FXTAS inclusions 355
- neurologic disorders, prenatal diagnosis 397–398
- neuronal ceroid lipofuscinoses (NCL) 773, 810t, **809–812**
- diagnosis/prenatal diagnosis 811
 - genetics 810t, 809–811
 - treatment (development) 811–812
 - types 810t, 809
- New Zealand
- genetic disorders in Maoris 29t
 - PGD regulation 1098
- next-generation aneuploidy test using SNPs (NATUS) 465
- next-generation sequencing (NGS) 381, 382–383, 386, 443
- advantages 382, 383
 - aneuploidy testing (NIPT) 442, 443, 464
 - applications and new trends 1102
 - carrier screening 34
 - cystic fibrosis 711, 713
 - ethics 1110
 - family/future health profile 1102
 - limitations 383
 - method 382
 - NIPD using cffDNA 462, 463, 733
 - PGD 419, 442, 443
 - policy issues and regulation 1102
 - for relative haplotype dosage (RHDO) analysis 463
 - skeletal dysplasia 684–685
 - socioeconomic impact 1102
 - targeted approach, aneuploidy screening 464–465
 - whole genome approach 464
- NF1 gene, microdeletions 393
- NGS *see* next-generation sequencing (NGS)
- nicotine, in Af 116
- Niemann–Pick disease (NPD) 776f, 778t, **802–806**
- type C (NPC) 778t, **804–806**
 - laboratory/prenatal diagnosis 805
 - NPC1, NPC2 groups 804, 805, 806
 - types A and B 778t, **802–804**
 - laboratory/prenatal diagnosis 803–804
- NIFTY (National Institute of Child Health Development Fetal Cell Isolation Study) 335
- NIPD *see* noninvasive prenatal diagnosis (NIPD)
- NIPT *see* noninvasive prenatal testing (NIPT)
- nonaggressive obstetric management 1117–1118
- nonallelic homologous recombination (NAHR) 367, 368t
- nondirective genetic counseling 13–15, 17, 1109–1110, 1113
- noninvasive prenatal diagnosis (NIPD) 20, 453, 1102
- cystic fibrosis 25
 - ethical and psychological issues **470–471**
 - fetal cells in maternal blood 732–733
 - fetal DNA in maternal plasma 733
 - see also* cell-free fetal DNA (cffDNA)
 - for fetal sex determination 456, 457
 - future developments 462, 463, 733
 - hemoglobinopathies 732–733
 - NIPT *vs* 453
 - for single gene disorders 458–463, 459t–461t, 733
 - trends and applications 1102
- noninvasive prenatal testing (NIPT) 185, 453, 1111
- by cffDNA *see* cell-free fetal DNA (cffDNA)
 - confined placental mosaicism 1035
 - discordant/inconclusive results 467–470, 468t–469t
 - ethical and psychological issues **470–471**, 1111
 - impact 242, 470–471
 - indications, maternal age 193
 - invasive testing *vs* 467
 - low fetal fraction 185, 467
 - microdeletion syndromes 185
 - mosaicism detection 205–206, 467
 - positive result, cytogenetic diagnosis indication 185
 - uptake and benefits 470–471
 - use in private sector/commercial companies 467–468, 471
- nonketotic hyperglycemia (NKH) 890–891
- nonmaleficence (do no harm) 18–19, 1107
- nonpaternity 16, 41
- cystic fibrosis carrier 21
 - disclosure of 16, 19
 - frequency increase 16
- Noonan syndrome 188, 386, 397, 579
- Norwegians, genetic disorders 29t
- NPC1 and NPC2 protein defects 804, 805, 806
- NPC1 gene, mutations 804–805
- NPC2 gene, mutations 805
- NTDs *see* neural tube defects (NTDs)
- nuchal cystic hygroma **579–580**
- nuchal edema 580
- cystic hygroma *vs* 188, 191
 - trisomy 21 580
- nuchal skinfold (NF) 191, 487
- nuchal translucency (NT) 566, 566f, **570–572**
- cystic hygroma 498
 - DS screening 186, 486, 487–488, 493, 570–571
 - additional ultrasound markers 499–500, 499t
 - crown–rump length relationship 570, 571, 572b
 - detection rate/false-positives 494–495, 495t, 571, 571t
 - first trimester contingent screening 498–499, 571
 - mixture model distribution 571
 - NT only *vs* combined serum markers 494–495, 495t, 571
 - second trimester Combined test 501–503, 502t
 - study list 570t
 - twin pregnancies 510
 - first trimester, measurement 566, 568
 - increased, disorders with 186, 191, 569
 - cardiac defects 518, 568
 - genetic syndromes 569
 - measurement, protocol 572b
 - twin pregnancies 510, 584
- numerical integration, DS screening 491–493, 492t
- nutritional supplementation, NTD prevention 141, 144–145
- OAT deficiency 881
- obesity, maternal, congenital anomaly prevalence 4–5
- obstetricians, giving bad news 1057–1058

- obstructive uropathy 562, 568, **998–999**
 bilateral 998
 fetal surgery 998–999
 ultrasound **562–563**, 563, 998
 urinary sodium and calcium 563, 563f
see also lower urinary tract obstruction (LUTO)
- OCTN2 deficiency 842–843
- ocular abnormalities 578
- oligodendrocytes, galactosyl ceramide synthesis 780, 781
- oligohydramnios 74, 99, 100, 566
 MRI 674
 obstructive uropathy 998
 renal agenesis and 557
 ultrasound 566
- oligonucleotide ligation assay 709t
- oligonucleotide primers, abnormal hemoglobins 745t, 747t
- oligonucleotide probes 739
- oligospermia 26, 276, 288
- Omenn syndrome 760t
- omental cysts 557
- omphalocele **626**
 AFChE positive 137, 138
 anomalies associated 552, 554, 626, 628
 chromosomal abnormalities 138, 552, 581, 626
 differential diagnosis 627
 gastroschisis *vs* 626
 giant 627
 incidence and cause 552, 626
 management/outcome 627–628
 MSAFP levels 518, 626–627
 recurrence risk 626
 ultrasound diagnosis **552–553**, 553f, 581
 first trimester 568, 626
 second trimester 552–553, 553f, 626
 third trimester 626–628, 627f
- oncogenesis, insertional 984
- oocytes
 aneuploidy 438
 biopsy 420–421
 chromosomal abnormality rate 439, 440, 440t
 genotyping 420
 karyotypes 421, 439
 polar body analysis 420, 421, 436
 unfertilized, cytogenetic analysis 438–439
- open spina bifida (OSB) 484
 complications 145–146, 146t
 fetal surgery 638, 641, **1003–1004**
 open *vs* minimal invasive 1004
 MSAFP levels and 485, 488, 488t, 496t, 545
 prenatal diagnosis and prognosis 484, 545
 ultrasound screening **505–506**, 542, 544–545
 biparietal diameter 505
 findings by gestational age 544t
 first trimester 505–506, 567–568
 second trimester anomaly scan 505
 second trimester signs 505, 542, 543f–544f, 544
 third trimester 636, 638–641, 639f
see also myelomeningocele
- opioid analgesics 116, 991
- opportunistic pathogens 756
- optic nerves, hypoplasia 666
- oral contraceptives 31, 1065, 1080
- oral–facial–digital syndrome type II 1084
- organic acid metabolism 877, 878f, 882
 disorders 882–883
- organophosphates 118
- ornithine aminotransferase (OAT) deficiency 881
- ornithine metabolism disorders 881–882
- ornithine transcarbamylase (OTC) deficiency 22, 879–880
- oropharyngeal teratoma **1003**
- OSCAR 493, 572
- osmotic dilators, endocervical canal 1012, 1013, 1018
- osmotic fragility test 729
- osteogenesis imperfecta (OI) 564, **687–690**
 clinical features 687–688
 mosaicism 688
 mutations associated 684, 688, 689
 prenatal diagnosis 689–690
 type I 689
 type II 681, 689
 type III 689, 689f, 690f
 type IV 689, 690
 ultrasound 689–690, 690f
- osteoporosis, Klinefelter syndrome 277
- otitis media, Turner syndrome 271
- ovary
 absence/removal, chromosomal abnormalities after 202
 cancer, risk in Ashkenazi Jews 36
 cysts 556–557
 polycystic ovary syndrome 907
 premature failure, fragile X premutation 353
- ovotesticular disorders of sex development 293–294
- oxygen, reduction, AF cell growth 127
- oxygen therapy, legal case involving 1076
- oxytocin 1021
- p53 tumor suppressor gene mutations 436–437
- p450 aromatase deficiency 976
- pachygyria 667
- pain
 amniocentesis 69
 control, fetal surgery and 991
 after suction aspiration 1015
- Pallister–Killian syndrome 231–232, 326
- palmitoyltransferase 781
- pancreas, CF and 701, 702, 704
- pancreas annulare 624, 625f
- pancreatitis, hereditary 29
- P-antigen 967
- PAPP-A (pregnancy-associated plasma protein-A) 185, 486
 45,X 186
 DS screening 486, 501, 505
 ethnicity and 513
 maternal diabetes and 512
 smoking and 513
 fetal demise and 518
 molar pregnancy 518
- paracervical block 1013, 1018
- parents
 attitudes to elective abortion 41
 autonomy 1068
 caring for, after perinatal loss 43, 1057–1059
see also perinatal death/loss
 carrier of genetic disorder **26–29**
 costs of raising child, legal issues 1066, 1067
 counseling 17, 32
see also genetic counseling
 decision making 10, 14, **40–41**, 1053
 failure of physician to inform on results 1074, 1075, 1080, 1086

1172 Index

- parents (*Continued*)
- genetic disorders, preconception genetic counseling
 - indication 21–22
 - genetic testing of other children 42–43
 - grief and mourning process 41–42, 44–45, 1049, 1050
 - gender differences in grief **1055–1056**, 1055t
 - see also* grief; perinatal death/loss
 - guilt 10–11, 44, 1050, 1052
 - prenatal diagnosis request 40
 - response to diagnosis and fetal surgery 989
 - response to surviving children after perinatal death 43, 46, 1052
 - right to privacy **1065**
 - wrongful life claims against **1068**
 - wrongful pregnancy 1065–1066
 - see also* family
- Parkinson disease 794
- “partially methylated domains” 1039
- parvovirus B19 infection **967–969**
- epidemiology, maternal infection 967
 - prenatal diagnosis 967–968
 - treatment 968–969
 - vertical transmission 967
- Patau syndrome *see* trisomy 13 (Patau syndrome)
- paternal age
- advanced, cytogenetic diagnosis indication 193–194
 - Klinefelter syndrome and 276
 - somatic mosaicism mutations 393
- paternal consent 1122
- paternalism 1114
- paternal transmission, triplet repeats and 38
- paternity *see* nonpaternity; parents
- pathogens, infections in immunodeficiency 756, 757t
- patient autonomy *see* autonomy
- patients 1108
- fetus as *see* fetus
 - rights 1108
- PCR *see* polymerase chain reaction (PCR)
- Pelizaeus–Merzbacher disease (PMD) 318
- legal cases involving 1083
- pelvic masses (fetal), MRI 674
- pelvis (fetal), MRI 674
- pentalogy of Cantrell 552
- pentanucleotide repeats 388
- pentasomy 49,XXXXY 280
- pentasomy X 282
- pentosuria 905t, **918**
- peptidases, in AF 106
- percutaneous ultrasound-guided fetal surgery 992–993
- percutaneous umbilical blood sampling (PUBS) *see* fetal blood sampling
- pericardial teratoma **1003**
- pericardiocentesis 1003
- perinatal death/loss 1048–1049
- clinical implications and therapy after **1056–1059**
 - after clinical release 1058
 - after delivery of dead child 1058
 - giving diagnosis 1057
 - obstetricians/midwives role/stress 1057–1058
 - doctor–patient conversation after 1058, 1059t
 - evaluating the cause 43, 44t
 - gender differences in response **1055–1056**, 1055t
 - giving diagnosis, caring for parents 1057
 - grief after **1048–1062**
 - impact on subsequent pregnancy 1052
 - impact on women’s identity 1050
 - incidence 1048
 - momentoes of baby 44–45
 - mourning process 42, 44–46
 - neonatal death 182, 184, 1049
 - no rituals of mourning 1050–1051
 - online support after 1057
 - parental guilt 10–11, 44, 1050, 1052
 - “replacement child” 46
 - seeing fetus/baby body 1051, 1053, 1058
 - sudden, grief 1050
 - surviving children after 46, 1052
 - see also* fetal loss; stillbirth
- perlecan 860
- peroxisomal disorders **838–856**
- biogenesis disorders (PBD) 851
 - fatty acid beta-oxidation **848–852**
 - primary **848–851**, 848t
 - secondary 848, 848t, **851–852**
- peroxisomes, fatty acid beta-oxidation 838, 841f
- mitochondrial beta-oxidation vs 838, **839–840**, 839f
- personality, grief after perinatal loss 1052
- “personalized medicine” 702
- pesticides, in AF 117t
- Peutz–Jeghers syndrome 402t
- PGD *see* preimplantation genetic diagnosis (PGD)
- phagocyte defects 762t, **767–768**
- diagnostic tests 758t
- pharyngotracheal duct 618
- phenotypic variation, awareness in genetic counseling 11
- phenylalanine hydroxylase (PAH) 105
- deficiency 886
 - gene mutations 887
- phenylalanine metabolism disorders **886–887**
- PKU *see* phenylketonuria (PKU)
 - tetrahydrobiopterin (BH4) deficiency 887–888
- phenylalanine/tyrosine ratio 105
- phenylketonuria (PKU) **886–887**
- incidence 886
 - maternal 24, 886–887, 982
- phosphatidylserine, in AF 102
- phosphoenolpyruvate carboxykinase (PEPCK) deficiency 905t, **917–918**
- phosphofructokinase deficiency (type VII GSD) 904t, 906, **913**
- phospholipids, in AF 101, 102–103
- phosphorylase b kinase deficiency (type IX GSD) 904t, **913–914**
- phthalates 117t, 118
- phytoestrogens 117t
- Pierson syndrome 400
- PIGF (placental growth factor) 486, 501, 502t, 1032, 1034
- PKD1 gene 35, 400
- PKHD1 gene 400
- PKU *see* phenylketonuria (PKU)
- PLA2 86
- PLAC4 gene 463
- placenta **1031–1047**, 1032, 1034
- angiogenesis 1032
 - CMV infection, ultrasound 955
 - development **1032–1033**
 - DNA methylation profiles 1040
 - epigenetic studies
 - clinical application 1039–1040
 - environment and 1040
 - evaluation, future prospects 1040
 - function **1032–1033**
 - genetic/chromosomal defects affecting 1037t

- immune function 1033
 implantation and invasion 1032
 failure 1032
 imprinted differentially methylated regions (DMRs) 1040
 insufficiency **1033**, 1034
 IUGR 1033–1034
 microparticles 1032, 1033
 molar changes *see* hydatidiform mole
 mosaicism *see* confined placental mosaicism (CPM)
 nutrient delivery 1032–1033
 pathology 1034
 pre-eclamptic *see* pre-eclampsia
 size 1031, 1040
 structure **1031**
 syncytial knots 1034, 1035
 transport of substances across 1032–1033
 in trisomy 1034
 vasculature 1032
 “placenta chromosome” (chromosome 19) 1032
 placental growth factor (PlGF) 486, 501, 502t, 1032, 1034
 placental mesenchymal dysplasia (PMD) 1036, **1039**, 1038f
 maternal serum screening 518
 plastic consumables, AFC cultures 127, 129
 PLEC gene 400
 plectin gene 400
 pleiomorphic genes 22
 pleiotropism 21, 31
 pleural effusions 551–552, 616
 congenital hydrothorax 618
 thoracoamniotic shunts 551–552, 552f
 ultrasound 551–552, 551f
PLP1 gene duplication 318
 PLUG (Plug the Lung Until it Grows) 997, 997f
 PLUTO trial 999
Pneumocystis jirovecii 756
 polar bodies 421, 439
 polar body analysis/sampling **420–421**, 424, 439
 detrimental effects 421
 embryo viability after 421
 first, PGD 421, 423, 424, 436, 439
 FISH 439–440
 fragile X mutations 356
 second 421, 424, 436, 439
 sequential (first then second polar bodies) 436, 439, 439f
 polyacrylamide gel electrophoresis (PAGE) 135, 136
 polyalanine tract expansion 389, 390t
 polybrominated diphenyl ethers (PBDEs) 117t
 polychlorinated biphenyls (PCBs) 117t
 polycystic kidney disease
 adult *see* adult polycystic kidney disease (APKD)
 autosomal dominant *see* autosomal dominant polycystic kidney disease (ADPKD)
 autosomal recessive 11, 400
 infantile (Potter type I), ultrasound 561
 legal cases involving 1083
 multicystic dysplastic (Potter type II) 561
 noninvasive prenatal diagnosis 460t
 Potter type III renal dysplasia 561
 ultrasound 561–562
 polycystic ovary syndrome 907
 polyhydramnios 99–100
 conditions associated 100, 565
 CCAM 549
 diaphragmatic hernia 621
 duodenal atresia 624
 esophageal atresia 622–623, 623f
 gastroschisis 628
 omphalocele 626
 VACTERL syndrome 623f
 incidence 565
 management 565
 twin-to-twin transfusion syndrome 565
 ultrasound 565–566
 polymerase chain reaction (PCR)
 ARMS-PCR *see* amplification refractory mutation system (ARMS)
 cell-free fetal DNA (cffDNA) 456, 464, 733
 CMV infection 953, 954, 958
 digital PCR 381, 733
 DNA contamination 423, 748
 fluorescence-PCR 381, 423
 fragile X syndrome diagnosis 355–356
 gap-PCR *see* gap-PCR
 hemoglobinopathies 718–719, 733, 747, 748
 nondeletion mutations, α -thalassemia 737, 737f
 β -thalassemia 738, 739, 740
 methylation-specific 356
 multiplex allele-specific 739
 multiplex fluorescent 356
 multiplex nested 423
 parvovirus B19 detection 967
 PGD DNA analysis 356, 423
 point mutations detected by 738–739, 740
 preferential amplification, PGD misdiagnosis 423
 primer-specific amplification 739–740
 QF-PCR *see* quantitative fluorescence PCR (QF-PCR)
 rapid, using chimeric PCR primer 356
 real-time 733, 945
 aneuploidy detection, cffDNA 464
 fetal sex determination by cffDNA 456
 PGD 423–424
 α -thalassemia 736
 RE (restriction endonuclease)-PCR 737
 rubella virus RNA 963
 single cell (fetal cell) 732
 toxoplasmosis 944–945
 varicella infection 965, 966
 polymicrogyria (PMG) 664, 667, 668f
 polymorphisms *see under* chromosome(s)
 Polyphen2 prediction program 382
 poly-X syndromes **280–282**
 mosaicism 281–282
 Pompe disease (type II GSD) 104, 904t, 906, **908–909**
 pontocerebellar hypoplasia 647, 669
 population screening programs
 CF carriers 706–708, 706t
 mucopolysaccharidoses 870
 Tay–Sachs disease carriers 27, 788
 porencephaly 670
 positive predictive value (PPV) 485
 posterior fossa abnormalities 578, 647, 650, 669
 posterior fossa cyst, MRI 665f, 666
 posterior urethral valves (PUV) 631, 998
 postpartum care, Marfan syndrome 23
 post-traumatic stress syndrome 1053
 potassium chloride (KCl), in pregnancy termination 1017, 1022, 1024
 Potocki–Shafer syndrome 315t
 Potter type I infantile polycystic kidney disease 561
 Potter type II multicystic dysplastic kidney 561
 Potter type III renal dysplasia 561

1174 Index

- “pouch sign” 623
- Prader-Willi syndrome
- Angelman syndrome vs 185
 - chromosome 15 SMC 231, 235
 - deletions 314, 315t
 - uniparental disomy 21
- preconception care 18–19
- carriers of genetic disorders 26–27
 - Marfan syndrome 22–23
 - sex-linked disorders 27
 - type 1 diabetes mellitus 25
- preconception genetic counseling 7, 20–22
- avoidance of environmental hazards 31
 - indications for 20–22
 - advanced maternal age 20
 - earlier fetus/child with a defect 20–21
 - infertility problems 25
 - parental genetic disorder 21–22
 - male partner attendance 20
 - risks, options available 31–32
- preconception genetic diagnosis 420
- “preconception tort” 1081
- predictive testing *see* presymptomatic testing
- pre-eclampsia 1032, 1035–1036
- cell-free fetal DNA levels 454
 - early diagnosis 1036
 - early-onset (EOPE) 1035, 1036
 - genetics 1036
 - late-onset (LOPE) 1035, 1036
 - maternal serum markers 519
 - prevention, aspirin prophylaxis 519
 - trisomy 13 (Patau syndrome) 1036
 - trisomy 16 215, 1036
- pre-embryonic diagnosis 424, 436
- see also* polar body analysis/sampling
- pregnancy
- alcohol intake 982
 - anesthesia in 990–991
 - bleeding disorders 983
 - bonding with fetus 1110
 - CMV infection *see* cytomegalovirus (CMV) infection
 - confidentiality 1111
 - continuation, with genetic disorders 1115
 - dexamethasone in 978
 - drugs in 116–118, 117t
 - ectopic 1015
 - epilepsy in *see* epilepsy
 - genetic disorders aggravated by 24–25
 - glucocorticoids in 978
 - in GSD type I 907
 - in GSD type II 908
 - losses *see* miscarriage (spontaneous abortion)
 - Marfan syndrome (maternal) 22–23, 694
 - maternal risks of fetal surgery 995
 - parvovirus B19 infection 967
 - phenylketonuria *see* phenylketonuria (PKU)
 - recurrent loss 25–26, 200–201
 - rubella 962
 - surgery in 990–991
 - intraoperative/postoperative monitoring 991
 - see also* fetal surgery
 - termination *see* abortion (induced/elective)
 - thyroid disorders 981, 982
 - toxoplasmosis prevention 947–948
 - toxoplasmosis risk factors 943–944
 - in Turner syndrome 270
 - unplanned, loss, grief 1052
 - varicella 964
 - wrongful 1065–1066
 - see also* maternal health
- pregnancy-associated plasma protein-A (PAPP-A) *see* PAPP-A
- pregnancy-specific glycoprotein (PSG) 506, 1032
- preimplantation embryo
- biopsy *see* embryo, biopsy
 - metabolism, aneuploidy and 420
- preimplantation genetic diagnosis (PGD) 419–452, 732, 734
- advantage over prenatal diagnosis 443–444, 1092
 - amino acid metabolic disorders 878
 - aneuploidy analysis 419, 438, 440–441
 - accuracy 442
 - array CGH 373–374, 440t, 442, 443f
 - benefits 440–441
 - embryo viability and 441
 - FISH 337, 374, 439–440, 442
 - goal 337, 440–441
 - limitations 441
 - next-generation sequencing 442
 - unfertilized oocyte analysis 438–439
 - whole genome amplification 442
 - approaches 374, 419–422, 734
 - biopsy at cleavage stage 422, 423
 - blastocyst biopsy 422, 442
 - blastomere biopsy 421–422
 - noninvasive methods 420
 - polar body sampling 420–421, 424
 - pre-embryonic method advantages 424, 436
 - spare embryo analysis 420
 - see also* polar body analysis/sampling
 - chromosomal disorders 438–444
 - common disorders with genetic predisposition 436–438
 - Alzheimer’s disease 437–438
 - inherited cardiac diseases 437
 - congenital adrenal hyperplasia 978
 - contamination sources 423
 - controversies 445
 - counseling before 1096
 - cystic fibrosis 713
 - for *de novo* mutations 436
 - ethics 444–446, 1092
 - fragile X mutations 356, 358
 - funding, control 1099
 - future prospects 1102
 - Gaucher disease 789, 796
 - genetic analysis methods 374, 422–438
 - array CGH 373–374, 440t, 442
 - FISH 336–338, 439–440, 442
 - nested PCR 423
 - next-generation sequencing 424, 1102
 - protocols 424
 - real-time PCR 423–424
 - sequence information requirement 424
 - whole genome amplification 424, 442–443
 - glycosphingolipidoses 784
 - goal/aims 1091, 1099–1100
 - in gonadal mosaicism 436
 - guidelines/recommendations 420, 1097–1099
 - Hb E disorders 724t
 - hemoglobinopathies 724t, 726t, 734
 - historical aspects 419–420
 - HLA typing *see* HLA typing, preimplantation

- increasing use and impact 419, 440, 441–442, 443, 445
 indications/uses 374, 419, 422–423, 437, 734, 1099
 international issues 1094–1096
 list of disorders 424, 425t–435t
 international perspectives **1091–1105**
 emerging technologies and 1101–1102
 legal and regulatory issues **444–446**, 1063, 1092, **1094–1099**
 countries permitting PGD 1094–1096
 countries prohibiting PGD 1096–1097
 “hybrid” regulatory approach 1097–1099
 professional guidelines 420, 1097–1099
 trends 1099, 1102
 maternal age and 422
 misdiagnosis, and prevention 423–424, 436
 mitochondrial disorders 403, 436
 mucopolysaccharidoses 870
 as prenatal diagnosis alternative 443–444, 1091, 1092
 professional guidelines (regulatory) **1097–1099**
 “hybrid” regulatory approach 1097–1099
 sex selection **1099–1101**
 nonmedical purposes, prohibition 1100
 sickle cell disease 726t
 single gene disorders 423–424, 436, 1094–1095
 number and list 424, 425t–435t
 X-linked disorders 424
 socioeconomic issues 1091
 success rate 734
 Tay–Sachs disease 789, 796
 trait selection 1100
 prekeratin 124
 premature birth *see* preterm labor/birth
 premature ovarian failure (POF) 353
 premature rupture of membranes (PROM) 74
 fetal surgery and 992, 995, 996
 congenital diaphragmatic hernia 997, 998
 pre-nasal thickness (PT), in DS 487, 502t, 503
 prenatal care, timing 18, 19
 prenatal diagnosis **484–485**, 1091
 access to, WHO statement 1092
 accuracy rate and errors 33
 anticipated burden and effects of 8–9, 17
 competence **1110**
 concerns over, D and E 1017
 decision-making after 10, 14, **40–41**, 1011, 1053
 delayed diagnosis in previous child 21
 dilemmas 16, 1011
 disclosure of results 1110–1111
 false-positive/-negative results 32
 genetic counseling after result *see* genetic counseling
 genetic counseling as prelude to *see under* genetic counseling
 goal and purpose **6–8**
 impacts 3, 39, 989, 1053
 indications 16
 international approaches 1093–1094
 international perspectives **1091–1105**
 legal approaches **1093**
 litigation, errors/failures involved 33, 34
 noninvasive *see* noninvasive prenatal diagnosis (NIPD)
 parental request 40
 professional guidelines **1093–1094**
 referral **1110**
 regulatory issues 1093–1094
 repeat study 40
 risks and limitations 32, 40
 screening vs 484–485
 socioeconomic issues 1091
 as standard of care 1092, 1093, 1101
 techniques 68, 85, 119
 see also amniocentesis; chorionic villus sampling (CVS);
 fetal blood sampling; fluorescence in situ hybridization
 (FISH)
 time requirement 32
 trends 1102
 presymptomatic testing (predictive testing) **34–37**
 breast cancer 36
 in childhood 36
 DNA testing *see* DNA analysis/testing
 harm from 18, 34–35
 Huntington disease 18, 34, 35, 36
 importance of, conditions 35
 model, themes and requirements 36
 motivations leading to 18, 34–35
 “no hope” results 18, 34–35
 other children (siblings of affected fetus) 43
 support program requirement 35
 uptake 35
 preterm labor/birth
 cocaine and 118
 congenital malformation prevalence 4
 cystic fibrosis in mothers 25
 fetal surgery and 992, 995, 996
 infections and 1033
 maternal serum markers 519
 prevalence of genetic disorders **1–5**, 2t
 factors influencing estimates 3t
 primed *in situ* labeling (PRINS) 333
 primer-specific amplification, β -thalassemia 739–740
 Primum non nocere 1107
 privacy, right to **1065**
 products of conception (POC)
 array CGH 373, Plate 8.3
 dilation and evacuation 1018, 1019
 karyotyping 373
 retained 1015, 1020
 professional guidelines
 PGD **1097–1099**
 prenatal diagnosis **1093–1094**
 professional responsibility model **1106–1109**, 1109, 1112
 pregnancy termination after viability 1117
 progesterone, in celomic fluid 115
 progesterone antagonists (mifepristone) 1013, 1020, 1021
 progressive myoclonic epilepsy 777t
 prolidase deficiency 891–892
 proline metabolism disorders 892
 propionic acidemia 105, **882**
 noninvasive prenatal diagnosis 460t
 propionylcarnitine 882
 propionyl-CoA carboxylase deficiency 882
 proportionality in medical ethics 1116
 propothiouracil (PTU) 982
 prosaposin (sap-precursor) 783
 deficiency 778t, 783, 807
 prostaglandin(s)
 as abortifacients 1020, 1021
 endogenous, cervical softening, suction aspiration 1013
 prostaglandin E2 (PGE2) 1020
 proteins, in AF 102
 proteinuria
 fetal 134
 pre-eclampsia 1035

1176 Index

- proteoglycans
 catabolism 860–861
 glycosaminoglycan component 860
 proteomics
 AF 102
 cystic fibrosis 713–714
 Proteus syndrome 395
 prothrombin 112
 proton-coupled folate transporter (PCFT) mutations 927, 928
 Provera 1076
 prune belly syndrome 569f, 631, 998
 pseudodeficiencies in lysosomal enzymes 783
 arylsulfatase A (ASA) 798
 hexosaminidase A (HexA; $\alpha\beta$) 788
 pseudodeficiency alleles 783
 pseudomosaicism 203–220
 AFC cultures 206
 autosomal trisomy 209–210, 210t
 concerns over 210–211
 frequency 206, 207t, 208t, 209t
 multiple cell 204, 207, 209, 209t, 210t
 single cell 204, 206, 209, 209t, 210t
 trisomy 16 mosaicism and 215
 see also mosaicism
 pseudovaginal perineoscrotal hypospadias 293
 pseudoxanthoma elasticum 23
 psychiatric disorders 398
 psychological support 43
 psychologic development/features
 47,XXX males 283–284
 fragile X mutations 352, 353
 Klinefelter syndrome 277–279
 triple X syndrome 281
 Turner syndrome 271–272
 psychologic issues
 distress, perinatal loss 1053, 1054, 1056, 1057, 1058
 noninvasive testing based on cfDNA 470–471
 psychopathology, fragile X mutations 352
 psychosine 802
 PTEN hamartoma tumor syndrome 402t
 pterin-4 α -carbinolamine dehydratase (PCD) 887, 888
 puberty 270, 274, 294
 publication bias 211, 268
 public policy, fairness 1125
 pulmonary abnormalities *see* lung
 pulmonary atresia 609
 pulmonary edema, maternal 995
 pulmonary hypoplasia *see* lung, hypoplasia
 pulmonary stenosis 609
 pulmonary surfactant 103
 pulmonary vasculature, hypoplastic left heart 611
 pulmonary vasoreactivity 611
 pulsatility index for veins (PIV) 500
 pulse oximetry 991, 992
 purine nucleoside phosphorylase (PNP) deficiency 759t, 765
 puromycin 439
 Pur α protein 355
 “pyramid of care” 519
 pyrimethamine 945, 945t, 947
 pyrosequencing, thalassemia 737, 740
 6-pyruvoyl tetrahydrobiopterin synthase (PTPS) deficiency 887, 888
 quality control, AF cell culture 130
 quantitative fluorescence PCR (QF-PCR) 178, 333
 karyotyping result discordance 241, 242
 maternal cell contamination detection 237
 radiation, maternal exposure 203
 Ras-Association Domain Family Member 1 (RASSF1A) 456
 RASopathy 397
 RB1 gene mutations 401
 reading disability 278
 Recombinant DNA Advisory Committee (RAC) (NIH) 1123
 recombinase activating gene (RAG-1, RAG-2) deficiency 759t, 765
 record keeping, AF cell culture 130
 red cell indices (MCH, MCV)
 Hb A₂ value 729, 730t
 reduced
 normal Hb A₂ value 730, 730t
 raised Hb A₂ value 729, 730t
 5 α -reductase deficiency 293
 referral
 for genetic counseling 8, 9, 27
 indirect, for abortion 1115
 in prenatal diagnosis 1110
 Refsum disease 838, 851
 relative haplotype dosage (RHDO) analysis 463
 relative mutation dosage (RMD) 462, 462f
 relatives *see* family
 relaxin 108, 111
 religion
 ethics of stem cell research 1124–1126
 perinatal loss 1052, 1054
 PGD and 424, 734
 renal agenesis 557, 558t
 renal amino acid transport disorders 892
 renal anomalies
 fetal aneuploidy risk 192
 trehalase in AF 108
 Turner syndrome 270
 see also kidney
 renal disease *see* kidney disorders
 renal failure, in open spina bifida 147
 renal function, fetus 99
 renal transplant, recipients, DS screening 512
 Rendu–Osler–Weber syndrome 669
 repeat measures, aneuploidy 504–505
 repeat sequence diseases 387
 prenatal diagnosis caveats 398
 repeat expansions 387–389, 388t
 replication fork stalling and template switching (FoSTeS) 367
 research, ethical issues *see* ethics
 restriction enzymes
 Hb S mutations involving 746, 748f
 β -thalassemia mutations 740
 restriction fragment length polymorphisms (RFLPs),
 β -thalassemia 740, 742, 744, 745t
 reticular dysgenesis 760t
 retina, gyrate atrophy 881
 retinitis pigmentosa 397, 461
 retinoblastoma 401, 402t
 retrognathia 692f
 reverse dot-blot hybridization 709t, 739
 rhabdomyolysis 912
 rhabdomyoma 22, 980

- RHD* gene, absence 457
RHD genotyping
 false-negatives/-positives 458
 fetal 453, 455, 457–458
 see also cell-free fetal DNA (cffDNA)
 timing (gestation age) 458
 validation studies 457–458, 457t
RHD pseudogene 457, 458
 Rhesus blood group system 457
 RhD– mothers, maternity care 457, 458
 Rh incompatibility, legal cases involving 1067, 1075, 1085
 Rh isoimmunization, in amniocentesis 72–73
 Rh (D) immunoglobulin (RhIG) 457
 adverse pregnancy outcomes 73
 amniocentesis and 72, 73
 after fetal blood sampling 86
 after induced abortion 1014, 1019, 1023
 rhizomelic chondrodysplasia punctata (RCDP) 851
 ribs, “beaded” 690, 690f
 Richner–Hanhart syndrome (tyrosinemia type II) 888
 “right to life” 1108
 right ventricular cardiomyopathy 397, 403t
 ring chromosomes
 formation 325–326
 prenatal detection 221
 X chromosome, Turner syndrome 273
 Y chromosome 289
 risk assessment
 routine offering of, ethics 1111–1114
 invasive diagnosis without 1113
 invasive prenatal diagnosis 1112–1113
 nondirective offer, woman’s response 1112–1113
 options 1112
 woman’s response to results 1114
 see also individual disorders
 risk screening, Down syndrome 488–489, 571
 RNA
 cell-free in AF 101–102
 messenger *see* mRNA
 RO491753 (mGluR5 antagonist) 357
 Robertsonian translocation 185, 195, 396
 balanced 195, 196
 uniparental disomy 232–233
 carriers
 prenatal diagnosis indication 195–196
 uniparental disomy 232–233, 233t
 chromosome 21 195–196, 196t
 frequency 181–182
 segregation 195, 196t
Roe v. Wade 1973 1065, 1069
 Romano–Ward syndrome 403t
 rubella 962–963
 fetal infection
 prenatal diagnosis 114, 963
 risk and outcome 962, 962t
 legal cases involving 1074, 1076–1077, 1084, 1085, 1087
 maternal 962–963
 vaccination 962, 963
 rubella virus 114, 963
 Rubenstein–Taybi syndrome 316t, 317

 S100B protein 102
 sacrococcygeal teratoma (SCT) 674, 1001
 SADDAN 669, 685
 Saethre–Chotzen syndrome 316t
 safety, laboratory 130
 salt and pepper pot syndrome 777t, 782
 salt-wasting 977, 979
 Sandhoff disease 424, 776f, 789–790
 carrier testing 27, 789
 hexosaminidase deficiency 104, 789
 prenatal diagnosis 789
 therapy 786
 variant AB 789–790
 Sanfilippo disease *see* mucopolysaccharidoses (MPS), MPS III
 Sanger sequencing 381–382, 719
 limitations 382
 saposin(s) 782, 783
 deficiency 783
 saposin B 783, 797, 798
 saposin C 793, 795
 deficiency 793, 795
 saposin D 807
 sapropterin 887
 “savior siblings” 1101–1102
 SB *see* spina bifida (SB)
 SCAD (short-chain acyl-CoA dehydrogenase) deficiency 839f,
 841f, 842t
 scapula, ultrasound 684, 684f
 Scheie syndrome *see* mucopolysaccharidoses (MPS), MPS I
 schizencephaly 645, 667
 MRI 667–668
 ultrasound 645, 646f
 schizophrenia 272, 351
 SCID *see* severe combined immunodeficiency (SCID)
 SCN1A mutations 398
 SCN2A mutations 398
 SCPM (single-cell pseudomosaicism) 204, 206, 209, 209t, 210t
 screening 484–485, 1111
 aims 484
 prenatal diagnosis *vs* 484–485
 strategies 1111–1112
 seizures 351, 353
 sensitivity, in genetic counselling 10
 septo-optic dysplasia 666
 sertraline 357
 serum proteins, maternal, in AF 102
 severe achondroplasia with developmental delay and acanthosis
 nigricans (SADDAN) 669, 685
 severe combined immunodeficiency (SCID) 756, 759t, 763–765
 genes defective in 764–765
 gene therapy 763
 genetic counseling 764
 incidence 756, 764
 Navago Indian 759t, 765
 prenatal diagnosis/treatment 764
 recurrence risk 765
 treatment 763, 764
 X-linked 759t, 763, 764
 sex chromosome abnormalities (SCA) 267–312
 47,XYY males *see* 47,XYY males
 gain/loss, pseudomosaicism 210
 genetic counseling 267, 268, 273–274, 295
 46,XX males 291
 47,XYY males 284
 Klinefelter syndrome 279
 ovotesticular DSD 294
 triple X syndrome 281

1178 Index

- sex chromosome abnormalities (SCA) (*Continued*)
- Turner syndrome 273–274, 275–276
 - X-autosome translocations 287
 - incidence 179, 180t, **267–268**
 - ascertainment bias 268
 - infertility and ICSI 26
 - inheritance patterns 268
 - inversions 197
 - Klinefelter syndrome *see* Klinefelter syndrome
 - marker chromosomes 321–322, 323t
 - mosaicism *see* mosaicism
 - polysomy, pregnancy termination 1011
 - poly-X syndromes 280–282
 - prenatal detection 267, **268**
 - cell-free fetal DNA 465, 467
 - CVS 221–222, 267
 - recurrence risk 268
 - sex development disorders *see* disorders of sex development (DSDs)
 - stereotypes associated 295
 - summary 294–295
 - triple X syndrome *see* triple X syndrome (47,XXX)
 - Turner syndrome *see* Turner syndrome
 - X structural abnormalities *see* X chromosome
 - Y structural abnormalities *see* Y chromosome
- sex determination (fetal) 32, 68, 178, **456–457**
- cell-free fetal DNA 455, **456–457**
 - disclosure of results 1110
 - Fabry disease 792
 - FISH 336
 - hemophilia 401
 - PGD ethics and 445
 - preimplantation FISH 337
 - for social reasons 203, 445
 - for X-linked disorders 202–203, 456
- sex-determining region Y (SRY)
- analysis, Turner syndrome 269
 - loss, Yp deletions 288
 - mutations 293
 - translocation, in Y-positive 46,XX males 290–291
- sex development disorders *see* disorders of sex development (DSDs)
- sex reversal syndromes 293
- sex selection
- abortion after 1100
 - nonmedical purposes 1100, 1101
 - prohibition 1100, 1101
 - PGD 1092, **1099–1101**
 - prenatal diagnosis and **1099–1101**
 - techniques 1100
 - see also* sex determination (fetal)
- sFLT-1 1034, 1035, 1036
- short-chain acyl-CoA dehydrogenase (SCAD) deficiency 839f, 841f, 842t
- short stature
- Down syndrome 503
 - skeletal dysplasia 683, 685, 686, 689
 - Turner syndrome 269–270, 273
- short tandem repeats (STR) 732
- polymorphisms, maternal DNA contamination 732, 748
- sialic acid 780
- sialidosis 776f
- siblings
- impact of perinatal loss 1052
 - legal cases involving 1073
 - NTD in child, effect 148
 - “savior siblings” 1101–1102
 - survivor guilt 11
 - see also* children
- sickle cell anemia (homozygous state) **725–726**, 726t, 746
- sickle cell disease **725–728**
- carriers, legal cases involving 1076
 - carrier screening 728–731
 - clinical features and mortality 725
 - compound heterozygous 725, 726t
 - genotypes/haplotypes 725–726
 - see also* entries beginning *Hb S*
 - Hb F in 719
 - incidence 725
 - legal cases concerning 1076, 1088
 - maternal, pregnancy risks 25
 - mutations 725, 746
 - prenatal diagnosis, methods 383, 746, 748f
 - NIPD 461t, 462, 732
 - rare variants 728
- sickle cell trait 746
- SIFT prediction program 382
- Silver–Russell syndrome (SRS) 212, 1034, 1035
- Singapore, PGD regulation 1098
- single cell genome wide SNP analysis 374
- single-cell pseudomosaicism (SCPM) 204, 206, 209, 209t, 210t
- single-copy probes 313, 319
- single gene disorders *see* monogenic disorders
- single nucleotide polymorphisms (SNPs) 367
- aneuploidy diagnosis in cfDNA 465
 - array technology 382
 - cell-free fetal DNA 455, 465, 466–467
 - NATUS (next-generation aneuploidy test using SNPs) 465
 - next-generation sequencing 383
 - noninvasive prenatal testing 465, 466–467
 - PGD 424
 - PLAC4* gene 463
 - Turner syndrome 269
- single nucleotide variants (SNVs) 398
- situs solitus 605
- skeletal defects/malformations
- legal cases involving 1082–1083, 1087
 - MRI 675
- skeletal dysplasias 563–564, **681–699**
- aberrant fetal growth 683
 - abnormal morphology as unexpected 683–684
 - CT 682
 - detection, gestational age 683
 - genetic counseling 682, 685, 687
 - lethal/survivability 683, 684
 - molecular tests 684–685
 - morphological diagnosis 682
 - MRI 675, 682
 - noninvasive prenatal diagnosis 458
 - recurrence probability estimation 685
 - types 681
 - diastrophic dysplasia sulfate transporter gene 692–693
 - FGFR3 *see* FGFR3 disorders
 - joint dislocations **693**
 - osteogenesis imperfecta *see* osteogenesis imperfecta (OI)
 - type II collagen disorders **690–692**
 - see also* Marfan syndrome
 - ultrasound 563–564, 564t, 565f, **681–683**, 685
 - diagnosis/reporting problems 682
- skin disorders, prenatal diagnosis 399–400

- skull abnormalities
 strawberry-shaped 578
 ultrasound detection 542, 543f–544f, 544, 545
 see also anencephaly
- SKY method 366
- SLC7A7* gene mutations 882
- SLC22A5* gene 842
- SLC46A1* gene mutations 927, 928
- Sly disease (MPS VII) 858t, **866–867**
- small bowel atresia 555
- small bowel stenosis 555
- small for gestational age (SGA) 1033
- small supernumerary marker chromosomes (sSMC) 326
- SMC *see* supernumerary marker chromosomes (SMCs)
- Smith–Lemli–Opitz syndrome (SLOS) 293, **517**
 7-dehydrocholesterol in AF 103
 first-trimester scan 569
 maternal serum screening 517
 second-trimester screening 187
- Smith–Magenis syndrome 314, 316t, 317f
- SMN1 gene 385
- smoke (tobacco) 116, 117t
- smoking
 biochemical markers of in AF 111–112, 116
 maternal 5, 513
- SNPs *see* single nucleotide polymorphisms (SNPs)
- social issues
 burdens of anomalies 1117
 Klinefelter syndrome 278
 Turner syndrome 272
- social support, after bereavement/perinatal loss 1051, 1056, 1058
- socioeconomic issues 1091
- sodium, urinary, obstructive uropathy 563, 563f
- sodium/carnitine symporter OCTN2 842
- somatic cell nuclear transfer 1125
- somatic mosaicism 12, 13, 39
 causes/mechanism 389–390
 definition 389
 deletions 393
 de novo mutations 389
 diagnosis 393, 395
 gonadal mosaicism *vs* 39, 390
 monogenic disorders with 390, 391t–393t, 393
 paternal origin of mutations 393
 transmissible 390, 393
- South Africa, guidelines on prenatal diagnosis 1094
- Southern blotting 381
 fragile X syndrome diagnosis 355–356
- SOX9 gene mutation 293
- SP-1 (pregnancy-specific glycoprotein) 506, 1032
- Spain, legal/regulatory status of PGD 444, 1095
- spatial thinking deficits 272
- speckle tracking echocardiography (STE) 614
- sperm
 donor, legal cases involving 1077
 duplication 420
 genotyping 420, 436
- SPG4 gene 398
- sphingolipid activator protein (SAP; saposin) *see* saposin(s)
- sphingolipidoses 783, 784
 see also Gaucher disease; Krabbe disease; metachromatic leukodystrophy (MLD); Niemann–Pick disease (NPD)
- sphingomyelin 781
 accumulation 804–805
- sphingosine 780, 781
- spina bifida (SB) 484
 AFP in amniotic fluid *see* α -fetoprotein (AFP)
 associated anomalies 638
 biparietal diameter 486
 closed 147, 484
 latex allergy 147
 legal cases involving 1077–1078, 1079, 1084–1085
 life expectancy 145–146, 484
 open *see* open spina bifida (OSB)
 screening markers 486
 ultrasound screening *see* ultrasound (US), prenatal diagnosis, NTD diagnosis
 see also neural tube defects (NTDs)
- spina bifida aperta *see* myelomeningocele; open spina bifida (OSB)
- spina bifida occulta 638
 recurrence risks 140–141
- spinal dysraphism 140
- spinal muscular atrophy (SMA) 385, 461t
- spine, visualization 487
- spinocerebellar ataxia 388
 prenatal diagnosis 398
 type 2 37, 398
 type 3 398
 type 10 388
- spiral arteries/arterioles 1032
- spiramycin 945
- SPMD1* gene, mutations 803
- spondylo–carpal–tarsal synostosis 693
- spondyloepimetaphyseal dysplasia (SEMD) Strudwick 691
- spondyloepiphyseal dysplasia congenita 690–692
- spotting, after amniocentesis 74
- ST3GAL3* gene mutations 782
- staff, burden, after perinatal loss 1056
- standard of care 1064, 1065
- STAP1* gene mutation 779
- Staphylococcus aureus*, inhibition by AF 113
- stapling device, absorbable 994, 995
- STAT3 mutations 768
- statins 779, 809
- stature *see* short stature; tall stature
- stem cells
 from AF 130
 embryonic *see* human embryonic stem cell (hESC) research
 mesenchymal (MSC) 130
 research ethics 1124–1128
- stem cell transplantation *see* hematopoietic stem cell transplantation (HSCT)
- sterilization, failed 1066
 legal cases concerning 1073, 1083–1084, 1086, 1087
- steroid 21-hydroxylase deficiency *see* congenital adrenal hyperplasia (CAH)
- steroids
 in AF 115–116, 115f
 congenital pulmonary airway malformations 1000
- steroid sulfatase (STS), gene probe 318
- steroid sulfatase (STS) deficiency 187, 316t, 516
 gene microdeletion 187, 316t, 318, 400
 prenatal diagnosis 187, 399–400, 516
 X-linked ichthyosis (XLI) 187, 516
- sterol carrier protein-X (SCPx) deficiency 848, 848t, 850
- sterols, in AF 103
- Stickler syndrome, types I/II/III 691
- stigma 1058, 1102

1180 Index

- stillbirth 182, 184, 1048
 action checklist 44, 45b
 care of parents after 1058
 chromosomal abnormalities incidence 2, 182, 184–185, 184t
 evaluating the cause 43, 44t
 giving diagnosis of 1057
 psychological impact 1050, 1051
see also perinatal death/loss
 stomach, fetal, ultrasound 554
 strawberry-shaped skull 578
Streptococcus agalactiae 113
 stress, perinatal loss 1051
 STS deficiency *see* steroid sulfatase (STS) deficiency
 subarachnoid cyst 1084
 subcortical band heterotopia 13
 subependymal cysts, MRI 670
 subfertility, cytogenetic causes 201–202
 subplate (brain) 663–664
 substrate restriction therapy 793
 subtelomeric probes 319, 328
 subtelomeric rearrangements 319, 328
 subtilisin/kexin 9 779
 succinylacetone 106
 succinyl-CoA 3-ketoacid CoA transferase (SCOT) deficiency 884
 suction aspiration/curettage **1012–1016**
 cervical dilation for 1012–1013
 complications 1014, 1015–1016
 delayed 1015–1016
 manual vs electric 1013–1014
 monitoring after 1014
 morbidity 1014–1015
 mortality 1016, 1016t
 technique 1012, 1014
 timing/gestation age 1012
 sudden death 19, 29
 sulfadiazine 945t
 sulfated N-acetylhexosamine (HNAcS) 865, 866
 sulfatide 797
 sulfatide sulfatase (ASA) 783, 797, 798
 sulfite oxidase deficiency 889–890
 with xanthine oxidase deficiency 889–890
 3-sulfo-galactosylceramide 797
 N-sulfoglucosamine sulfohydrolase (SGSH) deficiency (MPS IIIA) 863, 864
 sulfonamide 945, 947
 sulfur amino acid metabolism disorders **888–890**
SUMF1 gene mutations 799, 800
 supernumerary marker chromosomes (SMCs) 228, **230**
 abnormal phenotype risk 231, 232, 232t
 autosomal 322–324
 candidate chromosomes 231
 chromosome 15 231, 233–234
 chromosome 22 231–232
de novo 230–232, 231t
 FISH analysis 286, 289, 321–322, 323t, 326
 identification 231, 234
 incidence 230, 231t
 origin 322, 325–326
 satellited 231
 sex chromosomes 286, 289, 321–322, 323t
 small (SSMC) 326
 uniparental disomy and 231, 233–234
 support groups, perinatal death 44
 suprarenal cystic mass 672f
 supraventricular extrasystoles (SVES) 602, 603f
 supraventricular tachycardia 602, 603f, 979
 surgery
 delivery, EXIT procedure 993–994, 994f
 fetal *see* fetal surgery
 maternal risks 995, 1123–1124
 postnatal
 duodenal atresia 626
 esophageal atresia 624
 gastroschisis 631
 hypoplastic left heart 611
 omphalocele 627–628
 SURUSS study 487, 504
 survival rates, congenital defects 5
 survivor guilt 11
 sutures, absorbable 994
 sweat test 701
 Switzerland
 law relating to prenatal diagnosis 1093
 PGD prohibition, law amendment 1096
 Swyer syndrome 292
 SYCP3 gene mutation 26
 sympathomimetics 981
 syncytial trophoblast microvillus membranes (STMB) 1035–1036
 syndecans 860
 syntelencephaly 666
 syringes, AF/AFCs transport and toxicity 129, 239
 SYROCOT meta-analysis 946
 systemic lupus erythematosus, maternal 24, 980
 tachyarrhythmia, fetal 602, 603f, **979–980**
 detection 980
 therapy 981
 Taliglucerase alfa 796
 talipes calcaneovarus 582
 talipes equinovarus 582
 tall stature
 47,XYY males 283
 triple X syndrome (47,XXX) 281
 tandem duplications 327
 TaqMan 381, 424
 Tarui disease (GSD type VII) 904t, 906, **913**
 Tay–Sachs disease 776f, **787–789**
 Ashkenazi Jews 787, 788, 1079
 B1 variant 787–788
 carriers, false-positive 788
 gene therapy 786
 HEXA gene mutations 787, 788
 hexosaminidase A deficiency 104, 787, 788
 legal cases involving 1075, 1078–1079, 1082, 1085
 population screening for carriers 27, 788
 prenatal diagnosis 788–789
 therapy 786
 TBX1 transcription factor 766
 T cell(s) 756
 CD8, in MHC class II deficiency 766
 deficiencies **758, 763–766**
 combined B-cell *see under* lymphocyte deficiencies
 diagnostic tests 758
 T-cell disorders 756
 T-cell receptor (TCR), excision circles, assay 764
 telomere(s), short length 355
 telomere-associated repeat (TAR) 319
 telomeric probes 319
 telomeric regions, and loss of 319

- teratogenic drugs 31, 978, 982
 anticonvulsants 25, 118, 982
 teratoma 671, **1000–1003**
 cervical 1001–1003, 1002f
 fetal surgery **1000–1003**
 oropharyngeal 1003
 pericardial 1003
 sacrococcygeal 1001
 tongue 672f
 termination of pregnancy *see* abortion (induced/elective)
 testicular biopsy 275
 testicular feminizing syndrome 292
 testis-determining factor (SRY) gene *see* sex-determining region Y (SRY)
 testosterone
 in AF 115
 deficiency, 46,XX males 290
 Klinefelter syndrome 276
 tetrahydrobiopterin (BH4) deficiency 887–888
 tetralogy of Fallot 608f, 609
 tetranucleotide repeat (CTTG) 12
 tetraploidy, array CGH analysis 372
 tetrasomy X 282
 TGF- β signaling pathway 35
 Thailand, collaborative amniocentesis study 76t, 77–78
 thalassemia
 α - 720
 compound heterozygous 720–721, 720t
 DNA analysis 719, **734–737**
 gap-PCR 734–736, 735t, 736f
 hematological features 720, 720t
 homozygous 720, 720t
 microdeletions 315t, 720, 734
 MLPA method 736
 mutations causing 719, 720, 734, 737
 noninvasive prenatal diagnosis 460t, 461t
 PCR for nondeletion mutations 737, 737f
 PGD 734
 severe (α -1, α^0) and mild (α -2, α^+) forms 720, 721, 731, 737
 unstable variants 721
 β - 721–724
 allele-specific oligonucleotides 739
 ARMS-PCR 741–742, 742t, 743f, 744f
 β^0 and β^+ types 721, 730t
 carrier screening 729–731
 compound heterozygous 722t, 723
 deletion mutation diagnosis 740–741
 DNA analysis 737–744
 dominantly inherited inclusion body 723–724
 gap-PCR 740–744
 haplotype analysis 742, 744
 Hb E- 724
 Hb F in 719, 721
 homozygous 722t, 723
 intermedia 721, 723–724
 legal case involving 1080
 major 721
 Mediterranean mutations, ARMS test 741–742, 743f
 MLRA 740–744
 mutation detection 719, **737–744**
 mutations causing 721, 722t, 723, 737, 738t, 740, 741
 noninvasive prenatal diagnosis 460t, 461t, 462, 732
 PCR 738, 739, 740
 PGD 734
 point mutation detection 738–739, 740
 prenatal diagnosis requests 723
 primer-specific amplification 739–740
 red cell indices (MCH, MCV) 729, 730, 730t
 restriction enzyme analysis 740
 RFLP analysis 742, 744, 745t
 “silent” mutations 723
 unknown mutations, detection 741
 carrier screening **728–731**
 $\delta\beta$ 744–745, **745**
 molecular diagnosis 746
 Hb S/ β -thalassemia 726–727
 Hb S/ $\delta\beta$ -thalassemia 727
 prenatal diagnosis 718, 719
 thanatophoric dysplasia (TD) 458, 459t, 462, 681, **685–686**
 features 685, 686f, 687f
 lethality 684, 685
 mutations associated 684, 685, 686
 prenatal diagnosis 686
 ultrasound 564, 685, 687f, 688f
 therapeutic misconception 1121
 third trimester ultrasound *see* ultrasound (US), prenatal diagnosis
 thoracoamniotic shunts 551–552, 552f, 616, 618
 thorax, dimensions, skeletal dysplasias 683
 three-parent *in vitro* fertilization 403
 thrombocytopenia
 fetal 670, 968
 legal cases involving 1073
 neonatal alloimmune 983
 parvovirus B19 infection 968
 thromboembolic complications, pregnancy 22
 thrombophilia 26
 thrombophlebitis 22
 thyroid disorders **981–982**
 thyroid gland, MRI 672
 thyroid-stimulating hormone (TSH), in AF 116
 thyrotoxicosis 981, 982
 L-thyroxine 981
 tissue, for DNA banking 43
 tissue Doppler imaging (TDI), functional assessment of heart 614, 615
 T lymphocytes *see* T cell(s)
 tocolysis 991
 Torrance dysplasia 691
 torsion dystonia 459t
 Tort law (USA) 1063
 toxic agents, in AF 116–118, 117t, 118t
Toxoplasma gondii 942–943
 toxoplasmosis (fetal) 114, 668f, **942–948**
 epidemiology 943
 in utero therapy **945–947**, 945t
 efficiency 946–947
 indications 945–946
 therapeutic tools 945
 management at birth 947
 parasitology 942–943
 prenatal diagnosis **944–945**, 948
 indications 944
 negative 945–946, 947
 PCR 944–945
 positive 945, 947
 recommendations 943t
 prevention, education 947–948
 risk factors 943–944, 948
 trace elements, in AF 111–112, 111t, 117t

1182 Index

- tracheal occlusion (PLUG) therapy 997, 997f
- tracheo-esophageal (T-E) fistula 554, 618, 622
- “pouch sign” 623
- training, nondirective genetic counseling 13
- transabdominal CVS 82–83, 84t, 731
- transcervical CVS 82, 83, 84t, 731
- transcobalamin (TC)
- deficiency **930–931**
 - maternal transfer 931
- transcobalamin (TC) receptor 931
- translocations *see* chromosomal translocations
- transplacental infections *see* fetal infections
- transplantation
- bone marrow *see* bone marrow transplantation
 - HSCT *see* hematopoietic stem cell transplantation (HSCT)
 - liver 808, 907, 911
 - lung 702
 - renal, recipients, DS screening 512
- transport system, microvilli 106, 107f
- transudate 98
- trehalase 106
- in AF 106, 107, 107f, 108
- tremor, FXTAS *see* fragile X-associated tremor/ataxia syndrome (FXTAS)
- trichlorhexis nodosa 880
- trichorhinophalangeal (TRP) syndrome 317
- tricuspid atresia 609
- tricuspid dysplasia 609
- tricuspid regurgitation 500
- tricuspid valve abnormalities 500, 609
- “trident hand” 685, 686
- triglyceride, disorders 765t
- triiodothyronine, reverse, in AF 116
- trinucleotide repeats 12, 37
- CAG 12, 387
 - CGG *see* CGG-repeat expansions
- triplet pregnancies
- amniocentesis 72
 - fetal loss risk 584
- triplet repeats *see* trinucleotide repeats
- triple X syndrome (47,XXX) 202, **280–281**, 294, 295
- clinical features and management 281
 - cognitive/psychologic development 281
 - noninvasive prenatal diagnosis (cffDNA) 465
 - prenatal counseling 281
 - screening tests 186
- triploidy 574
- array CGH analysis 372
 - diandric 1037t
 - digynic 1037t
 - IUGR 583
 - second-trimester screening 187, 516
 - ultrasound abnormalities 574–576, 575t
- trisomy
- autosomal *see individual chromosomes*
 - error rates in detection 241
 - fetal fraction, of cffDNA 454
 - incidence/percentage
 - liveborn babies 180t
 - spontaneous abortions 182, 184t
 - more than one (complex aneuploidy) 219
 - mosaicism *see* trisomy mosaicism
 - NIPT, using cffDNA 463, 464, 465
 - origin/mechanism 203
 - potentially viable 201
 - pseudomosaicism 209–210, 210t
 - sex chromosomes *see* 47,XXX males; Klinefelter syndrome; triple X syndrome (47,XXX)
- trisomy 1 211
- mosaicism 211
- trisomy 2 211
- mosaicism 211
 - multiple cell pseudomosaicism 209
- trisomy 3 211–212
- mosaicism 212
- trisomy 4 mosaicism 212
- trisomy 5 mosaicism 212
- trisomy 6 mosaicism 212
- trisomy 7 1034
- mosaicism 212
 - multiple cell pseudomosaicism 209
- trisomy 8 mosaicism 212–213
- trisomy 9 213
- legal case involving 1076
 - mosaicism 213, 1076
- trisomy 10 mosaicism 213
- trisomy 11 mosaicism 213
- trisomy 12 mosaicism 213
- trisomy 13 (Patau syndrome) 484
- defects in 568, 574
 - fetal loss rate 5, 179
 - incidence 179
 - mosaicism 213–214
 - placental pathology 1037t
 - pre-eclampsia 1036
 - screening for 186, 515–516
 - second-trimester 187, 515
 - ultrasound abnormalities 574
 - brain 577
 - incidence 574–576, 575t
- trisomy 14
- legal cases concerning 1082, 1084
 - mosaicism 214, 1084
- trisomy 15 mosaicism 214
- trisomy 16 214
- causes and upd(16)mat 214–215
 - confined placental mosaicism 1034, 1035, 1036, 1037t
 - mosaicism 214–215
 - prevalence and detection 215
 - screening test 186, 187
 - pre-eclampsia 1036
- trisomy 17 mosaicism 215–216
- trisomy 18 (Edwards syndrome) 484
- defects in 568, 574
 - fetal loss rate 5, 179
 - FISH analysis 331, 332f, 335
 - incidence 179
 - IUGR 583
 - legal cases concerning 1082
 - maternal age and risk 514
 - maternal serum markers 515, 515t
 - mosaicism 39, **216**
 - placental pathology 1037t
 - screening for 51t, 186, **514–515**, 516
 - first-trimester 186, 515, 515t
 - second-trimester 187, 515, 515t
 - ultrasound abnormalities 574
 - brain abnormalities 576, 577
 - incidence 574–576, 575t
- trisomy 19 mosaicism 216

- trisomy 20 mosaicism 216–217
 cytogenetic testing 216–217, 218t
 frequency, abnormalities 216, 217t
- trisomy 21 *see* Down syndrome (DS)
- trisomy 21 mosaicism 199, 202, 217–218
- trisomy 22
 legal case involving 1085
 mosaicism 218
- trisomy mosaicism
 diagnosis recommendations 219–220
 pregnancy outcomes 219, 220t
see also mosaicism; *specific trisomy mosaicism*
- trophectoderm biopsy 422
- trophoblast cells 1031, 1032
 implantation/invasion 1032
 metaphase, mosaicism diagnosis 204
 NIPD using 732
- trophoblastic disease 201
- “true hermaphroditism” 293
- truthfulness in genetic counseling 15–16
- tryptophan metabolism 357
- TSC1 gene 980
- TSC2 gene 35, 980
- “T” sign 509
- tubal ligation, legal case concerning 1073, 1083–1084, 1086, 1087
- tuberous sclerosis 402t, 665f
 brain abnormalities, MRI 665f, 667
 cardiac rhabdomyomas 980
 polycystic kidney disease and (TSC2-PKD1) 11
 preconception genetic counseling 22
 prenatal diagnosis 980–981
- “Turner gene” 269
- Turner syndrome 202, **269–276**
 45,X karyotype 202, **272–273**
 abortion risk in later pregnancies 201
 chromosome loss mechanisms 272
 cystic hygroma 188
 first-trimester screening 186
 parental origin and stigmata 272–273
 second-trimester screening 187
 spontaneous abortion 201, 202, 272
- cardiac defects 568, 580
- clinical features 269–271, 273
- cognitive/psychologic development 271–272
- diagnosis 269
- DS screening and 516
- frequency 269, 272
- genetic counseling for 269, 273–274
 45,X/46,XY 275–276
- karyotypes associated with 269t, **272–273**
 45,X *see above*
 45,X/46,XY 273
 46, X,i(Xq) 273
 46,X,del(Xq) 273
 46,X,r(X) 273
 46,X,Xq2 273
 marker X (fragment X) 286
 rare karyotypes 273
 Xp deletions 284, 285
- life expectancy 270
- management 269–271
- maternal age as a risk factor 222
- mosaicism 221, 224, 273, **274–276**
 45,X/46,XX 221, 222, 223, **274**
 45,X,46,XX/47,XXX 275
 45,X/46,XY and variants 222–223, 232t, **275–276**
 45,X/47,XXX 274
 cryptic 269
 prenatal counseling 274
 prognoses 274
 nuchal cystic hygroma and 269, 579
 ultrasound abnormalities 269, 273–274
 incidence 574–576, 575t
 Y chromosomal material 269
- twin pregnancies
 acardiac twins 585
 amniocentesis 71–72, 71f, 72f
 cell-free fetal DNA (cffDNA) 466
 chorionicity **584**
 congenital anomaly incidence 4
 death of one twin 42, 43, 511
 dichorionic 584
 discordancy for abnormalities 584–585, 1022
 dizygotic 509, 584
 Down syndrome risk 509–511, 509t
 fetal loss risk 584
 fetal surgery in *see* fetal surgery
 increase in 238
 IUGR 585
 legal cases involving 1084
 monochorionic 584, 585
 fetal reduction contraindication 1025
 monochorionic vs dichorionic 4, 584
 monozygotic 509, 584
 NTDs 133
 nuchal translucency screening 510, 584
 prenatal diagnosis in 583–584
 prenatal screening accuracy 238–239
 ultrasound detection 239
 zygosity **584**
 indicators 509
see also multiple pregnancies
- twin reversed arterial perfusion (TRAP) sequence 585, **1005**
- twins, Huntington disease risk, nondirective counseling 14–15
- twin-to-twin transfusion syndrome 565, **585, 1004–1005**
 fetal laser therapy 1004–1005, 1005f
 fetoscopy, maternal risks 995
 functional assessment of heart 614
- tyrosine metabolism disorders **886–888**
- tyrosinemia type I 105–106, **888**
- tyrosinemia type II (Richner–Hanhart syndrome) **888**
- ubiquitination, inclusions, FXTAS 355
- UDPgal 915
- UDPgal-4-epimerase deficiency 905t, **916**
- uE₃ *see* estriol, unconjugated
- UK
 Abortion Act 1100
 collaborative amniocentesis study 76–77, 76t
 congenital CMV infection 950t
 legal/regulatory status of PGD 444, 1098
- Ullrich–Turner syndrome 321–322
- ultra-deep amplicon sequencing 733
- ultrasound (US)
 before dilation and evacuation (D and E) 1018
 guidance (for)
 amniocentesis 69, 70f, **71, 72f, 75**
 CVS 731
 fetal blood sampling 86

1184 Index

- ultrasound (US) (*Continued*)
 percutaneous fetal surgery 992–993
 selective abortion in multiple pregnancies 1022–1023
 before suction aspiration 1012
- ultrasound (US), prenatal diagnosis 541–598
 3D/4D imaging 572–574
 acquisition, storage and display 574
 fetal CNS 573–574
 fetal face 572–573, 573t
 skeletal dysplasia diagnosis 683
- abdominal wall defects 552–554, 581
 bladder exstrophy 553–554
 body stalk anomaly 553
 first trimester 568
 gastroschisis 553, 581, 628–631, 629f–630f
 omphalocele *see* omphalocele
 third trimester 626–631
see also gastroschisis; omphalocele
- abnormal, cytogenetic diagnosis indication 188–193, 189t–190t
 high risk for aneuploidy 192
 low risk for aneuploidy 192–193
 moderate risk for aneuploidy 192
 very high risk for aneuploidy 188, 191–192
- abnormal, in chromosomal defects 188, 189t–190t, 574–583, 575t
 abdominal wall abnormalities 581
 brain abnormalities 576–578
 cardiac defects 580
 facial abnormalities 578–579
 gastrointestinal abnormalities 580–581
 head shape 578
 incidence 574–576, 575t
 IUGR 582–583
 limb malformations 582
 neck abnormalities 579–580
 skeletal abnormalities 582
 thoracic abnormalities 580
 in trisomy 21 (Down syndrome) *see below*
 urinary tract 581–582
- achondroplasia 564
- AF volume abnormalities 564–566
- aneuploidies 188, 191, 191t, 192
 second trimester 574
- “anomaly scan” 193, 486–487
 second trimester, for OSB 505
- bladder exstrophy 553–554
- brachycephaly 578
- brain abnormalities 573, 576–578
 cavum septum pellucidum absence 573, 641, 645, 647, m 647f
 cerebellar abnormalities 543f–544f, 544, 545, 647, 650
 choroid plexus cysts 547, 577
 chromosomal abnormalities with 576–578
 corpus callosum agenesis 577, 577f, 641–642, 645
 holoprosencephaly 546, 576, 641, 642f
 hydranencephaly 546
 microcephaly 547, 576–577
 posterior fossa abnormalities 578, 647, 650
 schizencephaly 645, 646f
 short frontal lobe 577–578
 third trimester 635–650
 ventriculomegaly 576, 635–636, 637f
- bronchopulmonary sequestration 615–616, 617f
- cardiac defects 547–549, 580, 600
 4CV screening *see under* echocardiography (fetal)
 chromosomal abnormalities with 580
 detection rates (third trimester) 600, 601t
 first trimester 568
 real-time directed M-mode echocardiography 549
 second trimester 547–549
 third trimester 599–615
see also echocardiography (fetal)
- choroid plexus cysts 547, 577
- cloacal exstrophy 553–554
- CMV infections 954–955
 CNS abnormalities 954–955
 non-CNS abnormalities 955
 value/prognosis 955–956, 957
- CNS 573–574, 635
 abnormalities, third trimester 635–650
see also brain abnormalities (*above*)
- common defects
 second trimester scans 542–566
 third trimester scans 599–650
- congenital high airway obstruction sequence 618, 620f
- craniospinal defects 542–547
- cystic adenomatoid malformation of lung 549–550
 second trimester 549–550
 third trimester 616–6616, 618, 619f
- Dandy–Walker malformation 547, 548f
- diaphragmatic hernia 550, 550f, 580
 third trimester 618, 621–622, 621f
- Doppler 574
 abnormal ductus venosus 518
 cardiac imaging 601f, 602, 612, 614
 renal agenesis 557
 tricuspid valve insufficiency 609
- Down syndrome (trisomy 21) 574–576, 575t
 brain abnormalities 576, 577
 facial 578, 579
 gastrointestinal tract 581
 head shape 578
 incidence 574–576, 575t
 major and minor defects 576, 576t
 nuchal cystic hygroma 579
 screening planning 520
- Down syndrome screening markers 486–487, 493
 abnormal ductus venosus flow 500
 additional markers 499–501, 499t
 contingent test 500–501
 first trimester Combined test 499–501, 502t
 FMF angle 500, 503
 nasal bone absence 487, 499–500, 499t
 pre-nasal thickness (PT) 487, 502t, 503
 second trimester Combined test 401–503, 502t
 tricuspid regurgitation 500
see also nuchal translucency (NT)
- extremity malformations 582
- facial abnormalities 572–573, 573t, 578–579
- facial cleft 578
- first trimester 541
 abnormality detection 566–569
 cardiac defects 568
 chromosomal defects, markers 569–572
 Down syndrome 498, 499–501
 high-risk group 569–570
 megacystis 568–569, 569f
 NTD diagnosis 567–568
 nuchal translucency 570–572, 572b
 omphalocele 568
 other defects/syndromes 569

- gastrointestinal defects 554–557, 580–581
 abdominal cysts 556–557, 581
 bowel obstruction 555, 581
 chromosomal defects associated 580–581
 duodenal atresia 555, 581, 624–626, 625f
 echogenic bowel 556, 581
 esophageal atresia *see* esophageal atresia
 hepatosplenomegaly 556
 hyperechogenic bowel 192, 556
 meconium peritonitis 555–556
 third trimester 622–626
 genetic 503–504
 head shape abnormalities 578
 high-resolution, NTD detection 130–131
 hydrocephalus 545–546, 546f
 hydrops fetalis 550–551, 580, 618
 IUGR 582–583
 multiple pregnancies 585
 kidney and urinary tract 192, 557–563, 558t–560t, 581–582
 adult polycystic kidney disease 561–562
 hydronephrosis 562
 obstructive uropathy 562–563, 632, 635, 998
 pelvic kidney 561
 Potter's syndrome (types I–III) 561
 third trimester 631–635
 urethral obstruction 563, 563f, 632, 635, 998
 legal cases involving 1081, 1082
 liver (fetal) 554
 macroglossia 578–579
 megacystis 568–569, 569f, 633f
 micrognathia 578
 M-mode
 cardiac arrhythmias 602
 functional assessment of heart 612, 614
 multiple pregnancies 583–585
 abnormality discordancy 584–585
 IUGR 585
 neck abnormalities 579–580
 NTD diagnosis 131, 139, 542–545
 anencephaly 541, 542, 567, 567f
 diagnostic features 636, 638
 first trimester 567–568
 second trimester 505–506
 second trimester signs 505, 542, 543f–544f, 544
 third trimester 636, 638–641
see also open spina bifida (OSB); *spina bifida (below)*
 nuchal cystic hygroma 579–580
 nuchal translucency *see* nuchal translucency (NT)
 ocular and nasal abnormalities 578
 oligohydramnios 566
 pleural effusions 551–552, 551f
 polyhydramnios 565–566
 prenatal, at-risk pregnancies 119
 pulmonary abnormalities 549–552
 second trimester 549–552
 third trimester 615–622
 routine scans 541, 566
 advantages 541
 low-risk populations 541
 second trimester 541
 aneuploidies, phenotypic expression 574
 common defects diagnosed 542–566
 Down syndrome 193, 486–487
 fetal abnormality detection 40, 486–487
 OSB *see* open spina bifida (OSB)
 sex chromosome abnormalities 268
 skeletal abnormalities 582
 skeletal dysplasias 563–564, 564t, 565f, 681–683
 abnormal morphology as unexpected 683–684
 spina bifida 486, 487, 505–506
 first trimester 567–568
 third trimester 636, 638–641
 stomach (fetal) 554
 third trimester 599–659
 abdominal wall defects 626–631
 cardiac defects *see under* echocardiography (fetal)
 CNS abnormalities 635–650
 gastrointestinal tract 622–626
 lung lesions 615–622
 urinary tract anomalies 631–635
 Turner syndrome *see* Turner syndrome
 twin pregnancies 239
 volume contrast imaging (VCI) 574
 volume scan (3D) 573
 46,XX males 291
 umbilical artery, single, fetal blood sampling 88
 uniparental disomy (UPD) 21, 203, 396
 abnormalities with 204
 balanced translocations
 non-Robertsonian 233–234
 Robertsonian, carriers 196, 232–233, 233t
 chromosome 2 211
 chromosome 7 212
 chromosome 14 214, 232
 chromosome 15 232
 chromosome 16 214–215
 complete paternal 1039
de novo rearrangements 232–234
 mosaicism and 203, 204
 placental mosaicism and 1034
 prenatal diagnosis indications 396
 supernumerary marker chromosomes 231, 233–234
 universal healthcare systems 1093
 universal screening, parvovirus B19 967
 UPD *see* uniparental disomy (UPD)
 urea cycle 877, 878
 disorders 878–882
 ureteral dilation, MRI 674
 ureteropelvic junction obstruction 562, 998
 ureterovesical junction obstruction 562
 urethral atresia 635
 urethral obstruction
 management 635
 ultrasound 563, 563f, 632
 uridine diphosphate galactose (UDPgal) 915
 uridine diphosphate galactose-4-epimerase deficiency 905t,
 916
 urinary fistula 674
 urinary tract, normal, ultrasound 557
 urinary tract defects 631–635
 chromosomal abnormalities 581–582, 632
 fetal therapy 632, 634–635
 incidence and etiology 631–632, 631t
 lower tract obstruction *see* lower urinary tract obstruction
 (LUTO)
 MRI 674–675
 oligohydramnios in 100
 prenatal diagnosis 632
 prognosis 635
 third trimester 631–635

1186 Index

- urinary tract defects (*Continued*)
- ultrasound 557, 581–582
 - markers 632
 - second trimester 557, 632
 - third trimester 632
- urine
- amniotic fluid differentiation 70
 - fetal
 - AF cell origin 125
 - analysis, third trimester 632
 - kidney function 99, 100
 - production rate 99
 - sampling 999
 - maternal 99
 - aspiration, AFP measurement in AF 135
 - odors 883
- uropathy, obstructive *see* obstructive uropathy
- USA
- CF carrier screening 705–708, 711–712
 - collaborative amniocentesis studies 75–76, 76t
 - congenital CMV infection 950t
 - embryo research, legal status 445
 - federal court system 1064
 - legal/regulatory status of PGD 444–445, 1097
 - PGD services provided by IVF clinics 1099–1100
 - state court systems 1064
- Utah Wrongful Life Act 1088
- uterine arteries 1032
- uterine atony, postabortion 1015, 1019
- uterine membrane separation, fetal surgery 995–996
- uterine perforation
- after dilation and evacuation 1019
 - after suction curettage 1015
- uterine rupture, after fetal surgery 995
- uterine scar 995
- uterotonics 1014
- vaccination
- against CMV 958, 960–961
 - against rubella 962, 963
 - against VZV 966
- VACTERL syndrome 622, 623f, 674
- vacuum aspiration, manual 1013–1014
- vaginal bleeding, DS screening 514
- vaginal leakage, AF, after amniocentesis 74
- valaciclovir 959
- valine metabolism disorders 884–885
- valproate, in AF 118
- valvuloplasty, fetal 1005–1006
- “vanishing twin” 511
- variable number tandem repeat (VNTR) 748
- variance–covariance matrices 491
- variants of unknown significance (VOUS) 370, 373, 382, 383
 - cystic fibrosis 711
- varicella **963–967**
- congenital syndrome 964, 965, 965t, 966
 - consequences for pregnancy/fetus 964
 - epidemiology 964
 - fetal infection 114, 964, 965
 - diagnosis 965
 - pathogenesis 964–965
 - maternal 963, 964, 965
 - maternal exposure to vaccine 966
 - neonatal 963
 - transmission 964–965, 966
 - frequency 965–966
 - treatment 966–967
 - vaccination 966
- varicella-zoster immunoglobulin (VZIG) 966
- varicella-zoster virus (VZV) 963
 - DNA detection 964, 965
 - vaccines 966
- vascular endothelial growth factor (VEGF) 1036
- vascular malformations, brain 669
- vasectomy, failure 1077, 1087
- vasovagal syncope 1013, 1018
- VATER association 554
- vein of Galen aneurysm (VGAM) 669
- Velaglucerase alfa 796
- velocardiofacial syndrome 145, 314, 315t, 318
- ventricles (brain)
 - dilatation 667, 669
 - CMV infection 954
 - MRI indication 661, 669
 - see also* ventriculomegaly
 - size, brain development 662
- ventricles (heart), morphology anomalies 609–610
- ventricular ectopic beats 979
- ventricular septal defects 605, 608
- ventricular tachycardia 981
- ventriculoamniotic shunting 545–546
- ventriculocoronary arterial connection (VCAC) 612
- ventriculomegaly 576, **635–636**, 669, 1118
 - causes and associated anomalies 636t
 - fetal lateral cerebral 545, 546t
 - legal case involving 1076
 - moderate, severe 635, 637f
 - MRI 669–670
 - ultrasound 635–636
- vermian agenesis 669
- vertical pocket measurement (VPM) 99
- very long-chain acyl-CoA dehydrogenase (VLCAD)
 - deficiency 840, **845–846**
- very long-chain fatty acids (VLCFA), in D-bifunctional protein
 - deficiency 850
- vesicoamniotic shunts, ultrasound-guided percutaneous 634, 999
- vesicocentesis 634
- vesicoureteric reflux 562–563
- viability 1108
- vimentin filaments 124
- virilization, congenital adrenal hyperplasia 456, 976–977
- viruses
 - infections, immunodeficiency disorders 756, 757t
 - RNA, in AF 114
- vitamin A, in AF 111
- vitamin B12 *see* cobalamin
- VLCAD (very long-chain acyl-CoA dehydrogenase)
 - deficiency 840, **845–846**
- von Gierke disease (type I GSD) *see* glycogen storage diseases (GSDs), type I
- von Hippel–Lindau gene 35–36
- Von Hippel–Lindau syndrome 402t
- von Willebrand disease 86, 983
- vulnerable child syndrome 43
- Walker–Warburg syndrome 667
- WASP gene 768
- water, accumulation in pregnancy 99

- weight, maternal, DS screening 514
 West syndrome 777t
 white blood cells *see* leukocyte(s) (fetal)
 white matter damage 663
 whole-exome sequencing (WES) 380, 383, 386–387
 consanguineous couples 385
 genotype–phenotype correlations and 397
 limitations 387
 prenatal diagnosis 386–387
 targeted 387
 whole genome amplification (WGA), DNA analysis in PGD 424, 442–443
 whole-genome sequencing 380
 Williams syndrome 314, 316t
 Wilms tumor, WT1-related 402t
 Wiskott–Aldrich syndrome (WAS) 761t, 768
 Wolf–Hirschhorn syndrome 316t
 Wolman disease 778t, **807–809**
 World Health Organization (WHO), access to prenatal diagnosis 1092
 wrongful birth 1063, **1066–1067**
 impact of concerns about abortion on **1068–1069**
 legal cases involving 1065, 1066, 1067, 1069, 1070t–1072t, 1073–1088
 Statutes (US) 1069
 wrongful conception 1065–1066, 1078
 wrongful life 1063
 child's claim **1067**
 claims against parents **1068**
 impact of concerns about abortion on **1068–1069**
 legal cases involving 1065, 1067, 1069, 1070t–1072t, 1073–1088
 Statutes (US) 1069
 wrongful pregnancy **1065–1066**
 xanthine oxidase deficiency 889–890
 X-autosome translocations 228, 230, 269, **286–287**
 balanced 286, 287
 chromosomes most commonly involved 286
 de novo 230
 familial 228
 male carriers 287
 unbalanced 287
 X chromosome
 45,X females *see* Turner syndrome
 46,XX males 290–291
 47,XXY males *see* Klinefelter syndrome
 48,XXXX 282
 49,XXXXX 282
 extra *see* Klinefelter syndrome
 loss/partial loss *see* Turner syndrome
 monosomy 207
 mosaicism *see* mosaicism
 poly-X syndromes 280–282
 structural abnormalities **284–288**
 autosome translocations *see* X-autosome translocations
 inversion X (inv(X)) 197, 286
 isochromosome Xp (i(Xp)) 286
 isochromosome Xq (i(Xq)) 273, 286
 marker X (fragment X) 286, 321, 322
 ring X chromosome 273, 322
 Xp22 microdeletion 187
 Xp deletions (del(Xp); Xp2) 284–285, 314
 Xp duplications (dup(Xp)) 285, 293
 Xq deletions (del(Xq); Xq2) 285
 Xq duplications (dup(Xq)) 285–286
 triple X syndrome *see* triple X syndrome (47,XXX)
 two, fertility and 202
 X;X translocations 287–288
 X;Y translocations 290
 see also entries at start of index
 X-inactivation
 balanced X-autosome translocations 287
 DNA methylation evaluating 1040
 Fabry disease heterozygotes 791
 functional mosaicism 38
 X inactivation center (XIST), 46,X,r(X) 273
 X-linked disorders 30t
 adrenoleukodystrophy (X-ALD) 848–849, 848t
 agammaglobulinemia 760t, 767
 chronic granulomatous disease 767
 glycosphingolipidosis *see* Fabry disease
 hyper-IgM syndrome 760t, 766
 ichthyosis (XLI) **516–517**
 immunodysregulation, polyendocrinopathy and enteropathy (IPEX) 762t, 769
 lymphoproliferative disease 761t, 768–769
 PGD 424
 preconception visit 27
 prenatal sex determination 202–203, 456
 recessive disease
 in balanced X-autosome translocations 287
 female carriers 27, 30t
 recurrent pregnancy loss 26
 SCID 759t, 763, 764
 X;X translocations 287–288
 L-xylulose 918
 L-xylulose reductase 918
 XY sex reversal 293
 X;Y translocations 290
 Y-autosome translocations 235, **289–290**
 balanced 290
 unbalanced 290
 Y chromosome
 in 45,X cell line 269
 47,XYY males **282–284**
 48,XYYY 284
 49,XXYYY 284
 49,XYYYY 284
 fetal sex determination by cffDNA 456
 gene contributing to height 288
 mosaicism involving 224, 284
 occult 224–225
 polymorphisms 235
 polysomy 284
 structural abnormalities **288–290**
 inversion Y (inv(Y)) 197, 289
 isochromosome Yp (i(Yp)) 288
 isochromosome Yq (i(Yq)) 288
 isodicentric Yp (idic(Yp)) 288–289
 isodicentric Yq (idic(Yq)) 289
 marker Y (mar(Y)) 289, 322
 microdeletions 26, 277
 pericentric inversions 236
 ring Y (r(Y)) 289
 satellites 235, 289
 Yp deletions (del(Yp)) 288
 Yq deletions (del(Yq)) 288

1188 Index

Y chromosome (*Continued*)Y;autosome translocations *see* Y-autosome translocations

in Y-positive 46,XX males 290–291

Y;Y translocations 290

see also entries at start of index

ZAP-70 kinase deficiency 760t, 765

Zellweger spectrum disorders 851

Zellweger syndrome 385, 556, 667, 848, 848t, **851–852**

clinical features 851

zinc, in AF 111, 113

